KR20190020577A - Pyrimininone derivative compounds and use thereof - Google Patents

Abstract

The present invention provides a pyrimidinone derivative compound, an optical isomer thereof, and a pharmaceutically acceptable salt thereof. The compound of the present invention exhibits activities of treating, preventing, or alleviating hypertension and/or diabetes. The compound of the present invention is represented by chemical formula I.

Description

PYRIMININONE DERIVATIVES AND USES THEREOF Technical Field [0001]

The present invention relates to pyrimidone derivative compounds and their use.

Hypertension is a chronic disease that has not yet been elucidated. Essential hypertension (primary hypertension) accounts for 90% of all patients, and persistent hypertension increases the likelihood of fatal diseases such as heart attack and stroke. Particularly, when diabetes accompanies diabetes, which is one of the metabolic diseases, the durability is increased several times.

It is known that angiotensin II produced from angiotensin I by angiotensin converting enzyme increases blood pressure through angiotensin II receptor present in blood vessel wall as a plasma membrane protein. Thus, angiotensin II antagonists have been used to treat hypertension caused by angiotensin. So far, drugs developed as orally administered angiotensin II antagonists include losartan, candesartan cilexetil, olmesartan medoxomil, telmisartan, (fimasartan) and the like are known.

Diabetes, on the other hand, causes problems in the control of blood sugar in the blood, resulting in kidney disease, vascular disease, etc., and progressing to pressure ulcers, blindness, kidney failure and the like.

The drug group, known as TZD (thiazolidinediones), targets PPARγ and is a drug that regulates blood glucose regulation by alleviating insulin resistance in patients with glycemic control. These TZD drugs activate the nuclear receptor PPARγ, which is known to increase the expression of various genes such as lipid metabolism and glucose metabolism. Therefore, it has been attempted to develop a partial activator and a selective regulator to reduce the side effects and to achieve only the pharmacological effect of overcoming insulin resistance.

In order to treat patients with hypertension and diabetes, treatment with hypertension and diabetes has been developed, but drug development has not been achieved. Accordingly, the present inventors developed a drug that regulates insulin resistance along with hypertension treatment.

The present invention is intended to provide a pyrimidinone derivative compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, which exhibits therapeutic activity for hypertension and / or diabetes mellitus.

The present invention also provides a process for producing the pyrimidone derivative compound of the present invention.

The present invention also provides use of the pyrimidone derivative compounds of the present invention.

The present inventors have found a pyrimidone derivative compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, which exhibits therapeutic activity of hypertension and / or diabetes, and completed the present invention.

A compound of formula I, an optical isomer thereof, or a pharmaceutically acceptable salt thereof,

According to the above object, the present invention provides a compound represented by the following formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof:

(I)

In the formula (I)

Ra ₁ and Ra ₂ Are each independently selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, C2-C6 heterocycloalkyl, C2-C5 primary or secondary amine, C2-C5 alkoxy, or C2- Alkyl or C3-C7 cycloalkyl may be substituted with halo,

Rb ₁ , Rb ₂ , Rc ₁ and Rc ₂ Are each independently H, halo, Ci-C4 alkyl or Ci-C4 haloalkyl,

Rd Rd ₁ and ₂ are each independently H or C1-C4 alkyl,

X ₁ and X ₂ are each independently O or S,

Y is selected from the group consisting of C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl or none, wherein one or more H of said C1-C4 alkyl, C2-C4 alkenyl or C2- , Hydroxy, nitro, cyano or sulfonyl.

Z is OR ₁ or NR ₂ R _3,

R ₁ is H, C ₁ -C 6 alkyl, C 1 -C 4 alkyl-O (C 1 -C 4 alkyl), C 3 -C 7 cycloalkyl, phenyl or C 1 -C 4 alkyl-phenyl wherein the C 3 -C 7 cycloalkyl, Wherein at least one H of the C1-C4 alkyl-phenyl ring may be substituted with halo, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, nitro, carboxylic acid or sulfonyl,

R ₂ and R ₃ are each independently H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl or C 1 -C 6 alkoxy, wherein at least one H of said C 1 -C 6 alkyl is optionally substituted by C 1 -C 4 alkoxy, Heteroaryl, < / RTI > or

R ₂ and R _{3 taken} together with the connected nitrogen atom form a 5-membered to 7-membered monocyclic ring or a 7-to 12-membered ring, wherein one or more H of said single ring or double ring is optionally substituted with halo, Alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, hydroxy, carboxylic acid, nitro, sulfonyl, C3-C7 cycloalkyl, C2-C6 heterocycloalkyl, aryl or heteroaryl.

Also, according to one embodiment of the present invention, the compound represented by Formula (I)

In the formula (I)

Ra ₁ and Ra ₂ Are each independently C1-C6 alkyl or C3-C7 cycloalkyl, wherein one or more H of said C1-C6 alkyl or C3-C7 cycloalkyl may be substituted with halo,

Rb _1, Rb _2, Rc ₁ and Rc ₂ are each independently H or halo,

Rd Rd ₁ and ₂ are each independently H or C1-C4 alkyl,

X ₁ and X ₂ are each independently O or S,

Y is C1-C4 alkyl or is not null, wherein one or more H of said C1-C4 alkyl may be substituted with halo, hydroxy, nitro, cyano or sulfonyl,

Z is OR ₁ or NR ₂ R _3,

R ₁ is H, C ₁ -C 4 alkyl, C 1 -C 4 alkyl-O (C 1 -C 4 alkyl), C 3 -C 7 cycloalkyl, phenyl or C 1 -C 4 alkyl-phenyl wherein the C 3 -C 7 cycloalkyl, Wherein at least one H of the C1-C4 alkyl-phenyl ring may be substituted with halo, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, nitro, carboxylic acid or sulfonyl,

R ₂ and R ₃ are each independently H, C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl or C 1 -C 6 alkoxy wherein at least one H of said C 1 -C 4 alkyl is C 1 -C 4 alkoxy, hydroxy or heteroaryl , Or < RTI ID = 0.0 >

R ₂ and R ₃ together with the nitrogen atom to which they are attached form a 5- to 7-membered single ring, a 6-to 8-member bridge double ring, an 8-to-10-member fused double ring, or a 9- Wherein one or more H of the double ring may be substituted with halo, C1-C4 alkyl or C1-C4 haloalkyl, aryl or heteroaryl, wherein the single ring, the bridge double ring, the fused double ring or the spiro, .

Also, according to one embodiment of the present invention, the compound represented by Formula (I)

In the formula (I)

Ra ₁ and Ra ₂ Are each independently C1-C4 alkyl or C3-C6 cycloalkyl, wherein one or more H of said C1-C6 alkyl or C3-C7 cycloalkyl may be substituted with halo,

Rb _1, Rb _2, Rc ₁ and Rc ₂ are each independently H or halo,

Rd Rd ₁ and ₂ are each independently H or C1-C4 alkyl,

X ₁ and X ₂ are each independently O or S,

Y is C1-C4 alkyl or is not null, wherein one or more H of said C1-C4 alkyl may be substituted with halo, hydroxy, nitro, cyano or sulfonyl,

Z is OR ₁ or NR ₂ R _3,

R ₁ is H, C ₁ -C 4 alkyl, C 1 -C 4 alkyl-O (C 1 -C 4 alkyl), C 3 -C 7 cycloalkyl, phenyl or C 1 -C 4 alkyl-phenyl wherein the C 3 -C 7 cycloalkyl, One or more H of the C1-C4 alkyl-phenyl ring may be substituted by halo, C1-C4 alkyl, C1-C4 alkoxy or hydroxy}

R ₂ and R ₃ are each independently H, C 1 -C 4 alkyl, C 3 -C 7 cycloalkyl or C 1 -C 6 alkoxy wherein at least one H of said C 1 -C 6 alkyl is optionally substituted by C 1 -C 4 alkoxy, hydroxy or heteroaryl , Or < RTI ID = 0.0 >

R < ₂ > and R < ₃ > together with the connected nitrogen atom form one of the following rings wherein one or more H of said ring may be substituted by halo, C1-C4 alkyl or C1-

R ₄ is H, C 1 -C 4 alkyl, aryl or heteroaryl, wherein said aryl or heteroaryl may be substituted with halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, nitro, cyano or sulfonyl has exist}.

According to an embodiment of the present invention, the compound represented by Formula (I) is any one selected from the group consisting of the following compounds, an optical isomer thereof, or a pharmaceutically acceptable salt thereof have:

1) Ethyl 2- (2-butyl-4-isopropyl-6-oxo-1 - ((2 ' Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

2) Preparation of 2- (2-butyl-4-isopropyl-6-oxo-1 - ((2 '-( 5-oxo-4,5-dihydro- ) Biphenyl-4-yl) methyl) -l, 6-dihydropyrimidin-5-yl) acetic acid;

3) Preparation of methyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '-( 5-oxo-4,5-dihydro- ) Biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

4) propyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2- ) Biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

5) Synthesis of butyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- ) Biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

6) Pentyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '-( 5-oxo-4,5-dihydro- ) Biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

7) Isopropyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '-( 5-oxo-4,5-dihydro- Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

8) Preparation of isobutyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro- Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

9) Preparation of 2-methylbutyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

10) Benzyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '-( 5-oxo-4,5- dihydro- ) Biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

11) Synthesis of 2-methoxyphenethyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- Yl)) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

12) Cyclohexyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

13) (lr, 4r) -4-Methylcyclohexyl 2- (2-butyl-4-methyl-6-oxo- Yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

14) 2- (2-Butyl-4-cyclopropyl-6-oxo-1 - ((2 '-( 5-oxo-4,5-dihydro- ) Biphenyl-4-yl) methyl) -l, 6-dihydropyrimidin-5-yl) acetic acid;

15) Preparation of 2-methylbutyl 2- (2-butyl-4-isopropyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

16) pentan-3-yl 2- (2-butyl-4-isopropyl-6-oxo- Yl)) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

17) Isopropyl 2- (2-butyl-4-isopropyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro- Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

18) 1-Methoxypropane 2-yl 2- (2-Butyl-4-isopropyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro- -Oxadiazol-3-yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

19) Ethyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '-( 5-oxo-4,5-dihydro- ) Biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

20) Preparation of ethyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- ) Biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) propanoate;

21) Ethyl 2- (2-butyl-4-methyl-1 - ((2 '- (4-methyl- ) Biphenyl-4-yl) methyl) -6-oxo-1,6-dihydropyrimidin-5-yl) acetate;

22) Preparation of ethyl 2- (2- (1-bromobutyl) -4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- Diazo-3-yl) biphenyl-4-yl) methyl) -l, 6-dihydropyrimidin-5-yl) acetate trifluoroacetic acid salt;

23) Preparation of ethyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- ) Biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) -2-hydroxyacetate trifluoroacetic acid salt;

24) 3- [2- [4 - [[5- [2 - [(1R) -2,3,3a, 4,5,6,7,7a-octahydroindol- -Ethyl] -2-butyl-4-cyclopropyl-6-oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

25) Preparation of ethyl 2- (4-tert-butyl-2-butyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

26) Phenyl 2- (2-butyl-4-isopropyl-6-oxo-1 - ((2 '-( 5-oxo-4,5-dihydro- Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;

Methyl-6-oxo-5- (2-oxo-2-pyrrolidin- 1 -ylethyl) pyrimidin- 1 -yl] methyl ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

28) {2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylacetamide;

29) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-propylacetamide;

30) N-Butyl-2- [2-butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ) Phenyl] phenyl] methyl] pyrimidin-5-yl] acetamide;

31) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-diethylacetamide;

32) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-propan-2-ylacetamide;

33) 2- (2-Butyl-4-methyl-6-oxo-1 - ((2- Biphenyl-4-yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N-isopropyl-N-methylacetamide;

34) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methyl-N- (2-methylpropyl) acetamide;

35) {3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7a-octahydroisoindol- -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

36) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- (2-oxo-2-piperidin- 1 -ylethyl) pyrimidin- ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

37) 3- [2- [4 - [[2-Butyl-4-methyl-5- (2-morpholin- ] -4H-l, 2,4-oxadiazol-5-one;

38) 3- [2- [4 - [[2-butyl-5- [2- (3,5- dimethylpiperidin- 1 -yl) -2-oxoethyl] 1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

39) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N- (1 -hydroxypropan-2-yl) acetamide;

40) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-dimethylacetamide;

41) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methoxy-N-methylacetamide;

42) 2-butyl-N, N, 4-trimethyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidine-5-carboxamide;

43) Synthesis of 2-butyl-N, 4-dimethyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] -N-propan-2-ylpyrimidine-5-carboxamide;

44) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- (piperidine- 1- carbonyl) pyrimidin- 4H-1,2,4-oxadiazol-5-one;

45) 3- [2- [4 - [[2-Butyl-4-methyl-5- (morpholine- 4- carbonyl) -6-oxopyrimidin- 4H-1,2,4-oxadiazol-5-one;

46) 3- [2- [4 - [[5- (1,3,3a, 4,5,6,7a-octahydroisoindole- 2- carbonyl) 6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

47) 2-butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- -N-propan-2-ylpyrimidine-5-carboxamide;

48) Synthesis of 2-butyl-N-cyclohexyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Phenyl] methyl] pyrimidine-5-carboxamide;

49) 2-Butyl-N, 4-dimethyl-N- (2-methylpropyl) -6- Yl) phenyl] phenyl] methyl] pyrimidine-5-carboxamide;

50) 3- [2- [4 - [[2-Butyl-5- (3,5-dimethylpiperidine-1-carbonyl) -4-methyl-6- oxospi rimidin- Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

51) Synthesis of 2-butyl-4-methyl-N- (2-methylpropyl) -6-oxo-1 - [[4- [2- Yl) phenyl] phenyl] methyl] pyrimidine-5-carboxamide;

52) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a-octahydroisoindol- Methyl-6-oxo-2-propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

53) N-Methoxy-N-methyl-2- [4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H- Yl) phenyl] phenyl] methyl] -2-propylpyrimidin-5-yl] acetamide;

54) N, N-Dimethyl-2- [4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] phenyl] methyl] -2-propylpyrimidin-5-yl] acetamide;

55) 3- [2- [4- [[4-Methyl-6-oxo-5- (2-oxo-2- pyrrolidin- 1 -ylethyl) -2- propylpyrimidin- ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

56) 3- [2- [4 - [[4-Methyl-6-oxo-5- (2-oxo-2-piperidin- 1- ylethyl) -2-propylpyrimidin- ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

57) 3- [2- [4 - [[5- [2- (3,5-Dimethylpiperidin-1-yl) -2-oxoethyl] Pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

58) 3- [2- [4- [[5- [2- (3,5-Dimethylmorpholin-4-yl) -2-oxoethyl] -4-methyl- Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

59) N-methyl-2- [4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] -2-propylpyrimidin-5-yl] -N-propan-2-ylacetamide;

60) 3- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-dimethylpropanamide;

61) 3- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylpropanamide;

62) 3- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-cyclopropylpropanamide;

Methyl) -6-oxo-5- (3-oxo-3-piperidin- 1 -ylpropyl) pyrimidin- 1 -yl] methyl ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

64) 3- [2- [4 - [[2-Butyl-4-methyl-5- (3 -morpholin- ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

65) 3- [2- [4 - [[5- [3- (1,3,3a, 4,5,6,7a-octahydroisoindol-2-yl) -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

66) 3- [2- [4 - [[2-Butyl-4-methyl-5- [3- (4-methylpiperidin- 1 -yl) -3-oxopropyl] -6-oxopyrimidine -1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

67) Synthesis of 3- [2- [4 - [[2-butyl-5- [3- (3,3-dimethylpiperidin- 1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

68) 3- [2- [4 - [[2-butyl-5- [3- (3,5- dimethylmorpholin- Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

69) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a-octahydroisoindol- 2-yl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

70) 2- [2-Butan-2-yl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ) Phenyl] phenyl] methyl] pyrimidin-5-yl] -N-methoxy-N-methylacetamide;

71) 2- [2-Butan-2-yl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ) Phenyl] phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylacetamide;

72) 2- [2-Butan-2-yl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ) Phenyl] phenyl] methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylacetamide;

73) 3- [2- [4 - [[2-Butan-2-yl-5- [2- (2,6- dimethylpiperidin- 1 -yl) -6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

74) 3- [2- [4 - [[2-Butan-2-yl-5- [2- (2,6- dimethylmorpholin- 6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

75) 3- [2- [4 - [[2-Butyl-5- [2- (3,4-dihydro- lH-isoquinolin- -Oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

76) 3- [2- [4 - [[5- [2- (3,4,4a, 5,6,7,8,8a-octahydro-1 H -isoquinolin- Ethyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

77) 3- [2- [4 - [[2-Butyl-4-methyl-5- [2- (2-methylpyrrolidin- 1 -yl) -2-oxoethyl] -6-oxopyrimidine -1-yl] methyl] phenyl] phenyl] -2H-1,2,4-oxadiazol-5-one;

78) 3- [2- [4 - [[5- [2- (3,4,4a, 5,6,7,8,8a-octahydro-2H-quinolin- ] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -2H-1,2,4-oxadiazol-5-one;

79) 3- [2- [4 - [[2-Butyl-5- (2-indol- Phenyl] phenyl] -2H-1,2,4-oxadiazol-5-one;

80) 3- [2- [4 - [[2-butyl-4-methyl-5- [2- (2-methyl-1,3,3a, 4,6,6a- hexahydropyrrolo [ -c] pyrrol-5-yl) -2-oxoethyl] -6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

81) 3- [2- [4 - [[5- [2- (3,3a, 4,5,6,6a-hexahydro-1H-cyclopenta [ Ethyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

82) 3- [2- [4 - [[2-Butyl-5- [2- (1,3- dihydroisoindol- Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

83) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- [ Pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

84) Synthesis of 3- [2- [4 - [[2-butyl-5- [2- (2,3-dihydroindol- 1- yl) -2-oxoethyl] Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

85) 3- [2- [4 - [[2-butyl-5- [2- (4-fluoro-1,3- dihydroisoindol- -6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

86) 2- [2-Cyclopropyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylacetamide;

87) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7a-octahydroisoindol- 2-cyclopropyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

88) 3- (4'- ((2-Butyl-4-methyl-5- (2- (octahydro- lH- indol- 1 -yl) -2-oxoethyl) -6-oxopyrimidin- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

89) 3- (4'- ((2-Butyl-5- (2- (dihydro-lH-pyrido [1,2- a] pyrazin-2 (6H, 7H, 8H, 9H, 9aH) Yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -On;

90) 3- [2- [4 - [[5- [2- (7-Azabicyclo [2.2.1] heptan- -Oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

91) 3- [2- [4 - [[5- [2- (7-Azabicyclo [2.2.1] heptan-7-yl) -2-oxoethyl] -4- -Propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

92) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo- 5- [2-oxo- 2- [4- (trifluoromethyl) piperidin- ] Ethyl] pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

93) 3- [2- [4- [[5- [2- (8-Azaspiro [4.5] decan-8-yl) -2-oxoethyl] 1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

94) 3- [2- [4 - [[5- [2- (8-Azaspiro [4.5] decan-8- Pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

95) 3- [2- [4 - [[2-butyl-5- [2- (4,4-dimethylpiperidin- 1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

96) 3- [2- [4 - [[5- [2- (4,4-Dimethylpiperidin- 1 -yl) -2-oxoethyl] Pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

97) 3- [2- [4 - [[2- (2,5-Dimethylpyrrolidin- 1 -yl) -2-oxo-ethyl] Oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -2H-1,2,4-oxadiazol-5-one;

98) Synthesis of 3- [2- [4 - [[2-butyl-4-methyl-5- [2 - [(2S) -2- methylpyrrolidin- Oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

99) 3- [2- [4 - [[2-butyl-5- [2 - [(2S, 6R) -2,6-dimethylpiperidin- Methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

100) 3- [2- [4 - [[5- [2 - [(4aS, 8aR) -3,4,4a, 5,6,7,8,8a-octahydro-2H-quinolin- ] -2-oxoethyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

101) 3- (4 '- ((2-Butyl-4-methyl-5- (2- Yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one ;

102) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylacetamide;

103) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a-octahydroisoindol- 2-butyl-4-cyclopropyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

104) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylacetamide;

105) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-methyl-N- (2-methylpropyl) acetamide;

106) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-isopropyl-N-methylacetamide;

Oxo-2-pyrrolidin-1-ylethyl) pyrimidin-1-yl] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

108) 3- [2- [4 - [[2-Butyl-4-cyclopropyl-5- [2- (3,5- dimethylpiperidin- 1 -yl) Oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

109) 3- [2- [4 - [[2-Butyl-4-cyclopropyl-6-oxo-5- (2- oxo-2-piperidin- 1- ylethyl) pyrimidin- Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

110) 3- [2- [4 - [[2-Butyl-4-cyclopropyl-5- (2-morpholin- Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

111) 2- [2-butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N- (1-hydroxypropan-2-yl) acetamide;

112) N-Butyl-2- [2-butyl-4- cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H- Yl) phenyl] phenyl] methyl] pyrimidin-5-yl] acetamide;

113) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-propylacetamide;

114) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-propan-2-ylacetamide;

115) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-methoxy-N-methylacetamide

116) 3- (4'- ((2-Butyl-4-cyclopropyl-6-oxo-5- (2-oxo-2- (pyrrolidin- 1- yl) ethyl) pyrimidin- Yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

117) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (2,6- dimethylpiperazin- 1 -yl) -2-oxoethyl) (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

118) (S) -3- (4 '- ((2-Butyl-4-cyclopropyl- 5- (2- (2- methylpyrrolidin- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

119) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (3,5- dimethylpiperidin- 1 -yl) -2-oxoethyl) (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

120) 2- (2-Butyl-4-cyclopropyl-6-oxo-1 - ((2 '-( 5-oxo-4,5-dihydro- ) Biphenyl-4-yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N- cyclopropylacetamide;

121) 2- (2-Butyl-4-cyclopropyl-6-oxo-1 - ((2 '-( 5-oxo-4,5-dihydro- ) Biphenyl-4-yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N, N- diethylacetamide;

122) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (3,5- dimethylmorpholino) -2-oxoethyl) -6-oxopyrimidin- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

123) 3- (4 '- ((2-Butyl-4-cyclopropyll-5- (2 - ((2S, 6R) -2,6-dimethylpiperidin- Ethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

124) 3- (4 '- ((2-Butyl-4-cyclopropyl-5- (2-morpholino- 2- oxoethyl) -6-oxopyrimidin- Biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

125) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (2- methylpiperidin- 1 -yl) -2-oxoethyl) -6-oxopyrimidine- 1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

126) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (4- hydroxypiperidin- 1 -yl) -2-oxoethyl) -6-oxopyrimidine -1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

127) 3- [2- [4 - [[2-Butyl-6-oxo-5- (2-oxo-2-piperidin- 1 -ylethyl) -4- propan- -Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

128) 3- [2- [4 - [[2-butyl-5- [2- (2,6- dimethylpiperazin- 1 -yl) -2- oxoethyl] 2-ylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

129) 2- [2-butyl-6-oxo-1 - [[4- [2- (5-oxo- 4-propan-2-ylpyrimidin-5-yl] -N, N- dimethylacetamide;

130) 2- [2-butyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- 4-propan-2-ylpyrimidin-5-yl] -N, N-diethylacetamide;

Yl) phenyl] phenyl] methyl] - (2-methyl- 4-propan-2-ylpyrimidin-5-yl] -N-methyl-N-propan-2-ylacetamide;

132) 2- [2-butyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- 4-propan-2-ylpyrimidin-5-yl] -N-cyclopropylacetamide;

133) 3- (4'- ((2-Butyl-5- (2- (3,5-dimethylpiperidin- 1 -yl) -2-oxoethyl) -4-isopropyl- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

134) 3- (4 '- ((2-Butyl-5- (2 - ((2R, 6S) -2,6-dimethylpiperidin- Propyl-6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

135) 3- (4'- ((2-Butyl-4-isopropyl-5- (2- (2- methylpiperidin- 1 -yl) -2-oxoethyl) -6-oxopyrimidine- 1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

136) 3- (4'- ((2-Butyl-4-isopropyl-5- (2- (3-methylpiperidin- 1 -yl) -2-oxoethyl) -6-oxopyrimidine- 1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

137) 3- (4'- ((2-butyl-4-isopropyl-5- (2-morpholino- 2- oxoethyl) -6- oxopyrimidin- 1 (6H) Biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

138) 3- (4'- ((2-Butyl-5- (2- (2,6- dimethylmorpholino) -2-oxoethyl) -4-isopropyl-6-oxopyrimidin- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

139) (S) -3- (4 '- ((2-Butyl-4-isopropyl- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

140) 2- [2-Butyl-4-ethyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-dimethylacetamide;

141) 2- [2-Butyl-4-ethyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylacetamide;

142) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7a-octahydroisoindol- 2-butyl-4-ethyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

143) 3- [2- [4 - [[2-Butyl-4-ethyl-6-oxo-5- (2-oxo-2- pyrrolidin- 1 -ylethyl) pyrimidin- ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

144) 3- [2- [4 - [[2-Butyl-4-ethyl-6-oxo-5- (2- oxo-2-piperidin- 1- ylethyl) pyrimidin- ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

145) 3- [2- [4 - [[2-Butyl-4-ethyl-5- (2-morpholin- ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

146) 3- [2- [4 - [[2-Butyl-4-ethyl-5- [2- (4-methylpiperidin- 1 -yl) -2-oxoethyl] -6-oxopyrimidine -1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

147) 3- [2- [4 - [[2-Butyl-5- [2- (3,3- dimethylpiperidin- 1 -yl) 1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

148) 3- [2- [4 - [[2-butyl-5- [2- (3,5- dimethylmorpholin- Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

149) 3- (4'- ((2-Butyl-4-methyl-6-oxo-5- (2-oxo- 2- (thiazolidin- 3- yl) ethyl) pyrimidin- Yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

150) 3- (4'- ((2-Butyl-4-methyl-5- (2- (4- methylpiperidin- 1 -yl) -2-oxoethyl) -6-oxopyrimidin- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

151) 3- (4 '- ((2-Butyl-5- (2- (2,6- dimethylmorpholino) -2-oxoethyl) -4-methyl-6-oxopyrimidin- 6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

152) 2- (2-Butyl-4-methyl-6-oxo-1 - ((2- Yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N- (2-methoxyethyl) acetamide;

153) 2- (2-Butyl-4-methyl-6-oxo-1 - ((2- Yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N- (2- (thiophen-2-yl) ethyl) acetamide;

154) 2- (2-Butyl-4-methyl-6-oxo-1 - ((2- Yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N, N-diisopropylacetamide;

155) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-dimethylethanethioamide;

156) 3- (4 '- ((5- (2- (1H-isoindol-2 (3H, 3aH, 4H, 5H, 6H, 7H, 7aH) Butyl-4-methyl-6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

157) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methyl-N- (2-methylpropyl) ethanethioamide;

158) 3- [2- [4- [[2-Butyl-4-methyl-6-oxo-5- (2-piperidin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

159) 3- [2- [4 - [[2-Butyl-4-methyl-5- (2-morpholin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

160) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-propan-2-ylethanethioamide;

161) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylethanethioamide;

162) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- (2-pyrrolidin- 1 -yl-2-sulfanylidenemethyl) pyrimidin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

163) 3- [2- [4 - [[2- (3,5-Dimethylpiperidin-1-yl) -2-sulfanylidenemethyl] -Oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

164) 2-Butyl-N, 4-dimethyl-N- (2- methylpropyl) -6-oxo-1 - [[4- [2- Yl) phenyl] phenyl] methyl] pyrimidine-5-carbothioamide;

165) 2-butyl-N, N, 4-trimethyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidine-5-carbothioamide;

166) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- (piperidine- 1- carbothioyl) pyrimidin- -4H-l, 2,4-oxadiazol-5-one;

167) 3- [2- [4 - [[2-butyl-4-methyl-5- (morpholine- 4- carbothioyl) -6-oxopyrimidin- -4H-l, 2,4-oxadiazol-5-one;

168) Synthesis of 2-butyl-N, 4-dimethyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] -N-propan-2-ylpyrimidine-5-carbothioamide;

169) 3- [2- [4 - [[5- (1,3,3a, 4,5,6,7,7a-octahydroisoindole-2-carbothioyl) -6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

Methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- -N-propan-2-ylpyrimidine-5-carbothioamide;

171) 2-Butyl-N-cyclohexyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Phenyl] methyl] pyrimidine-5-carbothioamide;

172) 3- [2- [4 - [[2-Butyl-5- (3,5-dimethylpiperidine- 1- carbothioyl) -4-methyl-6-oxopyrimidin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

173) 2-Butyl-4-methyl-N- (2-methylpropyl) -6-oxo-1 - [[4- [2- Yl) phenyl] phenyl] methyl] pyrimidine-5-carbothioamide;

174) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-diethylethanethioamide;

175) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-propylethanethioamide;

176) N-butyl-2- [2-butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4- ) Phenyl] phenyl] methyl] pyrimidin-5-yl] ethanethioamide;

177) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a-octahydroisoindol-2-yl) -2-sulfanylidenemethyl ] -4-methyl-6-oxo-2-propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

178) N-Methoxy-N-methyl-2- [4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H- Yl) phenyl] phenyl] methyl] -2-propylpyrimidin-5-yl] ethanethioamide;

179) N, N-Dimethyl-2- [4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] phenyl] methyl] -2-propylpyrimidin-5-yl] ethanethioamide;

180) 3- [2- [4 - [[4-Methyl-6-oxo-2-propyl-5- (2- pyrrolidin- 1 -yl- 2- sulfanylideneethyl) pyrimidin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

181) 3- [2- [4 - [[4-Methyl-6-oxo-5- (2-piperidin- 1 -yl-2-sulfanylidenemethyl) -2-propylpyrimidin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

182) 3- [2- [4 - [[5- [2- (3,5-Dimethylpiperidin- 1 -yl) -2-sulfanylidenemethyl] -4-methyl- -Propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

183) 3- [2- [4 - [[5- [2- (3,5-Dimethylmorpholin-4-yl) -2-sulfanylidenemethyl] -4- Propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

184) N-methyl-2- [4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H- Phenyl] methyl] -2-propylpyrimidin-5-yl] -N-propan-2-ylethanethioamide;

185) 3- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-dimethylpropanethioamide;

186) 3- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methyl-N-propane-2-ylpropanethioamide;

187) 3- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-cyclopropylpropanethioamide;

188) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- (3-piperidin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

189) 3- [2- [4 - [[5- [3- (1,3,3a, 4,5,6,7,7a-octahydroisoindol-2-yl) -3-sulfanylidene propyl ] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

190) 3- [2- [4 - [[2-Butyl-4-methyl-5- [3- (4-methylpiperidin- 1 -yl) -3-sulfanylidenepropyl] -6- Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

191) 3- [2- [4 - [[2-butyl-5- [3- (3,3- dimethylpiperidin- 1 -yl) -3-sulfanylidenepropyl] -Oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

192) 3- [2- [4 - [[2-butyl-5- [3- (3,5- dimethylmorpholin- Oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

193) 3- [2- [4 - [[2-Butyl-4-methyl-5- (3 -morpholin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

194) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a-octahydroisoindol-2-yl) -2-sulfanylidenemethyl ] -2-butan-2-yl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

195) 2- [2-Butan-2-yl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ) Phenyl] phenyl] methyl] pyrimidin-5-yl] -N-methoxy-N-methylethanethioamide;

196) 2- [2-Butan-2-yl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ) Phenyl] phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylethanethioamide;

197) 2- [2-Butan-2-yl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ) Phenyl] phenyl] methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylethanethioamide;

198) 3- [2- [4 - [[2-Butan-2-yl- 5- [2- (2,6- dimethylpiperidin- 1 -yl) -2-sulfanylidenemethyl] Methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

199) 3- [2- [4 - [[2-butan-2-yl-5- [2- (2,6- dimethylmorpholin- Methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

200) 3- (4'- ((2-Butyl-5- (2- (3,5-dimethylpiperidin-1-yl) -2- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

201) Synthesis of 3- [2- [4 - [[2-butyl-5- [2- (3,4-dihydro-1H-isoquinolin-2-yl) -2-sulfanylidenemethyl] -6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

202) 3- [2- [4 - [[5- [2- (3,4,4a, 5,6,7,8,8a-octahydro-1H-isoquinolin- Methylidene] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

203) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- [2-sulfanylidene-2- (1,3-thiazolidin- ] Pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

204) Synthesis of 3- [2- [4 - [[2-butyl-4-methyl-5- [2- (4-methylpiperidin- 1 -yl) -2-sulfanylideneethyl] Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

205) Synthesis of 3- [2- [4 - [[2-butyl-5- [2- (2,6- dimethylmorpholin-4-yl) -2-sulfanylidenemethyl] Oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

206) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methoxy-N-methylethanethioamide;

207) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N- (2-methoxyethyl) -N-methylethanethioamide;

208) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N- (2-thiophen-2-ylethyl) ethanethioamide;

208) 2- (2-Butyl-4-methyl-6-oxo-1 - ((2- Yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N, N-diisopropylacetamide;

209) 2- [2-butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-di (propan-2-yl) ethanethioamide;

210) 3- [2- [4 - [[2-butyl-5- (2-indol- Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

211) Synthesis of 3- [2- [4 - [[2-butyl-4-methyl-5- [2- (2-methylpyrrolidin- 1 -yl) -2-sulfanylidenemethyl] Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

212) 2- [2-Cyclopropyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylethanethioamide;

213) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7a-octahydroisoindol-2-yl) -2-sulfanylidenemethyl ] -2-cyclopropyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

214) 3- [2- [4 - [[5- [2- (2,3,3a, 4,5,6,7,7a-octahydroindol- 1- yl) -2-sulfanylideneethyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

215) 3- [2- [4 - [[2-butyl-5- [2- (1,3- dihydroisoindol-2-yl) -2- sulfanylidenemethyl] Oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

216) Preparation of 3- [2- [4 - [[2-butyl-5- [2- (2,3-dihydroindol- 1 -yl) -2-sulfanylidenemethyl] 1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

217) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- [2- Ethyl] pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

218) 3- [2- [4 - [[5- [2- (3,3a, 4,5,6,6a-hexahydro-lH-cyclopenta [ Methylidene] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

219) 3- [2- [4 - [[2-Butyl-5- [2- (1,3- dihydroisoindol-2-yl) -2- sulfanylidenemethyl] Oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

220) 3- [2- [4 - [[2-Butyl-4-methyl-5- [2- [4- (4-nitrophenyl) piperazin- 1 -yl] -2-sulfanylidenemethyl] -6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

221) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7a-octahydroisoindol-2-yl) -2-sulfanylidenemethyl ] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] -4-fluorophenyl] -4H-1,2,4-oxadiazol-5-one;

222) 2- [2-butyl-1 - [[4- [5-fluoro-2- (5-oxo-4H-1,2,4-oxadiazol- -4-methyl-6-oxopyrimidin-5-yl] -N-methoxy-N-methylethanethioamide;

223) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo- 5- (2- pyrrolidin- 1 -yl- ] Methyl] phenyl] -4-fluorophenyl] -4H-1,2,4-oxadiazol-5-one;

224) 3- [2- [4 - [[2- (3,5-Dimethylpiperidin-1-yl) -2-sulfanylideneethyl] -Oxopyrimidin-1-yl] methyl] phenyl] -4-fluorophenyl] -4H-1,2,4-oxadiazol-5-one;

225) 3- [2- [4 - [[2-Butyl-5- [2- (3,5- dimethylmorpholin-4-yl) -2- sulfanylidenemethyl] Oxo-pyrimidin-1-yl] methyl] phenyl] -4-fluorophenyl] -4H-1,2,4-oxadiazol-5-one;

226) 2- [2-butyl-1 - [[4- [5-fluoro-2- (5-oxo-4H-1,2,4-oxadiazol- -4-methyl-6-oxopyrimidin-5-yl] -N-methyl-N- (2-methylpropyl) ethanethioamide;

227) 3- [2- [4 - [[2-Butyl-4-methyl-5- [2- (2-methyl-1,3,3a, 4,6,6a- hexahydropyrrolo [ -c] pyrrol-5-yl) -2-sulfanylidenemethyl] -6-oxopyrimidin-1- yl] methyl] phenyl] phenyl] -4H- On;

228) 3- (4'- ((2-Butyl-5- (2- (hexahydrocyclopenta [c] pyrrol- Oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

229) 3- [2- [4 - [[5- [2- (1,3,4,6,7,8,9,9a-octahydropyrido [1,2- a] pyrazin- ) -2-sulfanylideneethyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H- On;

230) 3- [2- [4 - [[5- [2- (2,3,3a, 4,5,6,7a-octahydroindol- -2-butyl-4-methyl-6-oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -2H-1,2,4-oxadiazol-5-one;

231) 3- [2- [4 - [[5- [2- (7-Azabicyclo [2.2.1] heptan-7-yl) -2-sulfanylidenemethyl] -4- -2-propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

232) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- [2-sulfanylidene-2- [4- (trifluoromethyl) piperidin- Yl] ethyl] pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

233) 3- [2- [4 - [[5- [2- (8-Azaspiro [4.5] decan-8-yl) -2- sulfanylidenemethyl] -Oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

234) 3- [2- [4 - [[5- [2- (8-Azaspiro [4.5] decan-8-yl) -2-sulfanylidenemethyl] -4- -Propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

235) 3- [2- [4 - [[2-butyl-5- [2- (4,4-dimethylpiperidin- 1 -yl) -2-sulfanylidenemethyl] -Oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

236) 3- [2- [4 - [[5- [2- (4,4-Dimethylpiperidin- 1 -yl) -2-sulfanylidenemethyl] -Propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

237) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-sulfanylidene-4H-1,2,4-oxadiazol- ] Phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylethanethioamide;

238) 5- [2- (1,3,3a, 4,5,6,7,7a-octahydroisoindol-2-yl) -2-sulfanylideneethyl] -2-butyl- 3 - [[4- [2- (5-sulfanylidene-4H-1,2,4-oxadiazol-3-yl) phenyl] phenyl] methyl] pyrimidin-4-one;

239) 2-Butyl-6-methyl-5- [2- (4-methylpiperidin- 1 -yl) -2-sulfanylidenemethyl] -3 - [[4- [2- Di-4H-1,2,4-oxadiazol-3-yl) phenyl] phenyl] methyl] pyrimidin-4-one;

240) 3- [2- [4 - [[2-butyl-5- [2- (2,5-dimethylpyrrolidin- 1 -yl) -2-sulfanylidenemethyl] -Oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

241) 3- [2- [4 - [[2-butyl-5- [2 - [(2S, 6R) -2,6- dimethylpiperidin- 1 -yl] -2-sulfanylidenemethyl] -4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H6- 1,2,4-oxadiazol-5-one;

242) 3- [2- [4 - [[5- [2 - [(4aS, 7aR) -1,3,4,4a, 5,6,7,7a-octahydrocyclopenta [c] Methyl] -6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazole- 5-one;

243) 3- [2- [4 - [[2-Butyl-4-methyl-5- [2 - [(2S) -2-methylpyrrolidin- 1 -yl] -2-sulfanylidenemethyl] 6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

244) 3- [2- [4 - [[2-Butyl-4-methyl-5- [2 - [(2R) -2- methylpyrrolidin- 6-oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

245) 3- [2- [4 - [[5- [2- (7-Azabicyclo [2.2.1] heptan-7-yl) -2-sulfanylideneethyl] -2- -6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

246) 3- (4 '- ((2-Butyl-4-methyl-5- (2- Yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) - On;

247) 3- (4'- ((2-Butyl-4-methyl-6-oxo-5- (2-thioxo-2- (3- (trifluoromethyl) -5,6-dihydro- [ Yl) methyl) biphenyl-2-yl) -1,2,3,4-tetrahydroisoquinoline; 4-oxadiazol-5 (4H) -one;

248) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylethanethioamide;

249) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylethanethioamide;

250) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a-octahydroisoindol-2-yl) -2-sulfanylidenemethyl ] -2-butyl-4-cyclopropyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

251) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-methyl-N- (2-methylpropyl) ethanethioamide;

252) 3- [2- [4 - [[2-Butyl-4-cyclopropyl-6-oxo-5- (2-piperidin- 1 -yl- 2- sulfanylideneethyl) pyrimidin- Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

253) 3- (4'- ((2-Butyl-4-cyclopropyl-6-oxo-5- (2- (pyrrolidin- 1 -yl) -2- thioxoethyl) pyrimidin- Yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

254) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (2,6- dimethylpiperazin- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

255) (S) -3- (4 '- ((2-Butyl-4-cyclopropyl- 5- (2- (2-methylpyrrolidin- Oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

256) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (3,5- dimethylpiperidin- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

257) 2- (2-Butyl-4-cyclopropyl-6-oxo-l - ((2 '-( 5-oxo-4,5-dihydro- ) Biphenyl-4-yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N- cyclopropylethanethioamide;

258) 2- (2-Butyl-4-cyclopropyl-6-oxo-1 - ((2 '-( 5-oxo-4,5- dihydro- ) Biphenyl-4-yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N, N-diethylethanethioamide;

259) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (3,5- dimethylmorpholino) -2- thioxo- ethyl) 1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

260) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2 - ((2S, 6R) -2,6-dimethylpiperidin- Ethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

261) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2-morpholino- 2- thioxoethyl) -6-oxopyrimidin- 1 (6H) ) Biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

262) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (2- methylpiperidin- 1 -yl) -2- thioxoethyl) -6-oxopyrimidine -1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

263) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (4- hydroxypiperidin- 1 -yl) -2- thioxoethyl) (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

264) 3- [2- [4 - [[2-Butyl-6-oxo-4-propan-2-yl- 5- (2- pyrrolidin- 1 -yl- 2- sulfanylideneethyl) -1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

265) 3- [2- [4 - [[2-Butyl-6-oxo-5- (2-piperidin- 1 -yl-2-sulfanylidenemethyl) -4- propan- -1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

266) 3- [2- [4 - [[2-butyl-5- [2- (2,6- dimethylpiperazin- 1 -yl) -2-sulfanylidenemethyl] Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

267) 2- [2-butyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Yl] -N, N-dimethylethanethioamide;

268) 2- [2-Butyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- 4-propan-2-ylpyrimidin-5-yl] -N, N-diethylethanethioamide;

269) 2- [2-butyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- 4-propan-2-ylpyrimidin-5-yl] -N-methyl-N-propan-2-ylethanethioamide;

270) 2- [2-Butyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- 4-propan-2-ylpyrimidin-5-yl] -N-cyclopropylethanethioamide;

271) 3- (4 '- ((2-Butyl-4-isopropyl-5- (2- Yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole (commercially available) ≪ / RTI > 5 (4H) -one;

272) 3- (4'- ((2-Butyl-5- (2- (3,5-dimethylpiperidin- 1 -yll) -2-thioxoethyl) Oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

273) 3- (4 '- ((2-Butyl-5- (2 - ((2R, 6S) -2,6-dimethylpiperidin- Isopropyl-6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

274) 3- (4'- ((2-Butyl-4-isopropyl-5- (2- (2-methylpiperidin- 1 -yl) -2-thioxoethyl) -6-oxopyrimidine -1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

275) 3- (4'- ((2-Butyl-4-isopropyl-5- (2- (3-methylpiperidin- 1 -yl) -2-thioxoethyl) -6-oxopyrimidine -1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

276) 3- (4'- ((2-butyl-4-isopropyl-5- (2-morpholino-2- thioxoethyl) -6-oxopyrimidin- ) Biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

277) 3- (4 '- ((2-Butyl-5- (2- (2,6- dimethylmorpholino) -2-thioxoethyl) -4-isopropyl-6-oxopyrimidine- 1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

278) (S) -3- (4 '- ((2-Butyl-4-isopropyl- Oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;

279) 2- [2-Butyl-4-ethyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-dimethylethanethioamide;

280) 2- [2-Butyl-4-ethyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylethanethioamide;

281) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a-octahydroisoindol-2-yl) -2-sulfanylidenemethyl ] -2-butyl-4-ethyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

282) 3- [2- [4 - [[2-Butyl-4-ethyl-6-oxo-5- (2- pyrrolidin- 1 -yl- 2- sulfanylideneethyl) pyrimidin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

283) 3- [2- [4 - [[2-Butyl-4-ethyl-6-oxo-5- (2-piperidin- 1 -yl-2-sulfanylidenemethyl) pyrimidin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

284) 3- [2- [4 - [[2-Butyl-4-ethyl-5- (2-morpholin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

285) 3- [2- [4 - [[2-Butyl-4-ethyl-5- [2- (4-methylpiperidin- 1 -yl) -2-sulfanylideneethyl] -6- Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;

286) 3- [2- [4 - [[2-butyl-5- [2- (3,3- dimethylpiperidin- 1 -yl) -2-sulfanylidenemethyl] -Oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one; And

287) 3- [2- [4 - [[2-Butyl-5- [2- (3,5- dimethylmorpholin-4-yl) -2- sulfanylidenemethyl] Oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one.

In the present invention, the pharmaceutically acceptable salt means a salt commonly used in the pharmaceutical industry. Examples of the salt include inorganic ion salts such as calcium, potassium, sodium and magnesium, hydrochloric acid, nitric acid, phosphoric acid, Inorganic acid salts prepared from iodic acid, perchloric acid, sulfuric acid and the like; But are not limited to, acetic, trifluoroacetic, citric, maleic, succinic, oxalic, benzoic, tartaric, fumaric, mandelic, propionic, lactic, glycolic, gluconic, galacturonic, glutamic, glutaric, Organic acid salts prepared from acids, ascorbic acid, carbonic acid, vanillyric acid, hydroiodic acid and the like; Methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and naphthalenesulfonic acid; Amino acid salts prepared with glycine, arginine, lysine and the like; And amine salts prepared by using trimethylamine, triethylamine, ammonia, pyridine, picoline, and the like. However, the types of salts used in the present invention are not limited by the listed salts.

The compounds of formula I of the present invention may contain one or more asymmetric carbons and may thus exist as racemates, racemic mixtures, single enantiomers, diastereomer mixtures and individual diastereomers have. Such isomers can be separated by conventional techniques, for example, by partitioning, such as by column chromatography or HPLC, the compounds of formula (I). Alternatively, stereoisomers of each of the compounds of formula (I) can be stereospecifically synthesized using optically pure starting materials and / or reagents of known sequence.

Process for the preparation of compounds of formula (I)

The present invention provides a process for preparing a compound represented by the formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof.

Compound 3 is obtained from a commercially available compound 1 and compound 2 via a base, and compound 5 is obtained through ring-forming reaction of amidyne 4. Compound 7 is obtained through polymerization using Compound 6 and a base, and then the cyano group is converted to an oxadiazolone by a known method to obtain Compound 11.

Compound 11 was hydrolyzed and then reacted with various alcohols to obtain various kinds of esters. Amide compounds were obtained by amine and transester reaction, and thioamide compounds were obtained using Lawson's reagent.

Compositions comprising a compound of formula I, use thereof and methods of treatment using the same

The present invention provides a pharmaceutical composition for the treatment or prevention of hypertension or diabetes comprising as an active ingredient a compound represented by the following formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof.

(I)

Wherein the formula (I) is as defined above.

In the present invention, the hypertension may be essential hypertension, and the diabetes may be type 2 diabetes.

According to one embodiment of the present invention, the compounds of the present invention exhibit pharmacological activity against both hypertension and diabetes. Accordingly, the pharmaceutical composition of the present invention can be usefully used for treating or preventing hypertension and diabetes simultaneously.

The pharmaceutical composition of the present invention may further comprise at least one pharmaceutically acceptable carrier in addition to the compound represented by the above-mentioned formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof for administration. The pharmaceutically acceptable carrier may be a mixture of saline, sterilized water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components. If necessary, an antioxidant, , And other conventional additives such as a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Accordingly, the composition of the present invention may be a patch, a liquid, a pill, a capsule, a granule, a tablet, a suppository, or the like. These formulations may be prepared by conventional methods used in the art for formulation, or by methods disclosed in Remington's Pharmaceutical Science (recent edition), Mack Publishing Company, Easton PA, and may be formulated into a variety of formulations, .

The composition of the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) depending on the intended method, and the dose may be appropriately determined depending on the patient's weight, age, , Diet, administration time, method of administration, excretion rate, and severity of the disease. The daily dose of the compound represented by the formula (I) of the present invention is about 1 to 1000 mg / kg, preferably 5 to 100 mg / kg, and can be administered once a day or divided into several times a day.

The pharmaceutical composition of the present invention may further comprise at least one active ingredient which exhibits the same or similar medicinal effect in addition to the compound represented by the above-mentioned formula (I), its optical isomer or its pharmaceutically acceptable salt.

The present invention provides a method of treating hypertension or diabetes comprising administering to a mammal, including a human, a therapeutically effective amount of a compound represented by formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof do.

As used herein, the term " therapeutically effective amount " refers to the amount of the compound of formula (I) effective in the treatment of hypertension or diabetes.

The therapeutic method of the present invention not only treats the disease itself before the onset of the symptoms, but also inhibits or avoids the symptoms thereof, by administering the compound represented by the above formula (I). In the management of disease, the prophylactic or therapeutic dose of a particular active ingredient will vary depending on the nature and severity of the disease or condition, and the route by which the active ingredient is to be administered. The frequency of dose and dose will vary with the age, weight and response of the individual patient. Appropriate dosing regimens can be readily selected by those of ordinary skill in the art which will of course consider these factors. In addition, the therapeutic method of the present invention may further comprise administration of a therapeutically effective amount of a further active agent which is useful in the treatment of the disease together with the compound represented by the above general formula (I) With synergy or supplementary effects.

The present invention also provides the use of a compound represented by formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of hypertension or diabetes mellitus. The compound represented by the above formula (I) for the preparation of a medicament may be mixed with an acceptable adjuvant, diluent, carrier or the like, and may be prepared as a combined preparation together with other active agents to have a synergistic action of the active ingredients.

The matters mentioned in the composition, use and treatment method of the present invention are applied as long as they are not mutually contradictory.

The pyrimidone derivative compounds of the present invention exhibit therapeutic activity for hypertension and / or diabetes.

Hereinafter, the present invention will be described in more detail with reference to the following examples and experimental examples. However, these examples and experimental examples are provided for illustrative purposes only in order to facilitate understanding of the present invention, and the scope of the present invention is not limited by the following examples and experimental examples.

< Example  1 > Ethyl 2- (2-butyl-4- Isopropyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine Yl) acetate { Ethyl  2- (2-butyl-4-isopropyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3- yl) biphenyl-4-yl ) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

[Step 1] Synthesis of ethyl 2- (2-butyl-1 - ((2'-cyanobiphenyl-4-yl) methyl) -4-isopropyl-6-oxo-1,6-dihydropyrimidine- Preparation of Ethyl 2- (2-butyl-1- (2'-cyanobiphenyl-4-yl) methyl) -4-isopropyl-6-oxo-1,6-dihydropyrimidin-

To a flask was added ethyl 2- (2-butyl-4-isopropyl-6-oxo-1,6-dihydropyrimidin-5-yl) acetate (28.0 g, Phenyl-2-carbonitrile (29.9 g, 0.11 mol) was added thereto, and then 132 mL of a mixed solution of 9: 1 ethyl acetate / dimethylformamide was injected. After stirring for 30 minutes at room temperature, lithium hydride (950 mg, 0.12 mol) was added in portions. The mixed solution was stirred at 65 ° C for 15 hours and then concentrated under reduced pressure to remove the solvent. 150 mL of ethyl acetate and 150 mL of purified water were added to separate the organic layer. The separated organic layer was dried with 1 g of magnesium sulfate, filtered and concentrated. The residue was purified by chromatography using 2: 1 ethyl acetate / n-hexane to give 22 g (yield: 47.3%) of the title compound as an off-white solid.

^{1 H-NMR (400MHz):} δ 0.93 (t, 3H), 1.29 (t, 3H), 1.42 (m, 2H), 1.71 (m, 2H), 2.33 (s, 3H), 2.69 (t, 2H) 2H), 7.27 (d, 2H), 7.53 (d, 2H), 7.73 (s, 2H) 7.80 (t, 1 H)

[Step 2] (Z) -ethyl 2- (2-butyl-1 - ((2 '- (N'-hydroxycarbamimidoyl) (2 '- (N'-hydroxycarbamimidoyl) biphenyl-4-yl) methyl) - (2- -4-isopropyl-6-oxo-1,6-dihydropyrimidin-5-yl) acetate}

To the flask was added the compound prepared in Step 1 (13.2 g, 28 mmole), 72 mL of dimethylsulfide was added, and then 50% ammonium hydroxide aqueous solution (7.2 mL, 118 mmole) Lt; / RTI &gt; After the completion of warm stirring, the mixture was concentrated under reduced pressure, 300 mL of ethyl acetate and 150 mL of purified water were added to separate the organic layer. The separated organic layer was dried with 1 g of magnesium sulfate, filtered and concentrated. The residue was purified by chromatography using 1: 2 ethyl acetate / n-hexane to obtain 11.7 g (yield: 86.0%) of the title compound as a pale yellow liquid.

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.28 (t, 3H), 1.41 (m, 2H), 1.68 (m, 2H), 2.32 (s, 3H), 2.67 (t, 2H) 2H), 4.63 (s, 2H), 3.64 (s, 2H), 4.21 (q, 2H), 4.42 7.80 (d, 1 H)

[Step 3] Preparation of ethyl 2- (2-butyl-4-isopropyl-6-oxo-l - ((2 '- (5-oxo-4,5- dihydro- Yl) methyl) -1,6-dihydropyrimidin-5-yl) acetate {Ethyl 2- (2-butyl-4-isopropyl-6-oxo- 4-yl) methyl) -1,6-dihydropyrimidin-5-yl) acetate}, which is a compound of formula

To the flask was added the compound prepared in Step 2 (12.3 g, 24.8 mmole) and 62 mL of a dimethylsulfide solution was introduced. 6.28 mL of dimethyl carbonate was added maintaining the temperature below 10 &lt; 0 &gt; C, and 28% sodium methoxide (9.4 mL, 73.8 mmole) was slowly added dropwise over 15 minutes. After the dropwise addition was completed, the mixture was stirred at room temperature for 10 minutes, 150 mL of cold purified water and 200 mL of chloroform were poured, 2N-hydrochloric acid aqueous solution was added dropwise to adjust the pH to 3 to 3.5 and the chloroform layer was separated. The separated chloroform layer was washed with 150 mL of purified water and 150 mL of brine, dried with 1 g of magnesium sulfate, filtered and concentrated. The residue was treated with 1: 1 ethyl acetate / n-hexane (100 mL) to obtain 6.65 g (Yield: 50.6%) of the title compound as a pale yellow solid.

^{1 H-NMR (400MHz):} δ 0.94 (t, 3H), 1.28 (t, 3H), 1.43 (m, 2H), 1.72 (m, 2H), 2.32 (s, 3H), 2.69 (t, 2H) 2H), 7.33 (d, 2H), 7.43 (m, IH), 7.53 (t, IH) 7.63 (d, 1 H), 7.82 (d, 1 H), 8.19 (b, 1 H)

<Example 2> 2- (2-butyl-4-isopropyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol- 3- yl) biphenyl-4-yl) methyl) -l, 6-dihydro-pyrimidin-5-yl) acetic acid {2- (2- butyl -4- isopropyl -6- oxo -1 - ((2 ' - (5- oxo- 4,5- dihydro- 1,2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1,6-dihydropyrimidin-5-yl) acetic acid }

The compound prepared in Example 1 (6.2 g, 11.7 mmole) was added to the flask and 50 mL of methyl alcohol was introduced. 10 mL of a 2.5N sodium hydroxide aqueous solution was added dropwise while keeping the temperature at 15 DEG C or lower, and the mixture was stirred at room temperature for 15 hours. After stirring at room temperature, the mixture was concentrated under reduced pressure, and 150 mL of chloroform and 150 mL of purified water were poured. A 2N hydrochloric acid aqueous solution was added dropwise to adjust the pH to 3 to 4 and the chloroform layer was separated. The separated chloroform layer was washed with 150 mL of purified water, dried with 1 g of magnesium sulfate, filtered and concentrated. The residue was treated with 1: 2 ethyl acetate / n-hexane (60 mL) to obtain 4.4 g (yield: 75.7%) of the title compound as a pale yellow solid.

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.42 (m, 2H), 1.72 (m, 2H), 2.33 (s, 3H), 2.65 (t, 2H), 3.49 (s, 2H) 2H), 7.28 (d, 2H), 7.41 (m, IH), 7.51 (t, IH), 7.61

< Example  3> methyl  2- (2-Butyl-4- methyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4-ox buy Yl) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine Yl) acetate { Methyl  2- (2- butyl -4- methyl -6- oxo -1 - ((2 '-( 5- oxo -4,5- dihydro -L, 2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

[Step 1] 2- (2-Butyl-4-methyl-6-oxo-1 - ((2- Yl) methyl) -1,6-dihydropyrimidin-5-yl) acetic acid {2- (2-butyl- 4- methyl- 5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1,6-dihydropyrimidin-5-yl) acetic acid}

The starting material was synthesized by the same synthetic procedure as in Examples 1 and 2 using ethyl 2- (2-butyl-4-methyl-6-oxo-1,6-dihydropyrimidin-5-yl) To obtain the title compound (yield: 50%) of white powder.

[Step 2] Synthesis of methyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro- Yl) methyl) -1,6-dihydropyrimidin-5-yl) acetate {Methyl 2- (2-butyl- - (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1,6-dihydropyrimidin-5-yl)

To the flask was added the compound prepared in Step 1 (5.0 mmole) and 50 mL of methyl alcohol was injected. 1 mL of sulfuric acid was added, and the mixture was refluxed for 16 hours. After cooling to room temperature, the mixture was concentrated under reduced pressure, then 150 mL of chloroform and 150 mL of purified water were injected, and the chloroform layer was separated. The separated chloroform layer was washed with 150 mL of purified water, dried with 1 g of magnesium sulfate, filtered and concentrated. The title compound was obtained as a white solid (yield: 90%, 4.5 mmole) using 60 mL of 1: 2 ethyl acetate / n-hexane as a residue.

¹ H-NMR (400 MHz, CDCl ₃ ):? 0.86-0.92 (3H, t), 1.31-1.40 (2H, m), 1.57-1.68 (2H, m), 2.24 2H), 3.56 (3H, s), 3.99-4.04 (2H, t), 5.23 (2H, s), 7.12-7.71

< Example  4 to Example  26>

Examples 4 to 26 were synthesized in the same manner as in Example 3 except that alcohols were used as solvents or 2 equivalents of alcohol and THF solvent.

< Example  4> propyl 2- (2-butyl-4- methyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine Yl) acetate { Propyl  2- (2- butyl -4- methyl -6- oxo -1 - ((2 '-( 5- oxo -4,5- dihydro -L, 2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

¹ H-NMR (400 MHz):? 0.86-0.92 (6H, m), 1.31-1.40 (2H, m), 1.57-1.68 (4H, m), 2.24 ), 3.50 (2H, s), 3.99-4.03 (2H, t), 5.23 (2H, s), 7.11-7.71 (8H,

< Example  5> Butyl 2- (2-butyl-4- methyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4-ox buy Yl) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine Yl) acetate { Butyl  2- (2- butyl -4- methyl -6- oxo -1 - ((2 '-( 5- oxo -4,5- dihydro -L, 2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

¹ H-NMR (400 MHz):? 0.86-0.92 (6H, m), 1.29-1.40 (4H, m), 1.54-1.68 (4H, m), 2.24 ), 3.49 (2H, s), 4.04-4.07 (2H, t), 5.23 (2H, s), 7.12-7.72

< Example  6> Pentyl  2- (2-Butyl-4- methyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4-ox buy Yl) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine Yl) acetate { Pentyl  2- (2- butyl -4- methyl -6- oxo -1 - ((2 '-( 5- oxo -4,5- dihydro -L, 2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

¹ H-NMR (400 MHz):? 0.86-0.90 (6H, m), 1.26-1.40 (6H, m), 1.56-1.68 (4H, m), 2.23 (3H, s), 2.59-2.63 ), 3.49 (2H, s), 4.02-4.06 (2H, t), 5.23 (2H, s), 7.11-7.71

< Example  7> Isopropyl  2- (2-Butyl-4- methyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine Yl) acetate; Isopropyl  2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3- yl) biphenyl-4-yl ) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

¹ H-NMR (400 MHz):? 0.87-0.91 (3H, t), 1.20-1.21 (6H, d), 1.31-1.41 (2H, m), 1.61-1.69 ), 2.60-2.64 (2H, t), 3.47 (2H, s), 4.93-5.02 (1H, m), 5.23 (2H, s), 7.12-7.73

< Example  8> Isobutyl  2- (2-Butyl-4- methyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine Yl) acetate { Isobutyl  2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3- yl) biphenyl-4-yl ) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

^{1 H-NMR (400MHz):} δ 0.87-0.91 (9H, m), 1.32-1.41 (2H, m), 1.62-1.70 (2H, m), 1.85-1.95 (1H, m), 2.26 (3H, s ), 2.62-2.66 (2H, t), 3.52 (2H, s), 3.84-3.85

< Example  9> 2- Methyl butyl  2- (2-Butyl-4- methyl -6-oxo-1 - ((2 '- (5-oxo- Below Yl) methyl) -1,6-dihydropyrimidin-5-yl) acetate {2- 메틸butyl  2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3- yl) biphenyl-4-yl ) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

¹ H-NMR (400 MHz):? 0.85-0.90 (9H, m), 1.09-1.20 (1H, m), 1.31-1.41 (3H, m), 1.61-1.72 ), 2.60-2.64 (2H, t), 3.51 (2H, s), 3.83-3.97 (2H, m), 5.23 (2H, s), 7.13-7.73

< Example  10> Benzyl 2- (2-butyl-4- methyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine Yl) acetate { Benzyl  2- (2- butyl -4- methyl -6- oxo -1 - ((2 '-( 5- oxo -4,5- dihydro -L, 2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

¹ H-NMR (400 MHz):? 0.87-0.91 (3H, t), 1.31-1.41 (2H, m), 1.61-1.69 (2H, m), 2.23 ), 3.56 (2H, s), 5.10 (2H, s), 5.23 (2H, s), 7.12-7.73

< Example  11> 2- Methoxyphenethyl  2- (2-Butyl-4- methyl -6-oxo-1 - ((2 ' - (5-oxo-4,5-dihydro- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyri 5- &lt; / RTI &gt; yl) acetate {2- 메틸oxyphenethyl  2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3- yl) biphenyl-4-yl ) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

¹ H-NMR (400 MHz, CDCl ₃ ):? 0.87-0.90 (3H), 1.30-1.42 (2H), 1.62-1.70 (2H), 2.23 (3H), 2.60-2.65 3.89 (3H), 5.11 (2H, s), 5.23 (2H, s), 7.12-7.73

< Example  12> Cyclohexyl  2- (2-Butyl-4- methyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine 5-yl) acetate { Cyclohexyl  2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3- yl) biphenyl-4-yl ) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

¹ H-NMR (400 MHz):? 0.89-0.93 (3H, t), 1.32-1.84 (14H, m), 2.28 (3H, s), 2.65-2.69 4.73-4.79 (1H, m), 5.28 (2H, s), 7.18-7.82 (8H, m)

< Example  13> (1r, 4r) -4- Methylcyclohexyl  2- (2-Butyl-4- methyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- die Yl) acetate &lt; RTI ID = 0.0 &gt; {( 1r, 4r )-4- methylcyclohexyl  2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3- yl) biphenyl-4-yl ) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

¹ H-NMR (400 MHz):? 0.89-0.93 (3H, t), 1.34-1.43 (2H, m), 1.64-1.72 ), 2.91-2.95 (2H, t), 3.51 (3H, s), 3.80 (3H, s), 4.25-4.288 7.08-7.79 (8 H, m)

< Example  14> 2- (2-Butyl-4- Cyclopropyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine Yl) acetic acid {2- (2- butyl -4- cyclopropyl -6- oxo -1 - ((2 '-( 5- oxo -4,5- dihydro -1,2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1,6-dihydropyrimidin-5-yl) acetic acid }

The starting material was synthesized in the same synthesis as in Examples 1 and 2 using ethyl 2- (2-butyl-4-cyclopropyl-6-oxo-1,6-dihydropyrimidin- (Yield: 35%) of the title compound as a white powder.

^{1 H-NMR (400MHz):} δ 0.95 (m, 5H), 1.20 (m, 2H), 1.38 (m, 2H), 1.71 (m, 2H), 2.05 (m, 1H), 2.61 (t, 2H) 2H), 7.31 (d, 2H), 7.41 (d, 1H), 7.54 (t, 1H) 7.66 (t, 1 H), 7.89 (d, 1 H)

< Example  15> 2- Methyl butyl  2- (2-Butyl-4- Isopropyl -6-oxo-1 - ((2 '- (5-oxo-4,5- Lee Hi Drow-1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydro Pyrimidin-5-yl) acetate {2- 메틸butyl  2- (2-butyl-4-isopropyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3- yl) biphenyl-4-yl ) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

¹ H-NMR (400 MHz):? 0.87-0.91 (9H, m), 1.15-1.16 (6H, d), 1.31-1.39 (2H, m), 1.60-1.70 (2H, s), 2.88-2.97 (1H, m), 2.61-2.66 (2H, t), 3.52 (2H, s), 3.83-3.85 , m)

< Example  16> pentan-3-yl 2- (2-butyl-4- Isopropyl -6-oxo-1 - ((2 '- (5-oxo-4,5- Lee Hi Drow-1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydro Pyrimidin-5-yl) acetate { Pentan -3- yl  2- (2-butyl-4-isopropyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3- yl) biphenyl-4-yl ) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

¹ H-NMR (400 MHz):? 0.87-1.10 (9H, m), 1.15-1.16 (6H, d), 1.31-1.39 (2H, m), 1.60-1.70 (2H, s), 2.88-2.97 (1H, m), 2.61-2.66 (2H, t), 3.52 (2H, s), 3.83-3.85 , m)

< Example  17> Isopropyl  2- (2-Butyl-4- Isopropyl -6-oxo-1 - ((2 '- (5-oxo-4,5- Lee Hi Drow-1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihyde Lt; RTI ID = 0.0 &gt; pyrimidin-5-yl) acetate { Isopropyl  2- (2-butyl-4-isopropyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3- yl) biphenyl-4-yl ) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

¹ H-NMR (400MHz):? 0.87-0.91 (9H, m), 1.15-1.16 (6H, d), 1.31-1.39 m), 2.61-2.66 (2H, t), 3.52 (2H, s), 3.83-3.85 (2H, d), 5.24 (2H, s), 7.13-7.76

< Example  18> 1- Methoxypropane 2 Yl 2- (2-Butyl-4- Isopropyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- die Yl) acetate &lt; RTI ID = 0.0 &gt; {1- methoxypropane -2- yl  2- (2-butyl-4-isopropyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3- yl) biphenyl-4-yl ) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

¹ H-NMR (400 MHz):? 0.87-0.91 (6H, m), 1.15-1.16 (6H, d), 1.31-1.39 (2H, m), 1.86-1.95 m), 2.61-2.66 (2H, t), 3.52 (2H, s), 3.83-3.85 (5H, m), 5.23 (2H, s), 7.13-7.77

< Example  19> Ethyl 2- (2-butyl-4- methyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine Yl) acetate { Ethyl  2- (2- butyl -4- methyl -6- oxo -1 - ((2 '-( 5- oxo -4,5- dihydro -L, 2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

^{1 H-NMR (400MHz):} δ 7.69-7.63 (m, 2H), 7.56-7.51 (m, 2H), 7.34 (d, 2H), 7.22 (d, 2H), 5.42 (s, 2H), 4.16 ( 2H), 1.25 (t, 3H), 0.88 (t, 2H), 3.63 (s, 2H) , 3H)

< Example  20> Ethyl 2- (2-butyl-4- methyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine -5-yl) propanoate { Ethyl  2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro- 1,2,4-oxadiazol-3- yl) biphenyl-4-yl ) methyl) -1,6-dihydropyrimidin-5-yl) propanoate}

^{1 H-NMR (400MHz):} δ 7.70-7.63 (m, 2H), 7.56-7.51 (m, 2H), 7.34 (d, 2H), 7.20 (d, 2H), 5.55 (s, 2H), 5.54- 2H), 2.31 (s, 2H), 1.60 (quint, 3H), 1.41-1.32 (m, 2H) m, 2H), 1.18 (t, 3H), 0.88 (t, 3H)

< Example  21 > Ethyl 2- (2-butyl-4- methyl -1 - ((2 ' - (4- methyl -5-oxo-4,5- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -6-oxo-1,6- Dihydropyrimidine 5-yl) acetate { Ethyl  2- (2-butyl-4-methyl-1 - ((2 '- (4-methyl-5-oxo-4,5- dihydro-1,2,4-oxadiazol- 3- yl) biphenyl-4-yl ) methyl) -6-oxo-1,6-dihydropyrimidin-5-yl) acetate}

^{1 H-NMR (400MHz):} δ 7.77-7.73 (m, 1H), 7.64-7.57 (m, 3H), 7.39 (d, 2H), 7.24 (d, 2H), 5.45 (s, 2H), 4.16 ( 2H), 1.25 (s, 2H), 2.65 (s, 3H), 2.65 (s, , 3H), 0.88 (t, 3H)

< Example  22 > Ethyl 2- (2- (1- Bromobutyl )-4- methyl -6-oxo-1 - ((2 ' - (5-oxo-4,5-dihydro- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyri 5-yl) acetate Trifluoroacetic acid salt  { Ethyl  2- (2- (1-bromobutyl) -4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3- yl) biphenyl -4-yl) methyl) -1,6-dihydropyrimidin-5-yl) acetate trifluoroacetic acid salt }

^{1 H-NMR (400MHz):} δ 7.71-7.65 (m, 2H), 7.58-7.50 (m, 2H), 7.38 (d, 2H), 7.25 (d, 2H), 5.97 (d, 1H), 5.13 ( (d, IH), 4.84 (m, IH), 4.21 (q, 2H), 3.68 (s, 2H), 2.37 , 1.28-1.26 (m, 3H), 1.25-1.18 (m, 2H), 0.80 (t, 3H)

< Example  23 > Ethyl 2- (2-butyl-4- methyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine 5-yl) -2-hydroxyacetate Trifluoroacetic acid salt  { Ethyl  2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3- yl) biphenyl-4-yl ) methyl) -1,6-dihydropyrimidin-5-yl) -2-hydroxyacetate trifluoroacetic acid salt }

^{1 H-NMR (400MHz):} δ 7.71-7.65 (m, 2H), 7.58-7.53 (m, 2H), 7.37 (d, 2H), 7.26 (d, 2H), 5.51 (m, 1H), 5.40 ( (m, 2H), 2.42 (s, 3H), 1.25 (t, 3H), 0.92

< Example  24> 3- [2- [4 - [[5- [2 - [(1R) -2,3,3a, 4,5,6,7,7a- Octahydroindole Yl] -2-oxo-ethyl] -2-butyl-4- Cyclopropyl -6-oxo-pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2 - [(1R) 3a, 4 , 5,6,7,7a- octahydroindol -One- yl ]-2- oxo - ethyl ]-2- butyl -4-cyclopropyl-6-oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

¹ H-NMR (400 MHz, CDCl ₃ ):? 0.95 (m, 5H), 1.15-1.17 (m, 4H), 1.35 (m, 4H), 1.63-1.67 2H), 7.15 (d, 2H), 2.2-2.4 (m, 2H), 2.64 (dd, 2H), 3.65-3.69 (m, 4H) , 7.26 (d, 2H), 7.41 (d, IH), 7.48 (t, IH), 7.61

< Example  25> Ethyl 2- (4- Rat Butyl-2-butyl-6-oxo-1 - ((2 '- (5- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine Yl) acetate { Ethyl  2- (4-tert-butyl-2-butyl-6-oxo-1 - ((2 '- (5-oxo- 4,5-dihydro-1,2,4-oxadiazol- -yl) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

^{1 H-NMR (400MHz):} δ 0.94 (t, 3H), 1.20 (t, 9H), 1.26 (t, 3H), 1.43 (m, 2H), 1.77 (m, 2H), 2.69 (t, 2H) 2H), 2.71 (s, 2H), 2.71 (s, 2H), 2.71 (s, 2H) 1H), 7.42 (d, IH), 7.51 (t, IH)

< Example  26> Phenyl  2- (2-Butyl-4- Isopropyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine 5-yl) acetate { Phenyl  2- (2-butyl-4-isopropyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3- yl) biphenyl-4-yl ) methyl) -1,6-dihydropyrimidin-5-yl) acetate}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.23 (d, 6H), 1.41 (m, 2H), 1.78 (m, 2H), 2.71 (t, 2H), 3.41 (q, 1H) 2H), 7.39 (d, 2H), 7.75 (m, 2H), 7.31 (m, 2H) 7.78 (d, 1 H)

< Example  27> 3- [2- [4 - [[2-Butyl-4- methyl -6-oxo-5- (2-oxo-2- Pyrrolidine -One- Yl ethyl Yl) methyl] phenyl] phenyl] -4H- 1,2,4-oxadiazol-5-one To a solution of 3- {2- [4 - [[2-butyl- -oxo-5- (2-oxo-2-pyrrolidin-1-ylethyl) pyrimidin-1-yl] methyl] phenyl] -4H-1,2,4-oxadiazol-

The compound (150 mg, 0.32 mmole) prepared in Step 1 of Example 3 was added to the flask and 10 mL of methylene chloride was introduced. Dimethylaminopropyl ethyl carbodiimide hydrochloride (81.1 mg, 0.41 mmole), hydroxybenzotriazole (55.4 mg, 0.41 mmole) and pyrrolidine (0.35 mmole) were added while keeping the temperature below 15 ° C, Triethylamine (97.1 mg, 0.96 mmole) was added dropwise and the mixture was stirred at room temperature for 15 hours. After stirring at room temperature, 50 mL of methylene chloride and 50 mL of purified water were added, and the organic layer was separated. The separated organic layer was dried with 1 g of magnesium sulfate, filtered and concentrated. The residue was purified by chromatography using 97: 3 chloroform / methyl alcohol to give the title compound (yield 81.3%) as a pale yellow liquid.

¹ H-NMR (400 MHz):? 0.91 (3H, t), 1.359-2.00 (8H, m), 2.29 (2H, s), 7.14-7.76 (8H, m)

&Lt; Examples 28 to 154 >

The following Examples 28 to 154 were synthesized in the same manner as in Example 27 using the respective amines.

< Example  28> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- methyl -N-propane-2- Diacetamide  Methyl] -6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylacetamide}

^{1 H-NMR (400MHz):} δ 0.86 (t, 3H), 1.08 (d, 3H), 1.19 (d, 3H), 1.43 (m, 2H), 1.74 (m, 2H), 2.28 (d, 3H) 2H), 2.67 (s, 3H), 2.67 (s, 2H), 2.67 2H), 7.19 (d, 2H), 7.26 (m, 2H), 7.41 (d,

< Example  29> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- Propyl acetamide  Methyl] -6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] pyrimidin-5-yl] -N-propylacetamide}

^{1 H-NMR (400MHz):} δ 0.86 (t, 3H), 0.92 (t, 3H), 1.41 (m, 4H), 1.71 (m, 2H), 2.41 (s, 3H), 2.67 (t, 2H) 2H), 7.41 (d, IH), 7.21 (d, IH), 7.13 (s, 7.50 (t, 1 H), 7.61 (t, 1 H), 7.78 (d, 1 H)

< Example  30> N-Butyl-2- [2-butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] Acetamide  Synthesis of {N-butyl-2- [2-butyl-4-methyl-6-oxo- 1 - [[4- [2- (5-oxo- phenyl] methyl] pyrimidin-5-yl] acetamide}

^{1 H-NMR (400MHz):} δ 0.86 (t, 3H), 0.92 (t, 3H), 1.28 (m, 2H), 1.41 (m, 4H), 1.71 (m, 2H), 2.38 (s, 3H) 2H), 2.67 (s, 2H), 2.67 (s, 2H), 3.67 (s, 2H) 1H), 7.41 (d, IH), 7.50 (t, IH)

< Example  31> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N, N- Diethylacetamide  Methyl] -6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] pyrimidin-5-yl] -N, N-diethylacetamide}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.12 (t, 3H), 1.21 (t, 3H), 1.39 (m, 2H), 1.71 (m, 2H), 2.31 (s, 3H) 2H), 2.64 (t, 2H), 3.35 (q, 3H), 3.46 (q, 3H), 3.58 (s, 2H) 7.61 (d, IH), 7.77 (d, IH)

< Example  32> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N-propane- 2-day acetamide  Methyl] -6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] pyrimidin-5-yl] -N-propan-2-ylacetamide}

^{1 H-NMR (400MHz):} δ 0.86 (t, 3H), 1.08 (d, 6H), 1.41 (m, 2H), 1.74 (m, 2H), 2.48 (s, 3H), 2.67 (t, 2H) 2H), 3.41 (s, 2H), 3.94 (s, 2H), 5.33 (s, 2H), 6.69 7.50 (t, 1 H), 7.61 (t, 1 H), 7.78 (d, 1 H)

< Example  33> 2- (2-Butyl-4- methyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4-ox buy Yl) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine 5-yl) -N-isopropyl-N-methylacetamide {2- (2-butyl- Preparation of 1,2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1,6-dihydropyrimidin-5-yl) -N-isopropyl-N-methylacetamide

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.04-1.06 (d, 6H), 1.37-1.75 (m, 4H), 2.45 (s, 2H), 3.90-3.99 (m, 4H), 5.32 (s, 2H), 6.54 (m, 1H), 7.1-7.8 (m, 8H)

< Example  34> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- methyl -N- (2- Methyl propyl ) Acetamide  Methyl] -6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] pyrimidin-5-yl] -N-methyl-N- (2-methylpropyl) acetamide}

^{1 H-NMR (400MHz):} δ 0.86 (d, 3H), 0.92 (t, 3H), 0.98 (d, 3H), 1.45 (m, 2H), 1.70 (m, 2H), 1.89-2.14 (mm, 2H), 2.29 (d, 2H), 2.29 (d, 2H), 2.29 (d, 2H), 7.19 (d, 2H), 7.26 (m, 2H), 7.41

< Example  35> 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- Octahydroisoindole Yl) -2- Oxoethyl ] -2-butyl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- 2-yl) -2-oxoethyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol- Produce

^{1 H-NMR (400MHz):} δ 0.89 (t, 3H), 1.37-1.69 (m, 14H), 2.19 (m, 1H), 2.28 (s, 3H), 2.29 (m, 1H), 2.64 (t, 2H), 3.34 (m, 2H), 3.36 (m, IH), 3.52 (d, 2H), 3.61 (m, ), 7.36 (d, IH), 7.45 (t, IH), 7.56 (t,

< Example  36> 3- [2- [4 - [[2-Butyl-4- methyl -6-oxo-5- (2-oxo-2-piperidin- Yl ethyl ) Pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Methyl-6-oxo-5- (2-oxo-2-piperidin-1-ylethyl) pyrimidin- phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.40 (m, 2H), 1.48-1.78 (m, 8H), 2.33 (s, 3H), 2.72 (t, 2H), 3.52 (t, 1H), 7.61 (d, IH), 7.41 (d, IH), 7.52 (s, 2H) ), 7.77 (d, 1 H)

< Example  37> 3- [2- [4 - [[2-Butyl-4- methyl -5- (2- Morpholine -4- Yl ethyl ) -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole 2-oxoethyl) -6-oxopyrimidin-1-yl] methyl] phenyl] -5- ] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.41 (m, 2H), 1.72 (m, 2H), 2.32 (s, 3H), 2.68 (t, 2H), 3.52-3.70 (m, 2H), 7.27 (d, 2H), 7.43 (m, 1H), 7.52 (t, 1H), 7.61 )

< Example  38> 3- [2- [4 - [[2-Butyl-5- [2- (3,5- Dimethylpiperidine Yl) -2- Oxoethyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5- one {3- [2- [4 - [[2-butyl-5- 2- (3,5-dimethylpiperidin- 1 -yl) -2-oxoethyl] -4-methyl-6- oxopyrimidin- -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

¹ H-NMR (400 MHz):? 0.92 (3H, t), 1.36-1.76 (14H, m), 2.31 (3H, s), 2.70 (2H, t), 3.51-3.57 2H, s), 7.20-7.84 (8H, m)

< Example  39> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- (1- Hydroxypropane -2 days) Acetamate Id {2- [2- butyl -4- methyl -6- oxo -1 - [[4- [2- (5- oxo -4H-1,2,4- oxadiazole 3-yl) phenyl] phenyl] methyl] pyrimidin-5-yl] -N- (1-hydroxypropan-2-yl) acetamide}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.05 (d, 3H), 1.39 (m, 2H), 1.78 (m, 2H), 2.31 (s, 3H), 2.71 (t, 2H) 2H), 7.28 (d, 2H), 7.41 (m, 1H, d, 2H), 3.21-3.35 ), 7.51 (t, IH), 7.61 (d, IH), 7.77 (d, IH)

< Example  40> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N, N- Dimethylacetamide  Methyl] -6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] pyrimidin-5-yl] -N, N-dimethylacetamide}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.39 (m, 2H), 1.70 (m, 2H), 2.34 (s, 3H), 2.62 (t, 2H), 2.94 (s, 3H) 2H), 7.28 (d, 2H), 7.41 (m, IH), 7.51 (t, IH) 7.61 (d, 1 H), 7.77 (d, 1 H)

< Example  41> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- Methoxy -N- Methyl acetamide  Methyl] -6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] pyrimidin-5-yl] -N-methoxy-N-methylacetamide}

^{1 H NMR (400 MHz, CDCl} 3): δ 0.92 (t, 3H), 1.36-1.45 (m, 2H), 1.67-1.74 (m, 2H), 2.18 (s, 4H), 2.30 (s, 3H) 2H), 3.20 (s, 3H), 2.71 (s, 2H)

< Example  42> 2-Butyl-N, N, 4- Trimethyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5- Carboxamide  2-butyl-N, N, 4-trimethyl-6-oxo-1 - [[4- [2- (5-oxo-4H- 1,2,4-oxadiazol- ] pyrimidine-5-carboxamide}

^{1 H-NMR (400MHz):} δ 0.88-0.92 (t, 3H), 1.32-1.42 (m, 2H), 1.60-1.70 (m, 2H), 2.21 (s, 3H), 2.67-2.70 (t, 2H ), 2.90 (s, 3H), 3.00 (s, 3H), 5.18-5.28 (m, 2H), 7.15-7.71

< Example  43> 2-Butyl-N, 4- Dimethyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] -N-propane-2- Ylpyrimidine -5- Carboxamide  Phenyl] phenyl] methyl] - &lt; / RTI &gt; (2-methyl- N-propan-2-ylpyrimidine-5-carboxamide}

^{1 H-NMR (400MHz):} δ 0.88-0.92 (t, 3H), 1.14-1.18 (m, 6H), 1.33-1.43 (m, 2H), 1.63-1.71 (m, 2H), 2.19-2.22 (d 2H), 2.74-2.87 (d, 3H), 3.77-3.83 (m, 0.5H), 4.84-4.95 (m, 0.5H), 5.17-5.31 , 7.16-7.73 (m, 8H)

< Example  44> 3- [2- [4 - [[2-Butyl-4- methyl -6-oxo-5- (piperidin-l- Carbonyl ) Pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Yl] methyl] phenyl] phenyl] -4H-pyrrolo [2,3-d] pyrimidin- -1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.90-0.94 (t, 3H), 1.35-1.45 (m, 4H, m), 1.65-1.73 (m, 6H), 2.26 (s, 3H), 2.68-2.72 (t 2H), 3.26-3.27 (m, 2H), 3.46-3.51 (m, 1H), 3.82-3.85

< Example  45> 3- [2- [4 - [[2-Butyl-4- methyl -5- ( Morpholine -4- Carbonyl ) -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Yl] methyl] phenyl] phenyl] -4H-pyrrolo [2,3-d] pyrimidin- 1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.90-0.94 (t, 3H), 1.34-1.45 (m, 2H), 1.61-1.73 (m, 2H), 2.30 (s, 3H), 2.69-2.73 (t, 2H ), 3.29-3.83 (m, 8H), 5.18-5.37 (m, 2H), 7.19-7.75 (m, 8H)

< Example  46> 3- [2- [4 - [[5- (1,3,3a, 4,5,6,7,7a- Octahydroisoindole -2- Carbonyl ) -2-butyl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[5- (1,3, 3a, 4 , 5,6,7,7a- octahydroisoindole -2- carbonyl )-2- butyl -4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

¹ H-NMR (400 MHz):? 0.90-0.94 (t, 3H), 1.35-1.46 (m, 4H), 1.65-1.74 ), 3.26-3.28 (m, 2H), 3.46-3.51 (m, IH), 3.82-3.85 (m, IH), 5.18-5.33 (m, 2H), 7.21-7.79

< Example  47> 2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] -N-propane-2- Ylpyrimidine -5- Carboxamide  2-butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo- propan-2-ylpyrimidine-5-carboxamide}

¹ H-NMR (400 MHz):? 0.90-0.94 (t, 3H), 1.20-1.21 (d, 6H), 1.35-1.450 (m, 2H), 1.69-1.76 , 5H), 4.12-4.20 (m, 1H), 5.34 (s, 2H), 7.21-7.85 (m, 8H)

< Example  48> 2-Butyl-N- Cyclohexyl -4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- buy Yl) Phenyl ] Phenyl ] methyl ] Pyrimidin-5- Carboxamide  4-methyl-6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] phenyl] methyl ] pyrimidine-5-carboxamide}

¹ H-NMR (400 MHz):? 0.90-0.94 (t, 3H), 1.18-1.95 (m, 14H), 2.70-2.74 (m, 5H), 3.85-3.92 ), 7.20-7.83 (m, 8H)

< Example  49> 2-Butyl-N, 4- Dimethyl -N- (2- Methyl propyl ) -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5- Carboxamide  Preparation of {2-butyl-N, 4-dimethyl-N- (2-methylpropyl) -6-oxo- 1 - [[4- [2- (5-oxo-4H- 1,2,4-oxadiazol- ) phenyl] phenyl] methyl] pyrimidine-5-carboxamide}

^{1 H-NMR (400MHz):} δ 0.79-0.98 (m, 10H), 1.36-1.45 (m, 2H), 1.66-1.74 (m, 2H), 2.01-2.10 (m, 2H), 2.27-2.28 (m 2H), 7.21-7.81 (m, 8H), 7.29 (s, 3H)

< Example  50> 3- [2- [4 - [[2-Butyl-5- (3,5- Dimethylpiperidine -One- Carbonyl )-4- methyl -6-ox Sophirimi 1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] phenyl} -1H-pyrazolo [3,4- ] -4H-1,2,4-oxadiazol-5-one}

¹ H-NMR (400 MHz):? 0.77-1.04 (m, 9H), 1.39-1.76 (m, 8H), 2.25-2.31 (m, 3H), 2.69-2.75 , 1.5H), 4.65-4.73 (m, 0.5H), 5.22-5.38 (m, 2H), 7.24-7.85 (m, 8H)

< Example  51> 2-Butyl-4- methyl -N- (2- Methyl propyl ) -6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] phenyl] methyl] pyrimidine- (2-butyl-4-methyl-N- (2-methylpropyl) -6-oxo-1 - [[4- [2- ] phenyl] methyl] pyrimidine-5-carboxamide}

¹ H-NMR (400 MHz):? 0.90-0.95 (m, 9H), 1.36-1.45 (m, 2H), 1.69-1.76 (m, 2H), 1.80-1.90 , 5H), 3.11-3.14 (t, 2H), 5.35 (s, 2H), 7.20-7. 84 (m, 8H)

< Example  52. 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- Octahydroisoindole Yl) -2- Oxoethyl ]-4- methyl -6-oxo-2- Propylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- 2-yl) -2-oxoethyl] -4-methyl-6-oxo-2-propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol- Produce

^{1 H-NMR (400MHz):} δ 0.95 (t, 3H), 1.35-1.49 (m, 8H), 1.70 (m, 2H), 2.17 (s, 2H), 2.27 (s, 3H), 2.61 (t, 2H), 7.07 (d, 2H), 7.17 (d, 2H), 7.29 (m, 2H) (d, IH), 7.35 (t, IH), 7.48 (t, IH), 7.59

< Example  53> N- Methoxy -N- methyl -2- [4- methyl Oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl ] Phenyl ] methyl ]-2- Propylpyrimidine -5 days] Acetamide  Phenyl-N-methoxy-N-methyl-2- [4-methyl-6-oxo- 1 - [[4- [2- (5-oxo- phenyl] methyl] -2-propylpyrimidin-5-yl] acetamide}

^{1 H-NMR (400MHz):} δ 0.95 (t, 3H), 1.68-1.74 (m, 2H), 2.28 (s, 3H), 2.61 (t, 2H), 3.17 (s, 3H), 3.69 (s, 2H), 7.27 (d, IH), 7.30 (d, IH), 7.42 (t, ), 7.55 (d, 1 H)

< Example  54> N, N- Dimethyl -2- [4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ]-2- Propylpyrimidine -5 days] Acetamide  Phenyl] phenyl] -1H-pyrazolo [3,4-d] pyrimidin-2-yl] methyl] -2-propylpyrimidin-5-yl] acetamide}

^{1 H-NMR (400MHz):} δ 1.02 (t, 3H), 1.74-1.80 (m, 2H), 1.84-1.87 (m, 1.7H), 2.40 (s, 3H), 2.91 (. S 3H), 3.13 2H), 7.38 (d, 2H), 7.38 (d, 2H), 3.57 (s, 2H) , 7.50 (t, IH), 7.60 (t, IH), 7.77 (d, IH)

< Example  55> 3- [2- [4 - [[4- methyl -6-oxo-5- (2-oxo-2- Pyrrolidine -One- Yl ethyl )-2- Propylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[4-methyl-6-oxo-5- (2-oxo- 2- pyrrolidin- 1 -ylethyl) -2-propylpyrimidin-1-yl] methyl] phenyl ] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.97 (t, 3H), 1.69-1.74 (m, 2H), 1.82-1.87 (m, 2H), 1.93-1.98 (m, 2H), 2.28 (s, 3H), 2H), 7.32 (s, 2H), 3.50 (s, 2H), 3.58 (t, 2H) (d, IH), 7.45 (t, IH), 7.56 (t, IH), 7.69

< Example  56> 3- [2- [4 - [[4- methyl -6-oxo-5- (2-oxo-2-piperidin- Yl ethyl )-2- Propylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[4-methyl-6-oxo-5- (2-oxo- 2- piperidin- 1 -ylethyl) -2-propylpyrimidin-1-yl] methyl] phenyl ] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.98 (t, 3H), 1.49-1.63 (m, 6H), 1.67-1.77 (m, 2H), 2.30 (s, 3H), 2.72 (t, 2H), 3.44- 2H), 7.26 (d, 2H), 7.38 (d, 1H), 7.46 (t, 1H), 7.58 (s, 2H) (t, 1 H), 7.70 (d, 1 H)

< Example  57> 3- [2- [4 - [[5- [2- (3,5- Dimethylpiperidine Yl) -2- Oxoethyl ]-4- methyl -6-oxo-2- Propylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5- one {3- [2- [4 - [[5- [2- (3,5-dimethylpiperidin-1-yl) -2-oxoethyl] -4-methyl-6-oxo-2- propylpyrimidine- 1 -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.83-0.96 (m, 9H), 1.42-1.61 (m, 2H), 1.66-1.72 (m, 2H), 1.80 (d, 1H), 1.95 (t, 1H), 2H), 2.91-2.98 (m, 0.3H), 3.20-3.27 (m, 0.3H), 3.47-3.66 (m, 3H), 2.27 (t, 2H), 7.37 (d, 1H), 7.44 (t, 1H), 7.89 (d, 2H) , 7.56 (t, 1 H), 7.65 (d, 1 H)

< Example  58> 3- [2- [4 - [[5- [2- (3,5- Dimethylmorpholine Yl) -2- Oxoethyl ]-4- methyl -6-oxo-2- Propylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[5- [2- (3,5-dimethylmorpholin-4-yl) -2-oxoethyl] -4-methyl-6-oxo-2-propylpyrimidin- -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.96 (t, 3H), 1.11-1.21 (m, 6H), 1.68-1.74 (m, 2H), 2.31 (s, 3H), 2.71 (t, 2H), 2.82 ( (d, 1H), 3.13-3.35 (m, 1H), 3.50-3.65 (m, 4H), 3.87 (s, 2H), 7.13 (d, 2H), 7.26 (d, 2H), 7.38

< Example  59> N- methyl -2- [4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ]-2- Propylpyrimidine -5-yl] -N-propan-2- Diacetamide  Phenyl] phenyl] methyl] -1H-pyrazolo [3,4-d] pyrimidin- -2-propylpyrimidin-5-yl] -N-propan-2-ylacetamide}

^{1 H-NMR (400MHz):} δ 0.98 (t, 3H), 1.04 (d, 3H), 1.21 (d, 3H), 1.66-1.76 (m, 2H), 2.34 (s, 3H), 2.67 (s, (M, 2H), 2.81 (s, 1H), 3.54 (s, 1H), 3.61 (s, 0.9H), 4.22-4.26 1H), 7.57 (d, 2H), 7.26 (d, 2H), 7.37 (d, 1H)

< Example  60> 3- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N, N- Dimethylpropanamide  Methyl] -6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] pyrimidin-5-yl] -N, N-dimethylpropanamide}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.40 (m, 2H), 1.85 (m, 2H), 2.43 (s, 3H), 2.52 (t, 2H), 2.64 (t, 2H) 2H), 2.86 (s, 3H), 3.21 (s, 3H), 5.26 (s, 2H), 7.27 (m, 5H), 7.42 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  61> 3- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- methyl -N-propane-2- Ylpropanamide Methyl] -6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylpropanamide}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.28 (t, 3H), 1.40 (m, 2H), 1.60 (m, 2H), 1.85 (m, 2H), 2.52 (t, 2H) 2H), 2.86 (t, 2H), 2.95 (s, 4H), 5.26 (s, 2H), 6.87 (d, 7.49 (t, 1 H), 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  62> 3- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- Cyclopropylpropanamide  Methyl] -6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] pyrimidin-5-yl] -N-cyclopropylpropanamide}

^{1 H-NMR (400MHz):} δ 0.80 (m, 5H), 0.91 (t, 3H), 1.40 (m, 2H), 1.85 (m, 2H), 2.64 (t, 2H), 2.86 (t, 2H) 2H), 7.27 (m, 5H), 7.42 (m, 1H), 7.49 (t,

< Example  63> 3- [2- [4 - [[2-Butyl-4- methyl -6-oxo-5- (3-oxo-3-piperidin- Sun Profile ) Pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Methyl-6-oxo-5- (3-oxo-3-piperidin-1-ylpropyl) pyrimidin- phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.40 (m, 2H), 1.70 (m, 3H), 1.96 (m, 2H), 2.10 (t, 2H), 2.36 (t, 2H) 2H), 7.25 (m, 2H), 7.42 (m, 1H), 7.94 (m, 2H) ), 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  64> 3- [2- [4 - [[2-Butyl-4- methyl -5- (3- Morpholine -4-yl-3- Oxopropyl ) -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Yl) methyl] phenyl] -5- {3- [2- [4 - [[2-butyl-4-methyl-5- (3-morpholin-4-yl-3-oxopropyl) -6-oxopyrimidin- ] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.40 (m, 2H), 1.70 (m, 2H), 2.64 (dd, 2H), 2.86 (t, 2H), 2.90 (m, 4H) 2H), 7.16 (d, IH), 7.27 (m, 4H), 7.42 (m, 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  65> 3- [2- [4 - [[5- [3- (1,3,3a, 4,5,6,7,7a- Octahydroisoindole Yl) -3- Oxopropyl ] -2-butyl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [3- (1,3,3a, 4,5,6,7,7a- 2-yl) -3-oxopropyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol- Produce

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.40 (m, 2H), 1.70 (m, 3H), 1.96 (m, 2H), 2.86 (t, 2H), 2.90 (m, 2H) 2H), 3.84 (m, 4H), 5.26 (s, 2H), 7.16 (d, 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  66> 3- [2- [4 - [[2-Butyl-4- methyl -5- [3- (4- Methylpiperidine Yl) -3- Oxopropyl ] -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole 5- {3- [4-methyl-5- [3- (4-methylpiperidin-1-yl) -3-oxopropyl] -6-oxopyrimidin-1-yl ] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.41 (m, 5H), 1.71 (m, 8H), 2.31 (s, 3H), 2.68 (t, 2H), 3.52 (m, 4H) , 7.28 (d, 2H), 7.42 (m, 1H), 7.48 (t, 1H), 7.61 7.77 (d, 1 H)

< Example  67> 3- [2- [4 - [[2-butyl-5- [3- (3,3- Dimethylpiperidine Yl) -3- Oxopropyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[2-butyl-5- 3- (3,3-dimethylpiperidin-1-yl) -3-oxopropyl] -4-methyl-6-oxopyrimidin- -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.43 (m, 6H), 1.52 (m, 5H), 1.85 (m, 3H), 2.64 (t, 2H), 2.86 (t, 2H) 2H), 3.20 (d, 2H), 3.50 (d, 2H), 3.85 (m, 4H), 5.26 (s, 2H) 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  68> 3- [2- [4 - [[2-butyl-5- [3- (3,5- Dimethylmorpholine Yl) -3- Oxopropyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[2-butyl-5-3- (3,5-dimethylmorpholin-4-yl) -3-oxopropyl] -4-methyl-6-oxopyrimidin- -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.20 (m, 6H), 1.40 (m, 2H), 1.70 (m, 2H), 2.64 (dd, 2H), 2.86 (t, 2H) 2H), 7.16 (d, 1H), 7.27 (m, 4H), 7.42 (m, 1H) 7.49 (t, 1 H), 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  69> 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- Octahydroisoindole Yl) -2- Oxoethyl ] -2-butan-2-yl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-yl] -one}

¹ H-NMR (400 MHz):? 0.72-0.76 (m, 3H), 1.16 (d, 3H), 1.36-1.87 (m, 12H), 2.31 2H), 7.36 (d, 1H), 7.46 (t, 2H), 7.24 (d, 2H) 1H), &lt; / RTI &gt; 7.71 (d, 1H)

< Example  70> 2- [2-butan-2-yl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- Methoxy -N- Methyl acetamide  4-methyl-6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol- phenyl] methyl] pyrimidin-5-yl] -N-methoxy-N-methylacetamide}

¹ H-NMR (400 MHz):? 0.76 (t, 3H), 1.16 (d, 3H), 1.46-1.55 (m, 2H), 7.27 (d, 2H), 7.39 (d, 2H), 3.78 (s, 3H) (d, IH), 7.47 (t, IH), 7.59 (t, IH), 7.71

< Example  71> 2- [2-butan-2-yl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N, N- Dimethylacetamide  4-methyl-6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol- phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylacetamide}

^{1 H-NMR (400MHz):} δ 0.75 (t 3H), 1.16 (d, 3H), 1.47-1.55 (m, 1H), 1.77-1.85 (m, 1H), 2.23 (s, 3H), 2.73-2.79 2H), 7.29 (d, 2H), 7.35 (m, 1H), 2.92 (s, 3H) (d, IH), 7.40 (t, IH), 7.54 (t, IH), 7.65

< Example  72> 2- [2-butan-2-yl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- methyl -N-propane-2- Acetic acid Di {2- [2- butan -2- yl -4- methyl -6- oxo -1 - [[4- [2- (5- oxo -4H-1,2,4- oxadiazole 3-yl) phenyl] phenyl] methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylacetamide}

^{1 H-NMR (400MHz):} δ 0.74 (t, 3H), 1.07 (d, 3H), 1.17 (d, 3H), 1.20 (d, 2H), 1.46-1.53 (m, 1H), 2.29 (s, 3H), 2.37-2.76 (m, 2.6H), 2.93 (s, 1.4H), 3.50-3.69 (m, 2H), 4.26-4.32 (m, 0.4H), 4.78-4.85 1H), 7.75 (d, IH), 7.37 (d, IH), 7.47 (d,

< Example  73> 3- [2- [4 - [[2-Butan-2-yl-5- [2- Dimethylpiperidine Yl) -2- Oxoethyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[2-butan-2-yl-5- [2- (2,6- dimethylpiperidin- 1- yl) -2-oxoethyl] -oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

¹ H-NMR (400 MHz):? 0.73 (t, 3H), 0.84-0.90 (m, 6H), 0.96 (d, 2H), 1.99 (t, 1H), 2.39 (s, 3H), 2.52 (t, 1H), 2.72-2.79 2H), 7.16 (d, 2H), 7.27 (d, &lt; RTI ID = 0.0 &gt; 2H), 7.37 (d, IH), 7.49 (d, IH), 7.59 (t, IH), 7.77

< Example  74> 3- [2- [4 - [[2-Butan-2-yl-5- [2- Dimethylmorpholine Yl) -2- Oxoethyl -4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H- 2-butan-2-yl-5- [2- (2,6-dimethylmorpholin-4-yl) -2-oxoethyl] -4-methyl-6-oxopyrimidin- -1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.76 (t, 3H), 1.15-1.22 (m, 9H), 1.48-1.55 (m, 1H), 1.66 (br, 1H), 1.78-1.84 (m, 1H), 4H), 3.92-4.03 (m, 1.4H), 4.39 (d, 2H), 2.33 (s, 3H), 2.74-2.86 2H), 7.60 (t, 2H), 7.80 (d, 2H), 7.37 (d, 2H) d, 1 H)

< Example  75> 3- [2- [4 - [[2-butyl-5- [2- (3,4- Dihydro -1H- Isoquinoline Yl) -2- Oxoethyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadai 2-yl) -2-oxoethyl] -4-methyl-isoxazol- 6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.90 (t, 3H), 1.38 (m, 2H), 1.66 (m, 3H), 1.96 (m, 3H), 2.66 (m, 2H), 3.21 (t, 2H) 2H), 7.21 (s, 2H), 7.02 (t, 1H), 7.14 (m, 4H), 7.25 7.62 (m, 1 H), 7.83 (d, 1 H), 8.14 (d, 1 H)

< Example  76> 3- [2- [4 - [[5- [2- (3,4,4a, 5,6,7,8,8a- Octahydro -1H- Isoquinoline Yl) -2- Oxoethyl ] -2-butyl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (3,4,4a, 5,6,7,8,8a- 2-yl) -2-oxoethyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol- -one}

^{1 H NMR (300 MHz, d6} -CDCl 3): δ 0.90 (t, 3H), 0.98-1.39 (m, 8H), 1.50-1.82 (m, 7H), 2.30 (d, 3H), 2.66 (m, 2H), 3.60 (s, 2H), 3.82-4.06 (dd, IH), 4.39-4.55 (dd, IH), 5.11 (m, 1 H), 7.62 (m, 1 H), 7.83 (d, 1 H)

< Example  77> 3- [2- [4 - [[2-Butyl-4- methyl -5- [2- (2- Methylpyrrolidine Yl) -2- Oxoethyl ] -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -2H-1,2,4- Oxadiazole Yl) -2-oxoethyl] -6-oxopyrimidin-1-yl- [ ] methyl] phenyl] phenyl] -2H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.90 (t, 3H), 1.12 (d, 2H), 1.27 (d, 1H), 1.38 (m, 2H), 1.66 (m, 3H), 1.96 (m, 3H) 2H), 2.27 (s, 3H), 2.65 (dd, 2H), 3.51 (m, 4H), 3.49 (m, 1H), 7.62 (m, 1H), 7.83 (m, 1H)

< Example  78> 3- [2- [4 - [[5- [2- (3,4,4a, 5,6,7,8,8a- Octahydro -2H-quinolin-1-yl) -2- Oxoethyl ] -2-butyl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -2H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (3,4,4a, 5,6,7,8,8a- 2H-quinolin-1-yl) -2-oxoethyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -2H-1,2,4-oxadiazol- -one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.38 (m, 6H), 1.66 (m, 6H), 1.96 (m, 3H), 2.27 (s, 3H), 2.65 (dd, 2H) 2H), 7.21 (m, 2H), 3.55 (m, 2H), 3.69 (m, 7.48 (m, 1 H), 7.62 (m, 1 H), 7.83 (d, 1 H)

< Example  79> 3- [2- [4 - [[2-butyl-5- (2-indol- Oxoethyl )-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -2H-1,2,4- Oxadiazole Methyl-6-oxopyrimidin-1-yl] methyl] phenyl] -5- ] phenyl] -2H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.38 (m, 2H), 1.66 (m, 2H), 2.37 (s, 3H), 2.67 (dd, 2H), 3.80 (s, 2H) 1H), 7.30 (s, 2H), 7.08 (m, 2H), 7.11 (m, 3H), 7.22 7.83 (d, 1 H)

< Example  80> 3- [2- [4 - [[2-Butyl- methyl -5- [2- (2- methyl -1,3,3a, 4,6,6a- Hexahydropyrrolo [3,4-c] pyrrole -5-yl) -2- Oxoethyl ] -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[2-butyl-4-methyl- 5- [2- (2- 3a, 4,6,6a-hexahydropyrrolo [3,4-c] pyrrol-5-yl) -2-oxoethyl] -6-oxopyrimidin-1-yl] methyl] phenyl] -oxadiazol-5-one} &lt; / RTI &gt;

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.38 (m, 6H), 1.66 (m, 2H), 2.41 (s, 3H), 2.67 (dd, 2H), 3.80 (m, 4H) 1H), 7.62 (m, 1H), 7.93 (m, 2H), 7.03 (d,

< Example  A mixture of 3- [2- [4 - [[5- [2- (3,3a, 4,5,6,6a- Hexahydro -1H- Cyclopenta [c] pyrrole Yl) -2- Oxoethyl ] -2-butyl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (3,3a, 4,5,6,6a-hexahydro- cyclopenta [c] pyrrol-2-yl) -2-oxoethyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4- -one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.38 (m, 2H), 1.46 (m, 2H), 1.66 (m, 3H), 1.82 (m, 3H), 2.27 (s, 3H) 1H), 3.67 (d, 2H), 3.67 (d, 2H), 2.67 (d, 1H), 7.62 (d, IH), 7.52 (d, 2H), 7.24 (m, 2H), 7.38

< Example  82> 3- [2- [4 - [[2-butyl-5- [2- (1,3- Dihydroisoindole Yl) -2-oxoethyl] -4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole 5- {3- [2- [4 - [[2- butyl -5- [2- (1,3- dihydroisoindole -2- yl )-2- oksoethyl ]-4- methyl -6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.38 (m, 2H), 1.66 (m, 2H), 2.37 (s, 3H), 2.67 (dd, 2H), 3.61 (s, 2H) 1H), 4.76 (s, 2H), 5.01 (s, 2H), 5.20 (s, 2H), 7.19 (m, 2H), 7.29 7.56 (m, 1 H), 7.76 (d, 1 H)

< Example  83> 3- [2- [4 - [[2-Butyl-4- methyl -6-oxo-5- [2-oxo-2- (4- Azeparidine -1-yl) ethyl] pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5- one {3- [2- [4 - [[2-butyl-4-methyl-6-oxo-5- [2-oxo- 2- (4-propan- 2- ylpiperidin- 1 -yl) ethyl] ] pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

^{1 H-NMR (400MHz):} δ 0.91 (m, 9H), 1.22 (m, 3H), 1.38 (m, 3H), 1.66 (m, 4H), 2.37 (s, 3H), 2.48 (t, 1H) 2H), 2.97 (t, 2H), 2.63 (s, 2H), 2.63 (t, 2H), 7.38 (m, IH), 7.48 (m, IH), 7.62

< Example  84> 3- [2- [4 - [[2-butyl-5- [2- (2,3- Dihydroindole Yl) -2- Oxoethyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Methyl-6-oxopyrimidin-1 &lt; / RTI &gt; -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.38 (m, 2H), 1.66 (m, 2H), 2.37 (s, 3H), 2.67 (dd, 2H), 3.61 (s, 2H) 2H), 7.19 (m, 2H), 7.29 (m, 5H), 7.38 (m, 3H), 7.48 7.56 (m, 1 H), 7.76 (d, 1 H)

< Example  85> 3- [2- [4 - [[2-butyl-5- [2- (4- Fluoro -1,3- Dihydroisoindole Yl) -2- Oxoethyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4-r2-butyl- 5- 2- (4- yl) -2-oxoethyl] -4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.38 (m, 2H), 1.66 (m, 2H), 2.37 (d, 3H), 2.67 (dd, 2H), 3.61 (s, 2H) (M, 3H), 7.08 (m, 3H), 7.08 (m, 2H) 7.48 (m, 1 H), 7.56 (m, 1 H), 7.76 (d, 1 H)

< Example  86> 2- [2- Cyclopropyl -4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- buy Yl) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N, N- Dimethylacetamide Id {2- [2- cyclopropyl -4- methyl -6- oxo -1 - [[4- [2- (5- oxo -4H-1,2,4- oxadiazole -3-yl) phenyl] phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylacetamide}

^{1 H-NMR (400MHz):} δ 0.96 (m, 2H), 1.17 (m, 2H), 1.81 (m, 1H), 2.21 (s, 3H), 2.91 (s, 3H), 3.55 (s, 2H) 1H), 7.74 (d, IH), 5.41 (s, 2H), 7.11 (m, 4H)

< Example  87> 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- Octahydroisoindole Yl) -2- Oxoethyl ]-2- Cyclopropyl -4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- 2-yl) -2-oxoethyl] -2-cyclopropyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol- Produce

^{1 H-NMR (400MHz):} δ 0.97 (m, 2H), 1.17 (m, 2H), 1.44-1.51 (m, 8H), 1.83 (m, 1H), 2.08 (m, 1H), 2.21 (s, (M, 2H), 2.32 (m, 2H), 3.32 (m, 2H), 3.45 ), 7.48 (m, IH), 7.62 (m, IH), 7.74 (d, IH)

< Example  88> 3- (4 '- ((2-Butyl-4- methyl -5- (2- ( Octahydro -1H-indol-1-yl) -2- Oxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadiazole -5 (4H) -one {3- (4 '- ((2- butyl -4- methyl -5- (2- ( octahydro -1H- indole -One- yl )-2- oksoethyl ) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H)

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.38 (m, 6H), 1.66 (m, 6H), 1.96 (m, 3H), 2.27 (s, 3H), 2.65 (dd, 2H) 2H), 7.21 (m, 2H), 3.55 (m, 2H), 3.69 (m, 7.48 (m, 1 H), 7.62 (m, 1 H), 7.83 (d, 1 H)

< Example  89> 3- (4 '- ((2-Butyl-5- (2- ( Dihydro -1H- Pyrido [l, 2-a] pyrazine -2 (6H, 7H, 8H, 9H, 9aH) -yl) -2- Oxoethyl )-4- methyl -6- Oxopyrimidine -1 (6H) -yl) methyl ) Bai Fee Yl) -1,2,4-oxadiazole-5 (4H) -one {3- (4 '- ((2-butyl- 5- 2- (dihydro- 2-a pyrazin-2 (6H, 7H, 8H, 9H, 9aH) -yl) -2-oxoethyl) -4-methyl- -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.42 (m, 4H), 1.67 (m, 6H), 1.96 (m, 3H), 2.27 (s, 3H), 2.40 (s, 2H) 2H), 7.33 (m, 3H), 7.41 (m, 2H), 2.73-3.20 (m, 5H), 3.51-4.05 , &Lt; / RTI &gt; 1H), 7.47 (m, 1H), 7.62

< Example  90> 3- [2- [4 - [[5- [2- (7- Azabicyclo [2.2.1] heptane -7-yl) -2- Oxoethyl ] -2-butyl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole 5- {3- [2- [4 - [[5- [2- (7- azabicyclo [2.2.1] heptane -7- yl )-2- oksoethyl ]-2- butyl -4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

^{1 H-NMR (400MHz):} δ 0.88 (t, 3H), 1.33-1.52 (m, 6H), 1.61-1.82 (m, 6H), 2.33 (s, 3H), 2.67 (t, 2H), 3.54 ( 2H), 7.25 (d, 2H), 7.36 (d, 1H), 7.43 (t, , 7.55 (t, 1 H), 7.66 (d, 1 H)

< Example  91> 3- [2- [4 - [[5- [2- (7- Azabicyclo [2.2.1] heptane -7-yl) -2- Oxoethyl ]-4- methyl -6-oxo-2- Propylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadia 5-one {3- [2- [4 - [[5- [2- (7- azabicyclo [2.2.1] heptane -7- yl )-2- oksoethyl ]-4- methyl -6-oxo-2-propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

^{1 H-NMR (400MHz):} δ 0.95 (t, 3H), 1.37-1.53 (m, 4H), 1.65-1.85 (m, 6H), 2.33 (s, 3H), 2.74 (t, 2H), 3.53 ( 2H), 7.26 (d, 2H), 7.36 (d, 1H), 7.44 (t, , 7.56 (t, 1 H), 7.66 (d, 1 H)

< Example  92> 3- [2- [4 - [[2-Butyl- methyl -6-oxo-5- [2-oxo-2- [4- ( Trifluoromethyl ) Piperidin-1-yl] ethyl] pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole 5- {2-oxo-2- [4- (trifluoromethyl) piperidin-1-yl] ethyl] pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.90-0.93 (t, 3H), 1.35-1.95 (m, 8H), 2.23-2.29 (m, 1H), 2.33 (s, 3H), 2.53-2.59 (m, 1H 2H), 7.21-7.84 (m, 8H, m), 2.66-2.70 (m, 2H) )

< Example  93> 3- [2- [4 - [[5- [2- (8- Azaz Spiro [4.5] decane -8-yl) -2- Oxoethyl ] -2-butyl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[5- [2- (8-Azaspiro [4.5] decan-8-yl) -2-oxoethyl] -2-butyl-4-methyl-6-oxopyrimidine -1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.87 (t, 3H), 1.32-1.48 (m, 10H), 1.58-1.66 (m, 6H), 2.26 (s, 3H), 2.63 (t, 2H), 3.46- 1H), 7.55 (t, 1H), 7.65 (d, 2H), 7.35 (d, 2H) (d, 1 H)

< Example  94> 3- [2- [4 - [[5- [2- (8- Azaz Spiro [4.5] decane -8-yl) -2- Oxoethyl ] -4-methyl-6-oxo-2- Propylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole 5- {3- [2- [4 - [[5- [2- (8- azaspiro [4.5] decan -8- yl )-2- oksoethyl ]-4- methyl -6- oxo -2-propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

¹ H-NMR (400 MHz):? 0.93 (t, 3H), 1.37 (t, 2H), 1.43-1.46 (m, 6H), 1.60-1.71 2H), 7.36 (d, 1H), 7.43 (d, 2H), 3.44-3.50 (m, 4H) (t, 1 H), 7.56 (t, 1 H), 7.64 (d, 1 H)

< Example  95> 3- [2- [4 - [[2-butyl-5- [2- (4,4- Dimethylpiperidine Yl) -2- Oxoethyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[2-butyl-5- 2- (4,4-dimethylpiperidin- 1 -yl) -2-oxoethyl] -4-methyl-6-oxopyrimidin- -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 0.97 (s, 6H), 1.32-1.44 (m, 6H), 1.65-1.73 (m, 2H), 2.32 (s, 3H), 2.70 ( 2H), 7.26 (d, 2H), 7.38 (d, 1H), 7.60 (s, 2H) (t, 1 H), 7.78 (d, 1 H)

< Example  96> 3- [2- [4 - [[5- [2- (4,4- Dimethylpiperidine Yl) -2- Oxoethyl ]-4- methyl -6-oxo-2- Propylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[5- [2- (4,4-dimethylpiperidin-1-yl) -2-oxoethyl] -4-methyl-6-oxo-2- propylpyrimidin- -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.95-1.00 (m, 9H), 1.29-1.39 (m, 4H), 1.69-1.77 (m, 2H), 2.29 (s, 3H), 2.65 (t, 2H), 2H), 7.26 (d, 2H), 7.38 (d, IH), 7.49 (t, IH) , 7.60 (t, 1 H), 7.78 (d, 1 H)

< Example  3- [2- [4 - [[2-butyl-5- [2- (2,5- Dimethylpyrrolidine Yl) -2-oxo-ethyl] -4- methyl -6-oxo-pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -2H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[2-butyl-5- 2- (2,5-dimethylpyrrolidin- 1 -yl) -2-oxo-ethyl] -4-methyl- -pyrimidin-1-yl] methyl] phenyl] phenyl] -2H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.26 (m, 4H), 1.33 (m, 6H), 1.71 (m, 4H), 2.05 (m, 2H), 2.29 (s, 3H) 2H), 2.67 (m, 2H), 4.00 (m, 1H), 4.26 (m, 7.88 (d, 1 H)

< Example  98> 3- [2- [4 - [[2-Butyl-4- methyl -5- [2 - [(2S) -2- Methylpyrrolidine -1-yl] -2-oxoethyl] -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5 - one {3- [2- [4 - [[2-butyl-4-methyl-5- [2 - [(2S) -2-methylpyrrolidin- 1 -yl] -2-oxoethyl] -6-oxopyrimidine -1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.26 (m, 4H), 1.33 (m, 3H), 1.71 (m, 4H), 2.05 (m, 2H), 2.29 (s, 3H) 2H), 2.67 (m, 2H), 3.42 (m, 2H), 4.00 (m, 7.88 (d, 1 H)

< Example  99> 3- [2- [4 - [[2-butyl-5- [2 - [(2S, 6R) Dimethylpiperidine -1-yl] -2-ox Cow Yl] -4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole 5- {3- [2- [4 - [[2- butyl -5- [2 - [( 2S, 6R ) -2,6- dimethylpiperidine -One- yl ]-2- oksoethyl ] -4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

¹ H-NMR (400 MHz):? 0.93 (m, 5H), 1.15 (m, 3H), 1.40 (m, 7H), 1.48-1.88 2H), 7.39 (m, 2H), 3.60 (d, 2H), 4.29 (m, ), 7.50 (m, 2H), 7.92 (d, IH)

< Example  100> 3- [2- [4 - [[5- [2 - [(4 aS , 8aR) -3,4,4a, 5,6,7,8,8a- Octahydro -2H-quinolin-1-yl] -2- Oxoethyl ] -2-butyl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2 - [(4aS, 8aR) -3,4,4a, 1H-quinolin-1-yl] -2-oxoethyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] , 4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.90 (t, 3H), 1.37 (m, 8H), 1.50-1.92 (m, 9H), 2.22 (s, 3H), 2.63 (m, 2H), 3.57 (m, 2H), 7.93 (d, 2H), 3.93 (dd, 1H), 4.33-4.54 (dd, (d, 1 H)

< Example  (3H-pyrimidin-6 (5H) -quinolin-2-yl) Yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one 4 - ((2-butyl-4-methyl-5- (2- (2-methyl-7,8- dihydropyrido [ -oxoethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.87-0.96 (m, 3H), 1.19-1.44 (m, 8H), 1.71-1.81 (m, 3H), 1.94-2.05 (d, 3H), 2.43-3.01 (m , 4H), 4.28-4.62 (m, 3H), 5.26-5.37 (m, 3H), 6.88-7.80 (m, 8H)

< Example  102> 2- [2-Butyl-4- Cyclopropyl -6-oxo-1 - [[4- [2- (5-oxo-4H- buy Yl) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N, N- Dimethylacetamide Id {2- [2- butyl -4- cyclopropyl -6- oxo -1 - [[4- [2- (5- oxo -4H-1,2,4- oxadiazole -3-yl) phenyl] phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylacetamide}

^{1 H-NMR (400MHz):} δ 0.89 (t, 3H), 0.92 (m, 2H), 1.19 (m, 2H), 1.39 (m, 2H), 1.70 (m, 2H), 1.92 (m, 1H) 2H), 2.84 (s, 3H), 3.14 (s, 3H), 3.74 (s, 2H) 7.61 (d, IH), 7.77 (d, IH)

< Example  103> 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- Octahydroisoindole Yl) -2- Oxoethyl ] -2-butyl-4- Cyclopropyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- 2-yl) -2-oxoethyl] -2-butyl-4-cyclopropyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol- Produce

^{1 H-NMR (400MHz):} δ 0.89 (m, 7H), 1.37-1.69 (m, 15H), 2.64 (t, 2H), 3.41 (m, 2H), 3.62 (6, 2H), 3.65 (m, 1H), 7.56 (s, 2H), 7.16 (d, 2H), 7.27 (d, 2H), 7.39 )

< Example  104> 2- [2-Butyl-4- Cyclopropyl -6-oxo-1 - [[4- [2- (5-oxo-4H- buy Yl) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- methyl -N-propan-2-ylacetamide &lt; / RTI &gt; {2- [2- butyl -4- cyclopropyl -6- oxo -1 - [[4- [2- (5- oxo -4H-1,2,4- oxadiazole 3-yl) phenyl] phenyl] methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylacetamide}

^{1 H-NMR (400MHz):} δ 0.89 (m, 7H), 1.08 (d, 3H), 1.19 (d, 3H), 1.42 (m, 2H), 1.71 (m, 2H), 1.94 (m, 1H) 2H), 4.28 (m, 2H), 2.79 (s, 2H), 2.79 (s, , 7.18 (d, 2H), 7.26 (m, 2H), 7.41 (d,

< Example  105> 2- [2-Butyl-4- Cyclopropyl -6-oxo-1 - [[4- [2- (5-oxo-4H- buy Yl) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- methyl -N- (2- Methyl propyl Phenyl) phenyl] &lt; RTI ID = 0.0 &gt; phenyl-4- ] methyl] pyrimidin-5-yl] -N-methyl-N- (2-methylpropyl) acetamide}

¹ H-NMR (400 MHz):? 0.89 (m, 2H), 1.07 (d, 3H), 1.15-1.18 (m, 5H), 1.31-1.37 (M, 2H), 5.21 (s, 2H), 7.16-7.80 (m, 2H) m, 8H)

< Example  106> 2- [2-Butyl-4- Cyclopropyl -6-oxo-1 - [[4- [2- (5-oxo-4H- buy Yl) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- Isopropyl -N- Methyl Phenyl] phenyl] &lt; RTI ID = 0.0 &gt; pyrrolidine-2- &lt; / RTI &gt; methyl] pyrimidin-5-yl] -N-isopropyl-N-methyl-acetamide}

^{1 H-NMR (400MHz):} δ 0.94 (t, 3H), 0.96 (m, 2H), 1.10 (d, 6H), 1.25 (d, 2H), 1.31 (m, 2H), 1.64 (m, 2H) , 1.94 (s, 1H), 2.01 (m, 1H), 2.62 (t, 2H), 3.17 (s, 1.5H), 3.30 2H), 7.25 (m, 2H), 7.46 (d, 2H), 4.30 (m, 1H), 7.58 (t, IH), 7.62 (t, IH), 7.75

< Example  107> 3- [2- [4 - [[2-Butyl-4- Cyclopropyl -6-oxo-5- (2-oxo-2- Pyrrolidine -One- Yl ethyl ) Pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Methyl] pyrimidin-1-yl] methyl} pyrimidin-2-yl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one

^{1 H-NMR (400MHz):} δ 0.89 (t, 3H), 0.92 (m, 2H), 1.19 (m, 2H), 1.41 (m, 2H), 1.70 (m, 4H), 1.89 (t, 2H) 2H), 3.64 (t, 2H), 3.64 (t, 2H), 3.93 (s, 2H) 1H), 7.71 (d, 2H), 7.28 (d, 2H), 7.41

< Example  108> 3- [2- [4 - [[2-Butyl- Cyclopropyl -5- [2- (3,5- Dimethylpiperidine Yl) -2- Oxoethyl ] -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadia 2-butyl-4-cyclopropyl-5- [2- (3,5-dimethylpiperidin-1-yl) -2-oxoethyl] -6-oxopyrimidin- 1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

¹ H-NMR (400 MHz):? 0.86-0.97 (m, 10H), 0.92 (m, 2H), 1.19 (m, 2H), 1.39 2H), 7.43 (m, 1H), 7.52 (t, 1H), 7.61 (d, 2H) (d, 1 H), 7.77 (d, 1 H)

< Example  109> 3- [2- [4 - [[2-Butyl-4- Cyclopropyl -6-oxo-5- (2-oxo-2-piperidin- Yl ethyl ) Pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Methyl] pyrimidin-1-yl] methyl} pyrimidin- phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.88-0.96 (m, 5H), 1.17-1.39 (m, 4H), 1.63-1.72 (m, 4H), 2.09-2.10 (m, 1H), 2.60-2.64 (t , 2H), 3.59-3.72 (m, 10H), 5.22 (s, 2H), 7.15-7.78 (m, 8H)

< Example  110> 3- [2- [4 - [[2-Butyl- Cyclopropyl -5- (2- Morpholine -4-yl-2- Oxoethyl ) -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Yl) methyl] phenyl] -5- {3- [2- [4 - [[2-butyl-4-cyclopropyl-5- (2-morpholin-4-yl-2-oxoethyl) -6-oxopyrimidin- ] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.89 (t, 3H), 0.92 (m, 2H), 1.19 (m, 2H), 1.41 (m, 2H), 1.58 (m, 2H), 1.75 (m, 4H) 2H), 7.24 (d, 2H), 7.24 (d, 2H), 2.04 (s, 2H) 1H), 7.52 (t, 1H), 7.61 (d, 1H), 7.77

< Example  111> 2- [2-butyl-4- Cyclopropyl -6-oxo-1 - [[4- [2- (5-oxo-4H- buy Yl) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- (1- Hydroxypropane 2-butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H- 1,2,4-oxadiazol- 3- yl ) phenyl] phenyl] methyl] pyrimidin-5-yl] -N- (1-hydroxypropan-2-yl) acetamide}

^{1 H-NMR (400MHz):} δ 0.94 (t, 3H), 0.96 (m, 2H), 1.10 (d, 6H), 1.25 (d, 2H), 1.31 (m, 2H), 1.64 (m, 2H) 1H), 4.76 (m, 0.5H), 5.19 (d, 2H), 1.94-2.01 (m, 3H) 1H), 7.62 (t, 1H), 7.75 (d, 2H), 5.90 (m, 2H) 1H)

< Example  112> N-butyl-2- [2-butyl-4- Cyclopropyl Oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] Acetamide  Phenyl-2 - [(2-butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo- phenyl] methyl] pyrimidin-5-yl] acetamide}

¹ H-NMR (400 MHz):? 0.87-0.97 (6H, m), 1.13-1.17 (4H, m), 1.29-1.39 (4H, m), 1.43-1.70 m), 3.50-3.55 (4H, m), 3.73 (2H, s), 5.23 (2H, s), 7.19-7.82

< Example  113> 2- [2-Butyl-4- Cyclopropyl -6-oxo-1 - [[4- [2- (5-oxo-4H- buy Yl) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- Propyl acetamide  Phenyl] phenyl] methyl] -1H-pyrazolo [3,4-d] pyrimidin- pyrimidin-5-yl] -N-propylacetamide}

¹ H-NMR (400 MHz):? 0.89-0.97 (6H, m), 1.13-1.17 (4H, m), 1.28-1.39 (2H, m), 1.43-1.69 m), 3.50-3.45 (4H, m), 3.71 (2H, s), 5.23 (2H, s), 7.19-7.85

< Example  114> 2- [2-Butyl-4- Cyclopropyl -6-oxo-1 - [[4- [2- (5-oxo-4H- buy Yl) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N-propan-2- Acetic acid Id {2- [2- butyl -4- cyclopropyl -6- oxo -1 - [[4- [2- (5- oxo -4H-1,2,4- oxadiazole -3-yl) phenyl] phenyl] methyl] pyrimidin-5-yl] -N-propan-2-ylacetamide}

^{1 H-NMR (400MHz):} δ 0.94 (t, 3H), 0.96 (m, 2H), 1.10 (d, 6H), 1.25 (d, 2H), 1.31 (m, 2H), 1.64 (m, 2H) 2H), 7.25 (m, 2H), 5.19 (d, 2H), 1.94-2.01 (m, 3H) ), 7.46 (d, IH), 7.58 (t, IH), 7.62

< Example  115> 2- [2-Butyl-4- Cyclopropyl -6-oxo-1 - [[4- [2- (5-oxo-4H- buy Yl) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- Methoxy -N- Methylacetate Mide {2- [2- butyl -4- cyclopropyl -6- oxo -1 - [[4- [2- (5- oxo -4H-1,2,4- oxadiazole -3-yl) phenyl] phenyl] methyl] pyrimidin-5-yl] -N-methoxy-N-methylacetamide}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.00-1.21 (m, 4H), 1.36-1.45 (m, 2H), 1.67-1.74 (m, 2H), 2.18 (s, 4H), 2H), 3.20 (s, 3H), 3.71 (s, 2H), 3.78 (s,

< Example  116> 3- (4 '- ((2-Butyl-4- Cyclopropyl -6-oxo-5- (2-oxo-2- ( Pyrrolidine -1-yl) ethyl) pyrimidin-1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadiazole -5 (4H) -one {3- (4 '- ((2- butyl -4- cyclopropyl -6- oxo -5- (2- oxo -2-( pyrrolidine -1-yl) ethyl) pyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H)

^{1 H-NMR (400MHz):} δ 0.95 (t, 3H), 0.96 (t, 3H), 1.18 (d, 2H), 1.20 (m, 2H), 1.69 (m, 2H), 2.01 (t, 1H) 2H), 7.28 (d, 2H), 7.41 (d, 1H), 7.48 (t, 7.61 (t, 1 H), 7.75 (d, 1 H)

< Example  117> 3- (4 '- ((2-Butyl-4- Cyclopropyl -5- (2- (2,6- Dimethylpiperazine Yl) -2- Oxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadai (2-butyl-4-cyclopropyl-5- (2- (2,6-dimethylpiperazin-1-yl) -2-oxoethyl) -6-oxopyrimidine -1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

¹ H-NMR (400 MHz):? 0.95 (t, 3H), 0.96 (m, 4H), 1.18 (t, 2H), 5.18 (s, 2H), 7.15 (d, 2H), 7.26 (d, 2H) 7.41 (d, 1H), 7.48 (t, 1H), 7.61 (t,

< Example  (S) -3- (4 '- ((2-butyl-4- Cyclopropyl -5- (2- (2- Methylpyrrolidine Yl) -2- Oxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadai (2-methylpyrrolidin-1-yl) -2-oxoethyl) -6- (4-fluoro- -oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

¹ H-NMR (400 MHz):? 0.95 (t, 5H), 0.96 (m, 4H), 1.18 (m, 3H), 1.20 2H), 7.22 (d, 2H), 7.41 (d, IH), 7.31 (d, 7.48 (t, 1 H), 7.61 (t, 1 H), 7.75 (d, 1 H)

< Example  119> 3- (4 '- ((2-Butyl- Cyclopropyl -5- (2- (3,5- Dimethylpiperidine Yl) -2- Oxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadai -5- (2- (3,5-dimethylpiperidin-1-yl) -2-oxoethyl) -6-oxopyrimidine -1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.95 (t, 3H), 1.22 (m, 4H), 1.36 (m, 2H), 1.67 (dd, 3H), 2.01 (m, 3H), 2.66 (dd, 2H) 2H), 3.40 (d, 2H), 3.56 (d, 2H), 3.56-3.73 (m, 4H), 4.45 (m, ), 7.41 (d, IH), 7.48 (t, IH), 7.61

< Example  120> 2- (2-Butyl-4- Cyclopropyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine 5-yl) -N-cyclopropylacetamide {2- (2-butyl-4-cyclopropyl-6-oxo- 4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1,6-dihydropyrimidin-5-yl) -N-cyclopropylacetamide}

^{1 H-NMR (400MHz):} δ 0.95 (t, 3H), 0.96 (m, 2H), 1.17 (s, 2H), 1.20 (m, 2H), 1.37 (dd, 2H), 2.01 (m, 5H) 2H), 7.26 (d, 2H), 7.41 (d, 1H), 7.48 (t, 1H) 7.61 (t, 1 H), 7.75 (d, 1 H)

< Example  121> 2- (2-Butyl-4- Cyclopropyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine 5-yl) -N, N-diethylacetamide {2- (2-butyl-4-cyclopropyl-6-oxo- 2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1,6-dihydropyrimidin-5-yl) -N, N-diethylacetamide}

^{1 H-NMR (400MHz):} δ 0.95 (m, 5H), 1.22 (m, 7H), 1.36 (m, 2H), 1.67 (dd, 2H), 2.01 (m, 1H), 2.66 (dd, 2H) (D, 2H), 3.40 (d, 2H), 3.40 (d, 2H) 7.48 (t, 1 H), 7.61 (t, 1 H), 7.75 (d, 1 H)

< Example  122> 3- (4 '- ((2-Butyl-4- Cyclopropyl -5- (2- (3,5- Dimethylmolpolino )-2- Oxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadia (2-butyl-4-cyclopropyl-5- (2- (3,5-dimethylmorpholino) -2-oxoethyl) -6-oxopyrimidin- 1 (6H ) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.95 (t, 3H), 1.22 (m, 4H), 1.36 (m, 2H), 1.67 (dd, 3H), 2.01 (m, 3H), 2.66 (dd, 2H) 2H), 3.40 (d, 2H), 3.56 (d, 2H), 3.56-3.73 (m, 4H), 4.45 (m, ), 7.41 (d, IH), 7.48 (t, IH), 7.61

< Example  123> 3- (4 '- ((2-butyl-4- Cyclopropyl 1- [5- (2 - ((2S, 6R) -2,6- Dimethylpiperidine Yl) -2- Oxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl 2 - ((2S, 6R) -l, 2,3,4-tetrahydroisoquinolin- -2,6-dimethylpiperidin-1-yl) -2-oxoethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol- one}

^{1 H-NMR (400MHz):} δ 0.95 (t, 5H), 1.22 (m, 4H), 1.36 (m, 5H), 1.67 (dd, 4H), 2.01 (m, 5H), 2.66 (dd, 2H) 2H), 7.18 (d, 2H), 7.28 (d, 2H), 7.41 (d, ), 7.61 (t, IH), 7.75 (d, IH)

< Example  124> 3- (4 '- ((2-Butyl-4- Cyclopropyl -5- (2- Molpolino -2- Oxoethyl ) -6-ox Sophirimi &Lt; RTI ID = 0.0 &gt; (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadiazole -5 (4H) -one {3- (4'- ((2-butyl-4-cyclopropyl-5- (2- morpholino- 2- oxoethyl) -6- oxopyrimidin- 1 (6H) -yl) methyl) biphenyl -2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.92-0.95 (m, 5H), 1.22 (m, 2H), 1.36 (m, 2H), 1.67 (dd, 2H), 2.19 (m, 1H), 2.68 (t, 2H), 3.70 (s, 2H), 3.70 (d, 2H), 3.70 ), 7.26 (d, 2H), 7.41 (d, IH), 7.48 (t, IH)

< Example  125> 3- (4 '- ((2-butyl-4- Cyclopropyl -5- (2- (2- Methylpiperidine Yl) -2- Oxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadia (2-methylpiperidin-1-yl) -2-oxoethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

¹ H-NMR (400 MHz):? 0.95 (t, 4H), 1.15-1.17 (m, 4H), 1.35-1.37 (m, 4H), 1.64-1.68 2H), 3.16 (d, 2H), 3.80 (dd, 2H), 4.30-4.70 (m, 2H), 5.18 , 7.41 (d, 1 H), 7.48 (t, 1 H), 7.61 (t,

< Example  126> 3- (4 '- ((2-Butyl-4- Cyclopropyl -5- (2- (4- Hydroxypiperidine Yl) -2- Oxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadai 2-oxoethyl) -6-oxopyrimidin-1 &lt; / RTI &gt; (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

¹ H-NMR (400 MHz):? 0.95 (t, 7H), 1.15-1.17 (m, 2H), 1.35-1.37 (m, 8H), 2.64 (dd, 2H), 3.71-3.73 1H), 7.61 (t, 1H), 7.75 (d, 2H), 7.18 (d, 2H) (d, 1 H)

< Example  127> 3- [2- [4 - [[2-Butyl-6-oxo-5- (2-oxo-2-piperidin- Yl ethyl ) -4-propane-2- Ylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[2-butyl-6-oxo-5- (2-oxo- 2-piperidin- 1 -ylethyl) -4-propan-2- ylpyrimidin-1- yl ] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz, CDCl} 3): δ 0.9 (m, 3H), 1.0 (m, 6H), 1.4 (m, 3H), 1.6 (m, 8H), 1.8 (m, 2H), 2.7 (m 2H), 7.0-7.2 (m, 4H), 7.4 (m, 2H), 3.0 (m, 7.6 (m, 4H)

< Example  128> 3- [2- [4 - [[2-butyl-5- [2- (2,6- Dimethylpiperazine Yl) -2- Oxoethyl ] -6-oxo-4-propane-2- Ylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole 5- {3- [2- [4 - [[2- butyl -5- [2- (2,6- dimethylpiperazine -One- yl )-2- oksoethyl ] -6- oxo -4-propan-2-ylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

^{1 H-NMR (400MHz, CDCl} 3): δ 0.9 (m, 4H), 1.0 (m, 5H), 1.4 (m, 10H), 1.6 (m, 2H), 1.8 (m, 2H), 2.7 (m 2H), 7.0 (m, 2H), 3.8 (m, 2H), 4.3 (m, 7.6 (m, 4H)

< Example  2- [2-butyl-6-oxo-1 - [[4- [2- (5- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] -4-propane-2- Ylpyrimidine -5-yl] -N, N- Dimethylacetamide  Phenyl] phenyl] methyl] -4-propane [0301] The title compound was prepared from {2- [2-butyl-6-oxo- -2-ylpyrimidin-5-yl] -N, N-dimethylacetamide}

^{1 H-NMR (400MHz, CDCl} 3): δ 0.9 (m, 3H), 1.0 (m, 6H), 1.4 (m, 2H), 1.6 (m, 2H), 1.8 (m, 2H), 2.7 (m 2H), 7.0 (m, 4H), 7.4 (m, 6H), 3.6 (m, 7.6 (m, 4H)

< Example  130> 2- [2-Butyl-6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] -4-propane-2- Ylpyrimidine -5-yl] -N, N- Diethylacetamide  Phenyl] phenyl] methyl] -4-propane [0301] The title compound was prepared from {2- [2-butyl-6-oxo- -2-ylpyrimidin-5-yl] -N, N-diethylacetamide}

¹ H-NMR (400 MHz, CDCl ₃ ): δ 0.9 (m, 3H), 1.0 (m, 4H), 1.4 2H), 7.0-7.2 (m, 4H), 7.4-7.6 (m, 4H)

< Example  131> 2- [2-butyl-6-oxo-1 - [[4- [2- (5- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] -4-propane-2- Ylpyrimidine -5-yl] -N- methyl -N-propane-2- Acetic acid Yl) phenyl] phenyl] methyl] -4- (4-oxo-4H-1,2,4- propan-2-ylpyrimidin-5-yl] -N-methyl-N-propan-2-ylacetamide}

^{1 H-NMR (400MHz):} δ 0.86 (d, 3H), 0.92 (t, 3H), 0.98 (d, 3H), 1.45 (m, 2H), 1.70 (m, 2H), 1.89-2.14 (mm, 2H), 5.26 (d, 2H), 7.19 (d, 2H), 2.91 (s, (d, 2H), 7.26 (m, 2H), 7.41 (d, IH), 7.50

< Example  132> 2- [2-butyl-6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] -4-propane-2- Ylpyrimidine -5-yl] -N- Cyclopropylacetamide  Phenyl] phenyl] methyl] -4-propane [0301] The title compound was prepared from {2- [2-butyl-6-oxo- -2-ylpyrimidin-5-yl] -N-cyclopropylacetamide}

^{1 H-NMR (400MHz):} δ 0.86 (d, 3H), 0.92 (t, 3H), 0.98 (d, 3H), 1.45 (m, 2H), 1.70 (m, 2H), 1.89-2.14 (m, 2H), 7.26 (m, 4H), 2.91 (m, 2H), 3.12 ), 7.41 (d, IH), 7.50 (t, IH), 7.61

< Example  133> 3- (4 '- ((2-butyl-5- (2- (3,5- Dimethylpiperidine Yl) -2- Oxoethyl )-4- Isopropyl -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadai 2-oxoethyl) -4-isopropyl-6-oxopyrimidine &lt; / RTI &gt; -1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.90 (t, 9H), 1.17 (m, 6H), 1.29 (dd, 6H), 1.68 (m, 2H), 1.70 (m, 2H), 1.93 (t, 1H) , 2.45 (m, 2H), 2.95 (m, 1H), 3.60 (m, 3H), 3.95 (d, 0.5H) 1H), 7.83 (m, 1H), 7.83 (d, IH)

< Example  134> 3- (4 '- ((2-butyl-5- (2 - ((2R, 6S) Dimethylpiperidine -1-yl) -2-oxoethyl) -4- Isopropyl -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl 5- (2 - ((2R, 6S) -2,6-dihydroxy-isoquinolin- yl) -2,2-oxoethyl) -4-isopropyl-6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol- one}

^{1 H-NMR (400MHz):} δ 0.93 (m, 5H), 1.15 (m, 3H), 1.21 (m, 6H), 1.40 (m, 7H), 1.48-1.88 (m, 9H), 2.95 (m, 2H), 7.01 (m, 2H), 2.31 (m, 2H), 2.69 (m, ), 7.39 (d, 1 H), 7.50 (m, 2 H), 7.92 (d,

< Example  135> 3- (4 '- ((2-Butyl-4- Isopropyl -5- (2- (2- Methylpiperidine -1-yl) -2-oxo Cow Yl) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadiazole -5 (4H) -one {3- (4'- ((2-butyl-4-isopropyl-5- (2- (2- methylpiperidin- 1- yl) -2-oxoethyl) -6-oxopyrimidin- 6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

¹ H-NMR (400 MHz):? 0.90 (t, 3H), 0.92 (m, 2H), 1.17 (m, 6H), 1.29 (dd, (M, 2H), 3.95 (d, 2H), 2.45 (m, 2H) ), 7.09 (m, 2H), 7.11 (m, 2H), 7.25 (m, IH), 7.33 (d,

< Example  136> 3- (4 '- ((2-Butyl-4- Isopropyl -5- (2- (3- Methylpiperidine -1-yl) -2-oxo Cow Yl) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadiazole -5 (4H) -one {3- (4 '- ((2-butyl-4-isopropyl-5- (2- (3- methylpiperidin- 1 -yl) -2-oxoethyl) -6-oxopyrimidin- 6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.90 (t, 6H), 1.17 (m, 6H), 1.35 (m, 5H), 1.70 (m, 5H), 2.52 (m, 2H), 2.95 (m, 1H) 2H), 7.09 (m, 2H), 7.11 (m, 2H), 7.25 (m, 7.83 (d, 1 H), 7.48 (m, 1 H), 7.62 (m,

< Example  137> 3- (4 '- ((2-butyl-4- Isopropyl -5- (2- Molpolino -2- Oxoethyl ) -6-oxopyrimidin-1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadiazole -5 (4H) -one {3- (4'- ((2-butyl-4-isopropyl-5- (2- morpholino- 2- oxoethyl) -6- oxopyrimidin- 1 (6H) -yl) methyl) biphenyl -2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.90 (t, 3H), 0.91 (m, 6H), 1.36 (m, 2H), 1.74 (m, 2H), 2.66 (m, 2H), 3.01 (m, 1H) 2H), 7.09 (m, 2H), 3.59 (m, 2H), 3.59 (m, 7.48 (m, 1 H), 7.62 (m, 1 H), 7.83 (d, 1 H)

< Example  138> 3- (4 '- ((2-Butyl-5- (2- (2,6- Dimethylmolpolino )-2- Oxoethyl ) -4-isopropyl-6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadiazole -5 (4H) -one {3- (4 '- ((2-butyl-5- (2- (2,6- dimethylmorpholino) -2-oxoethyl) -4-isopropyl-6-oxopyrimidin- -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.90 (t, 3H), 0.91 (m, 12H), 1.36 (m, 2H), 1.74 (m, 2H), 2.28 (m, 1H), 2.66 (m, 2H) 2H), 7.01 (m, 2H), 3.50 (m, 2H), 3.58 (m, 1H), 7.83 (d, IH), 7.48 (m, IH)

< Example  (S) -3- (4 '- ((2-butyl-4- Isopropyl -5- (2- (2- Methylpyrrolidine Yl) -2- Oxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadia (4-isopropyl-5- (2- (2-methylpyrrolidin-1-yl) -2-oxoethyl) -6 -oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.11 (d, 2H), 1.19 (m, 6H), 1.21 (d, 1H), 1.37 (m, 2H), 1.74 (m, 2H) , 1.92 (m, 3H), 2.66 (m, 2H), 3.01 (m, 1H), 7.83 (d, IH), 7.48 (m, IH)

< Example  140> 2- [2-Butyl-4-ethyl-6-oxo-1 - [[4- [2- (5- Oxadiazole Methyl] pyrimidin-5-yl] -N, N-dimethylacetamide {2- [2-butyl- Preparation of 2- (5-oxo-4H-1,2,4-oxadiazol-3-yl) phenyl] phenyl] methyl pyrimidin-5-yl] -N, N-dimethylacetamide}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 0.92-0.98 (m, 6H), 1.20-1.40 (m, 2H), 1.70 (m, 2H), 2.34 (s, 3H), 2.66 ( 2H), 7.24 (d, 2H), 7.42 (m, 2H), 3.84 (m, 3H) , 7.49 (t, IH), 7.62 (d, IH), 7.76 (d, IH)

< Example  Ethyl-6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- methyl -N-propane-2- Diacetamide  Phenyl] phenyl] methyl] -1H-pyrazolo [3,4-d] pyrimidin- pyrimidin-5-yl] -N-methyl-N-propan-2-ylacetamide}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 0.92-0.98 (m, 6H), 1.20-1.40 (m, 2H), 1.70 (m, 2H), 2.34 (s, 3H), 2.66 ( 2H), 7.24 (d, 2H), 7.42 (m, 2H), 3.84 (m, , 7.49 (t, IH), 7.62 (d, IH), 7.76 (d, IH)

< Example  142> 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- Octahydroisoindole Yl) -2- Oxoethyl ] -2-butyl-4-ethyl-6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- 2-yl) -2-oxoethyl] -2-butyl-4-ethyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol- Produce

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 0.92-0.98 (m, 6H), 1.20-1.70 (m, 19H), 2.34 (s, 2H), 2.66 (t, 2H), 3.84 ( 2H), 7.27 (d, 2H), 7.42 (m, 1H), 7.49 (m, 2H) , 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  143> 3- [2- [4 - [[2-Butyl-4-ethyl-6-oxo-5- (2- Pyrrolidine -One- Yl ethyl ) Pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Pyrimidin-1-yl] methyl} pyrimidin-4-yl] - (2- phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.9 (m, 3H), 1.0 (m, 8H), 1.4 (m, 5H), 1.6 (m, 4H), 1.8 (m, 2H), 2.7 (m, 2H) , 4.0 (m, 4H), 5.3 (d, 2H), 7.0-7.2 (m, 4H), 7.4-7.6

< Example  144> 3- [2- [4 - [[2-Butyl-4-ethyl-6-oxo-5- (2-oxo-2-piperidin- Yl ethyl ) Pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Pyrimidin-1-yl] methyl} piperidine-1-carboxylic acid tert-butyl ester and 2- (4- phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 0.92-0.98 (m, 5H), 1.40 (m, 2H), 1.70 (m, 4H), 2.34 (s, 3H), 2.66 (t, 2H), 3.72 (m, 4H), 3.84 (s, 2H), 3.95 (t, 2H), 4.34 (t, 2H), 5.26 ), 7.42 (m, IH), 7.49 (t, IH), 7.62

< Example  145> 3- [2- [4 - [[2-Butyl-4-ethyl- Morpholine -4-yl-2- Oxoethyl ) -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[2-butyl-4-ethyl-5- (2-morpholin-4-yl-2-oxoethyl) -6-oxopyrimidin- 1 -yl] methyl] phenyl ] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.20 (t, 3H), 1.40 (m, 2H), 1.70 (m, 2H), 2.64 (dd, 2H), 2.86 (t, 2H) 1H), 2.90 (m, 4H), 3.84 (s, 2H), 3.95 (m, 4H), 5.26 7.49 (t, 1 H), 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  146> 3- [2- [4 - [[2-Butyl-4-ethyl-5- [2- (4- Methylpiperidine Yl) -2- Oxoethyl ] -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Yl) -2-oxoethyl] -6-oxopyrimidin-1-yl- ] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.41 (m, 8H), 1.71 (m, 8H), 2.31 (s, 3H), 2.68 (t, 2H), 3.52 (m, 4H) 2H), 7.28 (d, 2H), 7.42 (m, 1H), 7.48 (t, 7.77 (d, 1 H)

< Example  147> 3- [2- [4 - [[2-butyl-5- [2- (3,3- Dimethylpiperidine Yl) -2- Oxoethyl ] -4-ethyl-6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[2-butyl-5- [2- (3,3-dimethylpiperidin- 1 -yl) -2-oxoethyl] -4-ethyl-6-oxopyrimidin- -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.43 (m, 9H), 1.52 (m, 5H), 1.85 (m, 3H), 2.64 (t, 2H), 2.86 (t, 2H) 2H), 3.85 (s, 2H), 7.27 (m, 4H), 7.42 (m, 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  148> 3- [2- [4 - [[2-Butyl-5- [2- (3,5- Dimethylmorpholine Yl) -2- Oxoethyl ] -4-ethyl-6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5- one {3- [2- [4 - [[2-butyl-5- 2- (3,5-dimethylmorpholin-4-yl) -2-oxoethyl] -4-ethyl-6-oxopyrimidin- -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.20 (m, 9H), 1.40 (m, 2H), 1.70 (m, 2H), 2.64 (dd, 2H), 2.86 (t, 2H) 1H), 2.90 (m, 3H), 3.84 (s, 2H), 3.95 (m, 3H), 5.26 (s, 7.49 (t, 1 H), 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  149> 3- (4 '- ((2-Butyl-4- methyl -6-oxo-5- (2-oxo-2- ( Thiazolidine Yl) ethyl) pyrimidin-1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadiazole -5 (4H) -one {3- (4'- ((2-butyl-4-methyl-6-oxo-5- (2- oxo- 2- (thiazolidin- 3- yl) ethyl) pyrimidin- 6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H NMR (400 MHz, CDCl} 3): δ 0.91 (t, 3H), 1.34-1.44 (m, 2H), 1.65-1.73 (m, 2H), 2.33 (d, 3H), 2.66 (t, 2H) 2H), 3.60-3.15 (m, 2H), 2.97-3.13 (m, 2H), 3.60 (d, 2H), 3.81-3.95 (m, 8H)

< Example  150> 3- (4 '- ((2-butyl-4- methyl -5- (2- (4- Methylpiperidine Yl) -2- Oxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadiazole -5 (4H) -one {3- (4'- ((2-butyl-4-methyl-5- (2- (4- methylpiperidin- 1- yl) -2-oxoethyl) -6-oxopyrimidin- 6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H NMR (400 MHz, CDCl} 3): δ 0.89-0.95 (m, 6H), 1.06-1.15 (m, 2H), 1.34-1.44 (m, 2H), 1.58-1.73 (m, 5H), 2.30 ( (m, 2H), 2.39 (s, 3H), 2.52-2.68 (m, 3H), 3.01-3.07 m, 8H)

< Example  151> 3- (4 '- ((2-Butyl-5- (2- (2,6- Dimethylmolpolino )-2- Oxoethyl ) -4-methyl-6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadiazole -5 (4H) -one {3- (4 '- ((2-butyl-5- (2- (2,6- dimethylmorpholino) -2-oxoethyl) -4-methyl-6-oxopyrimidin- -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H NMR (400 MHz, CDCl} 3): δ 0.91 (t, 3H), 1.14-1.22 (m, 6H), 1.35-1.44 (m, 2H), 1.65-1.73 (m, 2H), 2.32 (s, 2H), 2.79-2.85 (m, 1H), 3.19-4.40 (m, 6H), 7.18-7.80 (m, 8H)

< Example  152> 2- (2-Butyl-4- methyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4-ox buy Yl) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine 5-yl) -N- (2-methoxyethyl) acetamide {2- 4-yl) methyl) -1,6-dihydropyrimidin-5-yl) -N- (2-methoxyethyl) acetamide

^{1 H NMR (400 MHz, CDCl} 3): δ 0.93 (t, 3H), 1.37-1.46 (m, 2H), 1.67-1.75 (m, 4H), 2.43 (s, 3H), 2.71 (t, 2H) 2H), 3.25 (s, 3H), 3.33-3.39 (m, 4H), 3.45 (s, 2H), 5.29 , 1H)

< Example  153> 2- (2-Butyl-4- methyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4-ox buy Yl) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '-( 5-oxo 4-yl) methyl) -1,6-dihydropyrimidin-5-yl) -N- (2- (thiophen-2- yl) -4,5-dihydro-1,2,4-oxadiazol- ) ethyl) acetamide}

^{1 H NMR (400 MHz, CDCl} 3): δ 0.93 (t, 3H), 1.37-1.46 (m, 2H), 1.68-1.76 (m, 2H), 2.18 (s, 3H), 2.43 (s, 3H) , 2.70 (t, 2H), 2.95 (t, 2H), 3.41-3.46 (m, 4H), 5.27 (s, 2H), 6.74-6.79 -7.10 (m, 1 H), 7.18-7.84 (m, 8 H)

< Example  154> 2- (2-Butyl-4- methyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4-ox buy Yl) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine 5-yl) -N, N-diisopropylacetamide {2- (2-butyl-4-methyl-6-oxo- , 2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1,6-dihydropyrimidin-5-yl) -N, N-diisopropylacetamide

^{1 H NMR (400 MHz, CDCl} 3): δ 0.91 (t, 3H), 1.22-1.44 (m, 14H), 1.65-1.73 (m, 2H), 2.28 (s, 3H), 2.65 (t, 2H) 2H), 7.23-7.84 (m, 8H), 3.47 (s,

< Example  155> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N, N- Dimethylethanethioamide  Methyl] -6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] pyrimidin-5-yl] -N, N-dimethylethanethioamide}

To the flask was added the compound prepared in Example 39 (70 mg, 0.14 mmole), and toluene (7 mL) was poured, followed by the addition of a lysis reagent (44.4 mg, 0.11 mmole). After stirring at 85 ° C for 4 hours, the reaction mixture was concentrated under reduced pressure to remove the solvent. 150 mL of chloroform and 150 mL of purified water were added to separate the organic layer. The separated organic layer was washed with 150 mL of purified water, dried with 0.3 g of magnesium sulfate, filtered and concentrated. The residue was purified by chromatography with 99: 1 chloroform / methyl alcohol to give 32 mg (yield: 44.2%) of the title compound as a pale yellow solid.

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.39 (m, 2H), 1.71 (m, 2H), 2.38 (s, 3H), 2.63 (t, 2H), 3.45 (s, 3H) 2H), 7.28 (m, 2H), 7.42 (d, IH), 7.49 (t, IH) 7.61 (t, 1 H), 7.70 (d, 1 H)

< Example  156 - Example  287>

The following Examples 156 to 287 were synthesized in the same manner as in Example 155 from the starting materials corresponding to the Examples.

< Example  156> 3- (4 '- ((5- (2- (1H- Isoindole -2 (3H, 3 aH , 4H, 5H, 6H, 7H, 7 aH ) -Yl) -2- At iox Yl) -2-butyl-4- methyl -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl -2H-isoindol-2 (3H, 3aH, 4H, 5H) -lH- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-triazolo [ oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.39-1.74 (m, 14H), 2.28 (s, 3H), 2.36 (m, 1H), 2.38 (m, 1H), 2.63 (t, 2H), 7.28 (m, 2H), 7.48 (d, 1H), 7.49 (t, , &Lt; / RTI &gt; 1H), 7.70 (d, 1H)

< Example  157> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- methyl -N- (2- Methyl propyl ) Ethanthiourea 4-methyl-6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] phenyl] methyl ] pyrimidin-5-yl] -N-methyl-N- (2-methylpropyl) ethanethioamide}

^{1 H-NMR (400MHz):} δ 0.94 (m, 6H), 1.02 (d, 3H), 1.41 (m, 2H), 1.72 (m, 2H), 2.17 (m, 1H), 2.34 (d, 3H) 2H), 2.67 (d, 2H), 3.44 (d, 3H), 3.61 (d, 2H), 7.42 (d, 1H), 7.49 (t, 1H), 7.61 (t,

< Example  158> 3- [2- [4 - [[2-Butyl-4- methyl -6-oxo-5- (2-piperidin-l-yl-2- Sulfanylideneethyl ) Pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Methyl-6-oxo-5- (2-piperidin-1-yl-2-sulfanylideneethyl) pyrimidin- phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.41 (m, 2H), 1.71 (m, 8H), 2.31 (s, 3H), 2.68 (t, 2H), 3.52 (m, 4H) 2H), 7.28 (d, 2H), 7.42 (m, 1H), 7.48 (t, 7.77 (d, 1 H)

< Example  159> 3- [2- [4 - [[2-Butyl-4- methyl -5- (2- Morpholine -4-yl-2- Sulfanylideneethyl ) -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[2-butyl-4-methyl-5- (2- morpholin-4-yl- 2- sulfanylideneethyl) -6- oxopyrimidin- 1 -yl] methyl] phenyl ] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.40 (m, 2H), 1.70 (m, 2H), 2.34 (s, 3H), 2.66 (t, 2H), 3.72 (m, 4H) 2H), 7.24 (d, 2H), 7.42 (s, 2H), 3.84 (t, 2H) 7.49 (t, 1 H), 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  160> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N-propan-2- Yl ethanethioamide  Methyl] -6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] pyrimidin-5-yl] -N-propan-2-ylethanethioamide}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.11 (d, 6H), 1.37 (m, 2H), 1.68 (m, 2H), 2.58 (s, 3H), 2.67 (t, 2H) 2H), 7.41 (d, IH), 7.50 (t, IH), 7.30 (s, 7.61 (t, 1 H), 7.78 (d, 1 H)

< Example  161> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- methyl -N-propane-2- Sun Ethan Thioamai 4-methyl-6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] phenyl] methyl ] pyrimidin-5-yl] -N-methyl-N-propan-2-ylethanethioamide}

^{1 H-NMR (400MHz):} δ 0.86 (t, 3H), 1.17 (d, 3H), 1.29 (d, 3H), 1.43 (m, 2H), 1.74 (m, 2H), 2.31 (d, 3H) 2H), 7.29 (d, 2H), 7.29 (d, 2H) (m, 2H), 7.41 (d, IH), 7.50 (t, IH), 7.61

< Example  162> 3- [2- [4 - [[2-Butyl- methyl -6-oxo-5- (2- Pyrrolidine -1-yl-2- Sulfanylideneethyl ) Pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Methyl-6-oxo-5- (2-pyrrolidin-1-yl-2-sulfanylideneethyl) pyrimidin- phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.39 (m, 2H), 1.70 (m, 2H), 1.95 (m, 2H), 2.13 (m, 2H), 2.38 (s, 3H) 2H), 7.27 (d, 2H), 7.45 (m, 1H), 2.68 (s, 2H) 7.56 (t, 1 H), 7.64 (d, 1 H), 7.79 (d, 1 H)

< Example  163> 3- [2- [4 - [[2-butyl-5- [2- (3,5- Dimethylpiperidine Yl) -2- Sulfanylideneethyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole 5- {3- [2- [4 - [[2- butyl -5- [2- (3,5- dimethylpiperidine -One- yl )-2- sulfanylideneethyl ] -4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

^{1 H NMR (400 MHz, CDCl} 3): δ 0.90-0.96 (m, 9H), 1.02 (d, 1H), 1.36-1.76 (m, 6H), 1.88 (d, 1H), 2.31 (s, 3H) , 2.41 (t, 1H), 2.67-2.75 (m, 3H), 3.72-3.92 (m, 2H), 4.40 (d, -7.83 (m, 8 H)

< Example  164> 2-Butyl-N, 4- Dimethyl -N- (2- Methyl propyl ) -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5- Carbothioamide  Preparation of {2-butyl-N, 4-dimethyl-N- (2-methylpropyl) -6-oxo- 1 - [[4- [2- (5-oxo-4H- 1,2,4-oxadiazol- ) phenyl] phenyl] methyl] pyrimidine-5-carbothioamide}

¹ H-NMR (400 MHz):? 0.80-1.02 (m, 9H), 1.36-1.45 (m, 2H), 1.66-1.74 (m, 4H), 1.94-2.05 2H), 7.16-7.80 (m, 8H), &lt; RTI ID = 0.0 &gt;

< Example  165> 2-Butyl-N, N, 4- Trimethyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5- Carbothioamide ; 2-butyl-N, N, 4-trimethyl-6-oxo-1 - [[4- [2- (5-oxo- pyrimidine-5-carbothioamide}

^{1 H-NMR (400MHz):} δ 0.90-0.94 (t, 3H), 1.36-1.45 (m, 2H), 1.66-1.73 (m, 2H), 2.28 (s, 3H), 2.69-2.74 (m, 2H ), 3.14 (s, 3H), 3.49 (s, 3H), 5.14-5.34 (m, 2H), 7.17-7.79

< Example  166> 3- [2- [4 - [[2-Butyl- methyl -6-oxo-5- (piperidin-l- Carbosy oil ) Pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-pyrrolo [2,3-d] pyrimidin- -1,2,4-oxadiazol-5-one}

¹ H-NMR (400 MHz):? 0.90-0.93 (t, 3H), 1.35-1.73 (m, 10H), 2.25 (s, 3H), 2.68-2.72 (t, 2H), 3.26-3.34 ), 3.45-3.50 (m, 1H), 3.80-3.84 (m, 1H), 5.18-5.32 (m, 2H), 7.19-7.76

< Example  167> 3- [2- [4 - [[2-Butyl- methyl -5- ( Morpholine -4- Carbosy oil ) -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Yl] methyl] phenyl] phenyl] -4H-pyrrolo [2,3-d] pyrimidin- 1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.90-0.94 (t, 3H), 1.35-1.44 (m, 2H), 1.65-1.73 (m, 2H), 2.28 (s, 3H), 2.69-2.73 (t, 2H ), 3.27-3.79 (m, 8H), 5.18-5.35 (m, 2H), 7.22-7.79 (m, 8H)

< Example  168> 2-Butyl-N, 4- Dimethyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] -N-propane-2- Ylpyrimidine -5- Carbothioamide  Phenyl] phenyl] methyl] - &lt; / RTI &gt; (2-methyl- N-propan-2-ylpyrimidine-5-carbothioamide}

^{1 H-NMR (400MHz):} δ 0.88-0.92 (t, 3H), 1.14-1.18 (m, 6H), 1.33-1.43 (m, 2H), 1.63-1.71 (m, 2H), 2.19-2.22 (d 2H), 2.74-2.87 (d, 3H), 3.77-3.83 (m, 0.5H), 4.84-4.95 (m, 0.5H), 5.17-5.31 , 7.16-7.73 (m, 8H)

< Example  169> 3- [2- [4 - [[5- (1,3,3a, 4,5,6,7,7a- Octahydroisoindole -2- Carbosy oil ) -2-butyl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- (1,3,3a, 4,5,6,7,7a-octahydroisoindole-2 -carbothioyl) -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

¹ H-NMR (400 MHz):? 0.89-0.92 (t, 3H), 1.28-1.70 (m, 12H), 2.23-2.24 (m, 5H), 2.65-2.70 , 4H), 5.18-5.40 (m, 2H), 7.18-7.75 (m, 8H)

< Example  170> 2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] -N-propane-2- Ylpyrimidine -5- Carbothioamide  2-butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo- propan-2-ylpyrimidine-5-carbothioamide}

^{1 H-NMR (400MHz):} δ 0.88-0.92 (t, 3H), 1.14-1.18 (m, 6H), 1.33-1.43 (m, 2H), 1.63-1.71 (m, 2H), 2.65-2.71 (m (M, 2H), 2.74-2.87 (m, 2H), 2.74-2.87 (m, 2H), 3.77-3.83 (m, 0.5H), 4.84-4.95

< Example  171> 2-Butyl-N- Cyclohexyl -4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- buy Yl) Phenyl ] Phenyl ] methyl ] Pyrimidin-5- Carbothioamide  4-methyl-6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] phenyl] methyl ] pyrimidine-5-carbothioamide}

¹ H-NMR (400 MHz):? 0.88-0.96 (t, 3H), 1.12-1.76 (m, 10H), 1.96-1.98 ), 2.79-2.83 (t, 2H), 4.30-4.40 (m, 1H), 5.15-5.33 (m, 2H), 7.12-7.73

< Example  172> 3- [2- [4 - [[2-Butyl-5- (3,5- Dimethylpiperidine -One- Carbosy oil ) -4-methyl-6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] phenyl} -5- ] -4H-1,2,4-oxadiazol-5-one}

¹ H-NMR (400 MHz):? 0.76-1.07 (m, 9H), 1.33-1.80 (m, 8H), 2.16-2.29 (m, 3H, m), 2.57-2.73 (m, 2H), 4.98-5.58 (m, 3H), 7.12-7.75 (m, 8H)

< Example  173> 2-Butyl-4- methyl -N- (2- Methyl propyl ) -6-oxo-1 - [[4- [2- (5-oxo-4H- buy Yl) Phenyl ] Phenyl ] methyl ] Pyrimidin-5- Carbothioamide  (2-butyl-4-methyl-N- (2-methylpropyl) -6-oxo-1 - [[4- [2- ] phenyl] methyl] pyrimidine-5-carbothioamide}

^{1 H-NMR (400MHz):} δ 0.87-0.97 (m, 9H), 1.35-1.49 (m, 2H), 1.69-1.80 (m, 2H), 2.02-2.08 (m, 1H), 2.37 (s, 3H ), 2.81-2.85 (t, 2H), 3.45-3.48 (t, 2Ht), 5.18 (s, 2H), 7.16-7.79

< Example  174> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N, N- Diethyl ethanethioamide  Methyl] -6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] pyrimidin-5-yl] -N, N-diethylethanethioamide}

^{1 H NMR (400 MHz, CDCl} 3): δ 0.88 (t, 3H), 1.25-1.40 (m, 8H), 1.62-1.70 (m, 2H), 2.28 (s, 3H), 2.60 (t, 2H) , 3.76 (q, 2H), 3.99 (q, 2H), 5.23 (s, 2H), 7.14-7.73 (m, 8H), 9.56

< Example  175> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- Propyl ethanethioamide  Methyl] -6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] pyrimidin-5-yl] -N-propylethanethioamide}

^{1 H NMR (400 MHz, CDCl} 3): δ 0.84-0.91 (m, 6H), 1.31-1.41 (m, 2H), 1.49-1.59 (m, 2H), 1.63-1.70 (m, 2H), 2.56 ( 2H), 3.45 (s, 2H), 2.45 (s, 2H) (s, 1 H)

< Example  N-butyl-2- [2-butyl-4- methyl Oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] Ethanethioamide  Synthesis of {N-butyl-2- [2-butyl-4-methyl-6-oxo- 1 - [[4- [2- (5-oxo- phenyl] methyl] pyrimidin-5-yl] ethanethioamide}

^{1 H NMR (400 MHz, CDCl} 3): δ 0.84-0.90 (m, 6H), 1.25-1.70 (m, 8H), 2.55 (s, 3H), 2.64 (t, 2H), 3.47-3.52 (m, 2H), 3.94 (s, 2H), 5.29 (s, 2H), 7.13-7. 74 (m, 8H), 9.19

< Example  177> 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- Octahydroisoindole Yl) -2- Sulfanylideneethyl ]-4- methyl -6-oxo-2- Propylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- 2-yl) methyl] phenyl] -4H-1,2,4-oxadiazol-5-one} Produce

^{1 H-NMR (400MHz):} δ 0.93 (t, 3H), 1.39-1.72 (m, 10H), 2.30 (s, 3H), 2.33-2.39 (m, 2H), 2.63 (t, 2H), 3.65- 1H), 7.47 (t, 1H), 7.57 (t, 1H), 7.69 (d, 2H) (d, 1 H)

< Example  178> N- Methoxy -N- methyl -2- [4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- buy Yl) Phenyl ] Phenyl ] methyl ]-2- Propylpyrimidine -5 days] Ethanthiourea Id {N- 메틸oxy -N- methyl -2- [4- methyl -6- oxo -1 - [[4- [2- (5- oxo -4H-1,2,4- oxadiazole -3-yl) phenyl] phenyl] methyl] -2-propylpyrimidin-5-yl] ethanethioamide}

^{1 H-NMR (400MHz):} δ 0.95 (t, 3H), 1.68-1.74 (m, 2H), 2.28 (s, 3H), 2.64 (t, 2H), 3.66 (s, 3H), 3.84 (s, 2H), 7.39 (d, IH), 7.46 (t, IH), 7.59 (t, ), 7.72 (d, 1 H)

< Example  179> N, N- Dimethyl -2- [4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ]-2- Propylpyrimidine -5 days] Ethanethioamide  Phenyl] phenyl] -1H-pyrazolo [3,4-d] pyrimidin-2-yl] methyl] -2-propylpyrimidin-5-yl] ethanethioamide}

^{1 H-NMR (400MHz):} δ 0.96 (t, 3H), 1.67-1.77 (m, 2H), 2.29 (s, 3H), 2.62 (dd, 2H), 3.43 (s, 2H), 3.49 (s, (D, 2H), 7.39 (d, IH), 7.47 (t, IH), 7.59 ), 7.75 (d, 1 H)

< Example  180 > 3- [2- [4 - [[4- methyl -6-oxo-2-propyl-5- (2- Pyrrolidine -1-yl-2- Sulfanylideneethyl ) Pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Methyl-6-oxo-2-propyl-5- (2-pyrrolidin-1-yl-2-sulfanylideneethyl) pyrimidin- phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.97 (t, 3H), 1.68-1.75 (m, 2H), 1.92-2.00 (m, 2H), 2.05-2.15 (m, 2H), 2.33 (s, 3H), 2H), 7.38 (d, 2H), 3.78 (s, 2H), 3.78 (s, 2H) 1H), 7.46 (t, IH), 7.58 (t, IH), 7.73

< Example  181> 3- [2- [4 - [[4- methyl -6-oxo-5- (2-piperidin-l-yl-2- Sulfanylideneethyl )-2- Propylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[4-methyl-6-oxo-5- (2-piperidin- 1 -yl-2- sulfanylideneethyl) -2-propylpyrimidin-1-yl] methyl] phenyl ] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.94 (t, 3H), 1.64-1.76 (m, 8H), 2.27 (s, 3H), 2.60 (t, 2H), 3.82 (s, 4H), 4.26 (s, 2H), 5.23 (s, 2H), 7.14 (d, 2H), 7.27 (d, 2H), 7.38 (d, )

< Example  182> 3- [2- [4 - [[5- [2- (3,5- Dimethylpiperidine Yl) -2- Sulfanylideneethyl ]-4- methyl -6-oxo-2- Propylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5 - one {3- [2- [4 - [[5- [2- (3,5-dimethylpiperidin-1-yl) -2-sulfanylideneethyl] -4-methyl-6-oxo-2- propylpyrimidin- -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

¹ H-NMR (400 MHz):? 0.86-1.00 (m, 9H), 1.45-1.57 (m, (M, 3H), 2.39 (t, 2H), 2.39 (t, 2H) 2H), 7.35 (d, IH), 7.46 (d, 2H), 4.62 (d, t, 1 H), 7.58 (t, 1 H), 7.72 (d, 1 H)

< Example  183> 3- [2- [4 - [[5- [2- (3,5- Dimethylmorpholine Yl) -2- Sulfanylideneethyl ]-4- methyl -6-oxo-2- Propylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[5- [2- (3,5-dimethylmorpholin-4-yl) -2-sulfanylideneethyl] -4-methyl-6-oxo-2-propylpyrimidin- -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.98 (t, 3H), 1.19-1.25 (m, 6H), 1.71-1.78 (m, 2H), 2.32 (s, 3H), 2.62-2.66 (m, 3H), 2H), 5.55 (d, 0.7H), 2.39-3.01 (m, 1H), 3.62-3.28 , 7.19 (d, 2H), 7.29 (d, 2H), 7.39 (d,

< Example  184> N- methyl -2- [4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole Yl) Phenyl ] Phenyl ] methyl ]-2- Propylpyrimidine -5-yl] -N-propan-2- Sun ethane thioamine 4-methyl-2- [4-methyl-6-oxo-1 - [[4- [2- (5-oxo- ] -2-propylpyrimidin-5-yl] -N-propan-2-ylethanethioamide}

^{1 H-NMR (400MHz):} δ 0.97 (t, 3H), 1.18 (d, 3H), 1.29 (d, 3H), 1.70-1.78 (m, 2H), 2.33 (s, 3H), 2.74 (t, 2H), 3.19 (s, 1.7H), 3.28 (s, 1.3H), 3.89 (d, 2H), 4.73-4.80 1H), 7.59 (t, 1H), 7.74 (d, 1H), 7.19 (d, 2H), 7.29

< Example  185> 3- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N, N- Dimethyl propanethioamide  Methyl] -6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] pyrimidin-5-yl] -N, N-dimethylpropanethioamide}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.40 (m, 2H), 1.85 (m, 2H), 2.43 (s, 3H), 2.52 (t, 2H), 2.64 (t, 2H) 2H), 2.86 (s, 3H), 3.21 (s, 3H), 5.26 (s, 2H), 7.27 (m, 5H), 7.42 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  186> 3- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- methyl -N-propane-2- Yl propane thioamide 4-methyl-6-oxo-1 - [[4- [2- (5-oxo- ] pyrimidin-5-yl] -N-methyl-N-propan-2-ylpropanethioamide}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.28 (t, 3H), 1.40 (m, 2H), 1.60 (m, 2H), 1.85 (m, 2H), 2.52 (t, 2H) 2H), 2.86 (t, 2H), 2.95 (s, 4H), 5.26 (s, 2H), 6.87 (d, 7.49 (t, 1 H), 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  187> 3- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- Cyclopropylpropane thioamide  Methyl] -6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] pyrimidin-5-yl] -N-cyclopropylpropanethioamide}

^{1 H-NMR (400MHz):} δ 0.80 (m, 5H), 0.91 (t, 3H), 1.40 (m, 2H), 1.85 (m, 2H), 2.64 (t, 2H), 2.86 (t, 2H) 2H), 7.27 (m, 5H), 7.42 (m, 1H), 7.49 (t,

< Example  188> 3- [2- [4 - [[2-Butyl-4- methyl -6-oxo-5- (3-piperidin-l-yl-3- Sulfanilide propyl ) Pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Methyl-6-oxo-5- (3-piperidin-1-yl-3-sulfanylidenepropyl) pyrimidin- phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.40 (m, 2H), 1.70 (m, 3H), 1.96 (m, 2H), 2.10 (t, 2H), 2.36 (t, 2H) 2H), 7.25 (m, 2H), 7.42 (m, 1H), 7.94 (m, 2H) ), 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  189> 3- [2- [4 - [[5- [3- (1,3,3a, 4,5,6,7,7a- Octahydroisoindole Yl) -3- Sulfanilide propyl ] -2-butyl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [3- (1,3,3a, 4,5,6,7,7a- 2-yl) -3-sulfanylidenepropyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol- Produce

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.40 (m, 2H), 1.70 (m, 3H), 1.96 (m, 2H), 2.86 (t, 2H), 2.90 (m, 2H) 2H), 3.84 (m, 4H), 5.26 (s, 2H), 7.16 (d, 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  190> 3- [2- [4 - [[2-Butyl-4- methyl -5- [3- (4- Methylpiperidine Yl) -3- Sulfanilide propyl ] -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one 1 - yl] methyl] phenyl] -6-oxo- pyrimidin-1-yl] ] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.41 (m, 5H), 1.71 (m, 8H), 2.31 (s, 3H), 2.68 (t, 2H), 3.52 (m, 4H) , 7.28 (d, 2H), 7.42 (m, 1H), 7.48 (t, 1H), 7.61 7.77 (d, 1 H)

< Example  191> 3- [2- [4 - [[2-butyl-5- [3- (3,3- Dimethylpiperidine Yl) -3- Sulfanilide propyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5- one {3- [2- [4 - [[2-butyl-5- 3- (3,3-dimethylpiperidin-1-yl) -3-sulfanylidenepropyl] -4-methyl-6- oxopyrimidin-1 -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.43 (m, 6H), 1.52 (m, 5H), 1.85 (m, 3H), 2.64 (t, 2H), 2.86 (t, 2H) 2H), 3.20 (d, 2H), 3.50 (d, 2H), 3.85 (m, 4H), 5.26 (s, 2H) 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  192> 3- [2- [4 - [[2-butyl-5- [3- (3,5- Dimethylmorpholine Yl) -3- Sulfanilide propyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[2-butyl-5- [3- (3,5- dimethylmorpholin-4-yl) -3-sulfanylidenepropyl] -4-methyl-6-oxopyrimidin- -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.20 (m, 6H), 1.40 (m, 2H), 1.70 (m, 2H), 2.64 (dd, 2H), 2.86 (t, 2H) 2H), 7.16 (d, 1H), 7.27 (m, 4H), 7.42 (m, 1H) 7.49 (t, 1 H), 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  193> 3- [2- [4 - [[2-Butyl-4- methyl -5- (3- Morpholine -4-yl-3- Sulfanilide propyl ) -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[2-butyl-4-methyl-5- (3-morpholin-4- yl-3- sulfanylidenepropyl) -6- oxopyrimidin-1-yl] methyl] phenyl ] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.40 (m, 2H), 1.70 (m, 2H), 2.64 (dd, 2H), 2.86 (t, 2H), 2.90 (m, 4H) 2H), 7.16 (d, IH), 7.27 (m, 4H), 7.42 (m, 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  194> 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- Octahydroisoindole Yl) -2- Sulfanylideneethyl ] -2-butan-2-yl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7- Methyl-6-oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazole -5-one}

^{1 H-NMR (400MHz):} δ 0.75 (t, 3H), 1.17 (d, 3H), 1.38-1.62 (m, 11H), 1.77-1.88 (m, 1H), 2.38 (s, 3H), 2.73- 2H), 7.27 (d, 2H), 7.37 (d, IH), 7.47 (m, 2H) , 7.59 (t, 1 H), 7.76 (d, 1 H)

< Example  195> 2- [2-butan-2-yl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- Methoxy -N- Methyl ethanthioumai Di {2- [2- butan -2- yl -4- methyl -6- oxo -1 - [[4- [2- (5- oxo -4H-1,2,4- oxadiazole -3-yl) phenyl] phenyl] methyl] pyrimidin-5-yl] -N-methoxy-N-methylethanethioamide}

¹ H-NMR (400 MHz):? 0.73 (t, 3H), 1.15 (d, 3H), 1.46-1.53 (m, 2H), 7.26 (d, 2H), 7.37 (d, 2H), 3.76 (s, 3H) (d, IH), 7.46 (t, IH), 7.58 (t, IH), 7.70

< Example  196> 2- [2-butan-2-yl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N, N- Dimethylethanethioamide  4-methyl-6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol- phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylethanethioamide}

¹ H-NMR (400 MHz):? 0.76 (t, 3H), 1.18 (d, 3H), 1.48-1.56 (m, 2H), 7.17 (d, 2H), 7.27 (d, 2H), 7.37 (d, 2H) (d, IH), 7.48 (t, IH), 7.59 (t, IH), 7.78

< Example  197> 2- [2-Butan-2-yl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- methyl -N-propane-2- Sun ethane thio 2-butan-2-yl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H- 1,2,4-oxadiazol- 3- yl) phenyl] ] phenyl] methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylethanethioamide}

¹ H-NMR (400 MHz):? 0.74 (s, 3H), 1.18 (d, 6H), 1.26-1.29 (m, 3H), 1.49-1.56 2H), 4.75-4.82 (m, 0.5H), 5.33 (s, 2H), 2.33 (s, (s, 2H), 5.88-5.96 (m, 0.5H), 7.17 (d, 2H), 7.26 (d, 2H), 7.36 , 7.74 (d, 1 H)

< Example  198> 3- [2- [4 - [[2-Butan-2-yl-5- [2- (2,6- Dimethylpiperidine -1-yl) -2-sulfanylideneethyl] -4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadai 5-one {3- [2- [4 - [[2-Butan-2-yl-5- [2- (2,6- dimethylpiperidin- 1- yl) -2-sulfanylideneethyl] 6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

¹ H-NMR (400 MHz):? 0.71 (t, 3H), 0.86-1.00 (m, 7H), 1.18 (d, 3H), 1.49-1.89 (m, 3H), 2.70 (t, 1H), 2.79-2.84 (m, 1H), 7.56 (t, 1H), 7.67 (d, 2H), 5.59 (d, 0.6H), 7.14 , 1H)

< Example  Butan-2-yl) -5- [2- (2,6-dimethylmorpholin-4-yl) -2-sulfanylidenemethyl] -4- Methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4- 2-yl-5- [2- (2,6-dimethylmorpholin-4-yl) -2-sulfanylideneethyl] -4-methyl-6-oxopyrimidin-1- yl] methyl] phenyl] , 4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.77 (t, 3H), 1.19-1.28 (m, 9H), 1.51-1.58 (m, 1H), 1.81-1.88 (m, 1H), 2.34 (s, 2H), 2H), 2.64 (s, 2H), 2.98 (t, 1H), 3.62-3.69 (m, 2H), 3.84-4.00 (d, IH), 7.13 (d, 2H), 7.22 (d, 2H), 7.40

< Example  200> 3- (4 '- ((2-Butyl-5- (2- (3,5- Dimethylpiperidine Yl) -2- Thioxoethyl )-4- methyl -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadiazole -5 (4H) -one {3- (4 '- ((2-butyl-5- (2- (3,5- dimethylpiperidin- 1 -yl) -2-thioxoethyl) -4-methyl- 1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H NMR (400 MHz, CDCl} 3): δ 0.90-0.96 (m, 9H, m), 1.02 (d, 1H), 1.36-1.76 (m, 6H), 1.88 (d, 1H), 2.31 (s, 2H), 5.60-5.64 (m, 1 H), 2.40 (s, 3H) , 7.21-7.83 (m, 8H)

< Example  201> 3- [2- [4 - [[2-butyl-5- [2- (3,4- Dihydro -1H- Isoquinoline Yl) -2- Sulfanylideneethyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[2-butyl- 5- [2- (3,4- dihydro- I H- isoquinolin- 2- yl) -2-sulfanylideneethyl] -4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.20-1.30 (m, 2H), 1.40-1.80 (m, 2H), 2.64 (s, 3H), 2.66 (m, 2H), 2.90 ( (m, 2H), 3.95 (m, 2H), 4.30-4.60 (dd, IH), 5.26 (s, 2H), 7.27 -7.80 (m, 3 H), 8.10 (d, 1 H)

< Example  202. 3- [2- [4 - [[5- [2- (3,4,4a, 5,6,7,8,8a- Octahydro -1H- Isoquinoline Yl) -2- Sulfanylideneethyl ] -2-butyl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl] -4H-1,2,4-oxadiazol-5-one; 2- [4 - [[5- [2- (3,4,4a, 5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl) -2-sulfanylideneethyl] -2- methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

¹ H-NMR (400 MHz):? 0.91 (t, 3H), 1.20-1.30 (m, 8H), 1.40-1.80 (m, 9H), 2.64 2H), 5.50-5.70 (dd, 1H), 7.27 (m, 4H), 7.42 (m, 1H), 3.95 (m, 4H), 4.30-4.60 (dd, , 7.49 (t, IH), 7.62 (d, IH), 7.76 (d, IH)

< Example  203> 3- [2- [4 - [[2-Butyl- methyl -6-oxo-5- [2- Sulfanilide -2- (1,3- Thiazolidine Yl) ethyl] pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5- one {3- [2- [4 - [[2-butyl-4-methyl-6-oxo-5- 2 -sulfanylidene- 2- (1,3- thiazolidin- 3- yl) ethyl] -1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H NMR (400 MHz, CDCl} 3): δ 0.91 (t, 3H), 1.34-1.74 (m, 4H), 2.34 (d, 3H), 2.68 (t, 2H), 3.07-3.23 (m, 2H) 2H), 4.81 (d, 2H), 5.25 (s, 2H), 7.16-7.79 (m, 8H), 8.77

< Example  204> 3- [2- [4 - [[2-Butyl-4- methyl -5- [2- (4- Methylpiperidine Yl) -2- Sulfanylideneethyl ] -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[2-butyl-4-methyl-5- [2- (4-methylpiperidin- 1 -yl) -2-sulfanylideneethyl] -6-oxopyrimidin- ] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H NMR (400 MHz, CDCl} 3): δ 0.89 (t, 3H), 0.96 (d, 3H), 1.17-1.41 (m, 4H), 1.63-1.78 (m, 5H), 2.27 (s, 3H) , 2.62 (t, 2H), 2.97-3.24 (m, 2H), 3.82 (q, 2H), 4.43 (d, , 8H), 9.49 (s, 1 H)

< Example  205> 3- [2- [4 - [[2-butyl-5- [2- (2,6- Dimethylmorpholine Yl) -2- Sulfanylideneethyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[2-butyl-5- [2- (2,6- dimethylmorpholin-4-yl) -2-sulfanylideneethyl] -4-methyl-6-oxopyrimidin- -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

¹ H NMR (400 MHz, CDCl ₃ ):? 0.90 (t, 3H), 1.20-1.73 (m, 10H), 2.31 (s, 3H), 2.62-2.66 2H), 5.54 (d, 1H), 7.16-7.77 (m, 8H), 9.00 (s, 1H)

< Example  206> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- Methoxy -N- Methyl ethanethioamide  Methyl] -6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] pyrimidin-5-yl] -N-methoxy-N-methylethanethioamide}

^{1 H NMR (400 MHz, CDCl} 3): δ 0.88 (t, 3H), 1.31-1.40 (m, 2H), 1.62-1.70 (m, 2H), 2.25 (s, 3H), 2.60 (t, 2H) , 3.66 (s, 3H), 3.90 (s, 2H), 3.66 (s, 2H)

< Example  207> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- (2- Methoxyethyl ) -N- Methylethanethioamide 4-methyl-6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] phenyl] methyl ] pyrimidin-5-yl] -N- (2-methoxyethyl) -N-methylethanethioamide}

^{1 H NMR (400 MHz, CDCl} 3): δ 0.93 (t, 3H), 1.37-1.46 (m, 2H), 1.68-1.76 (m, 2H), 2.59 (s, 3H), 2.72 (t, 2H) , 3.25 (s, 3H), 3.45-3.49 (m, 2H), 3.72-3.76 (m, 2H), 5.32 (s, 2H), 7.23-7.84 (s, 1 H)

< Example  (2-butyl-4-methyl-6-oxo-1 - [[4- [2- ] Methyl] pyrimidin-5-yl] -N- (2-thiophen-2-ylethyl) ethanthioamide 2- {2-butyl- Pyrimidin-5-yl] -N- (2-thiophen-2-ylethyl) ethanethioamide} &lt; / RTI &gt;

^{1 H NMR (400 MHz, CDCl} 3): δ 0.93 (t, 3H), 1.37-1.76 (m, 4H), 2.17 (s, 2H), 2.59 (s, 3H), 2.70 (t, 2H), 3.09 2H), 3.81 (s, 2H), 3.98 (s, 2H), 5.26 (s, 2H), 6.77-7.85

< Example  209> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N, N- Di (propan-2-yl) ethane thioamide Di {2- [2- butyl -4- methyl -6- oxo -1 - [[4- [2- (5- oxo -4H-1,2,4- oxadiazole 3-yl) phenyl] phenyl] methyl] pyrimidin-5-yl] -N, N-di (propan-2-yl) ethanethioamide}

^{1 H NMR (400 MHz, CDCl} 3): δ 0.91 (t, 3H), 1.25-1.74 (m, 18H), 2.31 (s, 3H), 2.65 (t, 2H), 3.87 (s, 2H), 5.31 (s, 2H), 7.22-7.83 (m, 8H), 8.32 (s, 1H)

< Example  210> 3- [2- [4 - [[2-butyl-5- (2-indol- Sulfanylideneethyl )-4- methyl -6-ox Sophirimi 1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Methyl-6-oxopyrimidin-1-yl] methyl] phenyl] -5-oxo-2- {4- [2- ] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.39 (m, 2H), 1.70 (m, 2H), 2.34 (s, 3H), 2.62 (t, 2H), 3.63 (m, 2H) 2H), 7.28 (d, 7H), 7.41 (m, IH), 7.51 (t, IH), 7.61

< Example  211> 3- [2- [4 - [[2-Butyl-4- methyl -5- [2- (2- Methylpyrrolidine Yl) -2- Sulfanylideneethyl ] -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Yl) -2-sulfanylideneethyl] -6-oxopyrimidin-1-yl (2-methylpyrrolidin- ] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.39 (m, 5H), 1.70 (m, 4H), 1.80-2.10 (m, 5H), 2.34 (s, 3H), 2.62 (t, 2H), 3.63 (m, 2H), 5.25 (s, 2H), 7.18 (d, 2H), 7.28 ), 7.77 (d, 1 H)

< Example  212> 2- [2- Cyclopropyl -4- methyl -6-oxo-1 - [[4- [2- (5-oxo-4H- buy Yl) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N, N- Dimethylethanethiol Amide {2- [2- cyclopropyl -4- methyl -6- oxo -1 - [[4- [2- (5- oxo -4H-1,2,4- oxadiazole -3-yl) phenyl] phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylethanethioamide}

^{1 H-NMR (400MHz):} δ 2.40-2.63 (m, 8H), 3.45 (s, 3H), 3.51 (s, 3H), 5.26 (s, 2H), 7.19 (d, 2H), 7.28 (m, 2H), 7.42 (d, IH), 7.49 (t, IH), 7.61

< Example  213> 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- Octahydroisoindole Yl) -2- Sulfanylideneethyl ]-2- Cyclopropyl -4- methyl -6- Oxopyrimidine -1 day] methyl Phenyl] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (1,3,3a, 2-yl) methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5 -one}

^{1 H-NMR (400MHz):} δ 1.39-1.74 (m, 14H), 2.28 (m, 4H), 2.36 (m, 1H), 2.38 (m, 1H), 2.63 (t, 2H), 3.58 (m, 1H), 7.61 (t, 1H), 7.61 (t, 2H), 7.35 (s, 2H) ), 7.72 (d, 1 H)

< Example  214> 3- [2- [4 - [[5- [2- (2,3,3a, 4,5,6,7,7a- Octahydroindole -1-yl) -2- Phanylidene Yl] -2-butyl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (2,3,3a, 4,5,6,7,7a- 1-yl] methyl] phenyl] -4H-1,2,4-oxadiazol-5-one} Produce

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.40 (m, 2H), 1.70 (m, 3H), 1.96 (m, 2H), 2.86 (t, 2H), 2.90 (m, 2H) 2H), 7.26 (s, 2H), 7.16 (d, 1H), 7.27 (m, 4H), 7.42 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  215> 3- [2- [4 - [[2-butyl-5- [2- (1,3- Dihydroisoindole -2-yl) -2-sulfanylidenemethyl] -4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadai 2-yl) -2-sulfanylideneethyl] -4-methyl-6-oxopyrimidin- 1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.20-1.30 (m, 2H), 1.40-1.80 (m, 2H), 2.64 (s, 3H), 2.90 (m, 2H), 3.95 ( 2H), 7.62-7.80 (m, 3H), 7.27 (m, 2H), 7.30 (m, 2H), 4.30-4.60 (dd, , 8.10 (d, 1 H)

< Example  216> 3- [2- [4 - [[2-butyl-5- [2- (2,3- Dihydroindole Yl) -2- Sulfanylideneethyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole 5- {3- [2- [4 - [[2- butyl -5- [2- (2,3- dihydroindole -One- yl )-2- sulfanylideneethyl ] -4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.20-1.40 (m, 2H), 1.50-1.80 (m, 2H), 2.63 (s, 3H), 2.90 (m, 2H), 3.80 ( 2H), 7.62-7.80 (m, 3H), 7.28 (m, 2H), 7.44 (m, , 8.10 (d, 1 H)

< Example  217> 3- [2- [4 - [[2-Butyl- methyl -6-oxo-5- [2- (4-propane-2- Azeparidine Yl) -2- Sulfanylideneethyl ] Pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[2-butyl-4-methyl-6-oxo- 5- [2- (4- pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

¹ H-NMR (400 MHz):? 0.91 (t, 3H), 1.20-1.30 (m, 9H), 1.40-1.80 (m, 4H), 2.64 1H), 7.62 (d, 1H), 8.10 (d, 2H), 7.26 (s, (d, 1 H)

< Example  218> 3- [2- [4 - [[5- [2- (3,3a, 4,5,6,6a- Hexahydro -1H- Cyclopenta [c] pyrrole Yl) -2- Sulfanylideneethyl ] -2-butyl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl] phenyl] -4H- 1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (3,3a, 4,5,6,6a- methylhexahydro-1H-cyclopenta [c] pyrrol-2-yl) -2-sulfanylideneethyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] -oxadiazol-5-one} &lt; / RTI &gt;

¹ H-NMR (400 MHz):? 0.91 (t, 3H), 1.20-1.30 (m, 2H), 1.40-1.60 (m, 6H) 2H), 7.27 (m, 4H), 7.42 (d, 1H), 7.49 (m, 4H) (d, 1 H), 7.62 (d, 1 H), 8.10 (d, 1 H)

< Example  219> 3- [2- [4 - [[2-butyl-5- [2- (1,3- Dihydroisoindole -2-yl) -2-sulfanylidenemethyl] -4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadai 2-yl) -2-sulfanylideneethyl] -4-methyl-6-oxopyrimidin- 1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.40-1.60 (t, 2H), 1.80 (t, 2H), 2.80 (d, 2H), 3.95 (m, 4H), 4.30-4.60 ( (d, 2H), 5.26 (s, 2H), 7.27 (m, 9H), 7.42

< Example  220 > 3- [2- [4 - [[2-Butyl- methyl -5- [2- [4- (4- Nitrophenyl ) Piperazin-1-yl] -2- Sulfanylideneethyl ] -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadai 5-one {3- [2- [4 - [[2-butyl-4-methyl-5- [2- [4- (4- nitrophenyl) piperazin- 1 -yl] -2-sulfanylideneethyl] -6 -oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.90 (t, 3H), 1.34-1.40 (m, 2H), 1.65-1.71 (m, 2H), 2.36 (s, 3H), 2.65 (t, 2H), 3.58- 2H), 7.25 (d, 2H), 7.24 (d, 2H), 7.24 (d, 2H) (d, 2H), 7.36 (d, IH), 7.47 (t, IH), 7.58

< Example  221 is 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- Octahydroisoindole Yl) -2- Sulfanylideneethyl ] -2-butyl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ]-4- Fluoro 4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7- 1-yl] methyl] phenyl] -4-fluorophenyl] -4H-1,2,4-oxadiazol-2-yl} -2-sulfanylideneethyl] -2-butyl-4-methyl-6-oxopyrimidin- 5-one}

^{1 H-NMR (400MHz):} δ 0.88 (t, 3H), 1.34-1.68 (m, 12H), 2.32 (s, 2H), 2.35-2.39 (m, 1H), 2.68 (br, 2H), 3.64- 2H), 7.07 (d, 1H), 7.13-7.25 (m, 5H), 7.62-7.67 (m, 1H)

< Example  222> 2- [2-Butyl-1 - [[4- [5- Fluoro -2- (5-oxo-4H-1,2,4- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ]-4- methyl -6- Oxopyrimidine -5-yl] -N- Methoxy -N- Methylethanethio Phenyl] phenyl] methyl] -4- (4-oxo-4H-1,2,4-oxadiazol- methyl-6-oxopyrimidin-5-yl] -N-methoxy-N-methylethanethioamide}

^{1 H-NMR (400MHz):} δ 0.88 (t, 3H), 1.32-1.39 (m, 2H), 1.64-1.70 (m, 2H), 2.28 (s, 2H), 2.65 (t, 2H), 3.66 ( 2H), 7.09 (d, 1H), 7.13-7.27 (m, 5H), 7.69-7.72 (m,

< Example  223> 3- [2- [4 - [[2-Butyl- methyl -6-oxo-5- (2- Pyrrolidine -1-yl-2- Sulfanylideneethyl ) Pyrimidin-1-yl] methyl ] Phenyl ]-4- Fluorophenyl ] -4H-1,2,4- Oxadiazole Methyl-6-oxo-5- (2-pyrrolidin-1-yl-2-sulfanylideneethyl) pyrimidin- phenyl] -4-fluorophenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.85 (t, 3H), 1.32-1.39 (m, 2H), 1.63-1.68 (m, 2H), 1.93-2.18 (m, 4H), 2.36 (s, 3H), 2H), 3.74-3.86 (m, 6H), 5.28 (s, 2H), 7.07 (d, 1H), 7.11-7.24 (m, 5H), 7.66-7.82

< Example  224> 3- [2- [4 - [[2-Butyl-5- [2- (3,5- Dimethylpiperidine Yl) -2- Sulfanylideneethyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ]-4- Fluorophenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[2-butyl- 5- 2- (3,5- dimethylpiperidin- -sulfanylideneethyl] -4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] -4-fluorophenyl] -4H-1,2,4-oxadiazol-

^{1 H-NMR (400MHz):} δ 0.87-0.95 (m, 9H), 1.33-1.42 (m, 2H), 1.65-1.90 (m, 4H), 2.27 (s, 3H), 2.40 (t, 1H), 2H), 2.70 (t, 2H), 2.70 (t, 2H), 2.70 (t, , 7.14-7.19 (m, 3H), 7.25-7.28 (m, 2H), 7.75 (dd,

< Example  225> 3- [2- [4 - [[2-butyl-5- [2- (3,5- Dimethylmorpholine Yl) -2- Sulfanylideneethyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ]-4- Fluorophenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[2-butyl- 5- 2- (3,5- dimethylmorpholin- -sulfanylideneethyl] -4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] -4-fluorophenyl] -4H-1,2,4-oxadiazol-

^{1 H-NMR (400MHz):} δ 0.85 (t, 3H), 1.13-1.25 (m, 6H), 1.32-1.41 (m, 2H), 1.64-1.72 (m, 2H), 2.36 (s, 3H), 2H), 3.64 (s, 2H), 3.75-3.87 (m, 4H), 4.28 (br, 6H), 7.65 (d, 1 H)

< Example  226> 2- [2-Butyl-1 - [[4- [5- Fluoro -2- (5-oxo-4H-1,2,4- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ]-4- methyl -6- Oxopyrimidine -5-yl] -N- methyl -N- (2- Methyl propyl Phenylthio] methyl] methyl} -2-methyl-2-oxo- ] -4-methyl-6-oxopyrimidin-5-yl] -N-methyl-N- (2-methylpropyl) ethanethioamide}

^{1 H-NMR (400MHz):} δ 0.83 (t, 3H), 0.92 (d, 3H), 0.99 (d, 3H), 1.32-1.39 (m, 2H), 1.64-1.70 (m, 2H), 2.42 ( (s, 3H), 3.06 (t, 2H), 3.38 (d, 2H), 3.55 (d, 1H), 3.74-3.83 , 7.67 (d, 1 H)

< Example  227> 3- [2- [4 - [[2-Butyl-4- methyl -5- [2- (2- methyl -1,3,3a, 4,6,6a- Hexahydropyrrolo [3,4-c] pyrrole -5-yl) -2- Sulfanylideneethyl ] -6- Oxopyrimidine -1 day] methyl Phenyl] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[2-butyl- 3,3a, 4,6,6a-hexahydropyrrolo [3,4-c] pyrrol-5-yl) -2-sulfanylideneethyl] -6-oxopyrimidin-1-yl] methyl] phenyl] , 2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.39-1.74 (m, 13H), 2.28 (s, 3H), 2.36 (m, 1H), 2.38 (m, 1H), 2.63 (t, 2H), 7.48 (d, 1H), 7.49 (t, 1H), 7.61 (d, 2H), 7.28 , &Lt; / RTI &gt; 1H), 7.70 (d, 1H)

< Example  228> 3- (4 '- ((2-Butyl-5- (2- ( Hexahydrocyclopenta [c] pyrrole -2 (lH) -yl) -2- Thioxoethyl )-4- methyl -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl (2-butyl-5- (2- (hexahydrocyclopenta [c] pyrrol-2 (lH) -quinolin- 2-yl) -1,2,4-oxadiazol-5 (4H) -one} was prepared in accordance with the general method of example 1 Produce

^{1 H-NMR (400MHz):} δ 0.93 (t, 3H), 1.30-1.74 (m, 12H), 2.03 (m, 2H), 2.63 (t, 2H), 2.91 (s, 3H), 3.58-3.86 ( 1H), 7.61 (t, 1H), 7.70 (d, 2H), 7.28 (d, 2H) , 1H)

< Example  229> 3- [2- [4 - [[5- [2- (1,3,4,6,7,8,9,9a- Octahydropyrido [l, 2-a] pyrazine Yl) -2- Sulfanylideneethyl ] -2-butyl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (1,3,4,6,7,8,9, Methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4a, 6a-hexahydropyrido [1,2- a] pyrazin- , 4-oxadiazol-5-one}

¹ H-NMR (400 MHz):? 0.92 (t, 3H), 1.39-1.74 (m, 14H), 2.28 (s, 2H), 7.28 (m, 2H), 7.48 (d, 1H), 7.49 (t, 1H), 7.61 , &Lt; / RTI &gt; 1H), 7.70 (d, 1H)

< Example  230> 3- [2- [4 - [[5- [2- (2,3,3a, 4,5,6,7,7a- Octahydroindole -1-yl) -2- A house Ethyl] -2-butyl-4- methyl -6-oxo-pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -2H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (2,3,3a, 4,5,6,7,7a- yl] methyl] phenyl] phenyl] -2H-1,2,4-oxadiazol-5-yl} -2-oxo-pyrrolidin- -one}

^{1 H-NMR (400MHz):} δ 0.93 (t, 3H), 1.29-1.75 (m, 14H), 2.05 (m, 2H), 2.64 (t, 2H), 2.91 (s, 3H), 3.68-3.86 ( 1H), 7.70 (t, 1H), 7.70 (d, 1H), 7.25 (s, 2H), 7.17-7.28

< Example  231> 3- [2- [4 - [[5- [2- (7- Azabicyclo [2.2.1] heptane -7-yl) -2- Sulfanylideneethyl ]-4- methyl -6-oxo-2- Propylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (7-azabicyclo [2.2.1] heptan- -sulfanylideneethyl] -4-methyl-6-oxo-2-propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

^{1 H-NMR (400MHz):} δ 0.99 (t, 3H), 1.58-1.65 (m, 2H), 1.71-2.05 (m, 8H), 2.61 (s, 3H), 2.68 (t, 2H), 3.97 ( (d, 2H), 7.31 (d, 2H), 5.30 (s, 2H), 5.52-5.64 (t, 1 H), 7.82 (d, 1 H)

< Example  232> 3- [2- [4 - [[2-butyl-4- methyl -6-oxo-5- [2- Sulfanilide -2- [4- ( Trifluoromethyl ) Piperidin-1-yl] ethyl] pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[2-butyl- 4- methyl- 6- oxo-5- [2-sulfanylidene- 2- [ 1-yl] methyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.89-0.93 (t, 3H), 1.34-1.43 (m, 2H), 1.63-1.74 (m, 4H), 1.98-2.01 (m, 2H), 2.33 (s, 3H ), 2.38-2.46 (m, 1H), 2.64-2.68 (t, 2H), 2.98-3.31 (m, 2H), 3.79-3.92 , 2H), 5.68-5.71 (m, IH), 7.17-7.79 (m, 8H)

< Example  -2-butyl-4-methyl-6-thiophen-2-yl) -2- Yl} methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one To a solution of 3- {2- [4 - [[5- [2- -azaspiro [4.5] decan-8-yl) -2-sulfanylideneethyl] -2-butyl-4-methyl-6-oxopyrimidin-1- yl] methyl] phenyl] phenyl] -4H- 1,2,4- 5-one}

^{1 H-NMR (400MHz):} δ 0.85 (t, 3H), 1.33-1.39 (m, 2H), 1.48-1.69 (m, 14H), 2.39 (s, 3H), 2.97 (t, 2H), 3.73- 2H), 7.38 (d, 1H), 7.46 (t, 1H), 7.58 (t, 1H), 7.72 (d, 2H) (d, 1 H)

< Example  234> 3- [2- [4 - [[5- [2- (8- Azaz Spiro [4.5] decane -8-yl) -2- Sulfanylideneethyl ]-4- methyl -6-oxo-2- Propylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadia 5-one {3- [2- [4 - [[5- [2- (8-Azaspiro [4.5] decan-8- yl) -2-sulfanylideneethyl] -4-methyl- propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.97 (t, 3H), 1.47-1.76 (m, 14H), 2.38 (s, 3H), 2.87-2.92 (m, 2H), 3.75-3.86 (m, 6H), 2H), 7.27 (d, 2H), 7.38 (d, IH), 7.45 (t, IH), 7.58 (t,

< Example  235> 3- [2- [4 - [[2-butyl-5- [2- (4,4- Dimethylpiperidine Yl) -2- Sulfanylideneethyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole 5- {3- [2- [4 - [[2- butyl -5- [2- (4, 4- dimethylpiperidine -One- yl )-2- sulfanylideneethyl ] -4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

^{1 H-NMR (400MHz):} δ 0.81 (t, 3H), 1.03 (s, 6H), 1.32-1.36 (m, 2H), 1.46-1.50 (m, 4H), 1.64-1.68 (m, 2H), 2H), 7.26 (d, 2H), 7.36 (d, IH), 7.22 (s, 2H) , 7.44 (t, IH), 7.57 (t, IH), 7.68 (d, IH)

< Example  236> 3- [2- [4 - [[5- [2- (4,4- Dimethylpiperidine Yl) -2- Sulfanylideneethyl ]-4- methyl -6-oxo-2- Propylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[5- [2- (4,4-dimethylpiperidin-1-yl) -2-sulfanylideneethyl] -4-methyl-6-oxo-2-propylpyrimidine- 1 -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

¹ H-NMR (400 MHz):? 0.94 (t, 3H), 1.02 (s, 6H), 1.45-1.50 (m, 4H), 1.68-1.78 (t, 2H), 3.70-3.82 (m, 6H), 5.32 (s, 2H), 7.20-7.27 (m, 4H), 7.36 (d, , 7.67 (d, 1 H)

< Example  237> 2- [2-Butyl-4- methyl -6-oxo-1 - [[4- [2- (5- Sulfanilide -4H-1,2,4- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N, N- Dimethylethanethioamide  Methyl] -6-oxo-1- [4- [2- (5-sulfanylidene-4H-1,2,4-oxadiazol- pyrimidin-5-yl] -N, N-dimethylethanethioamide}

^{1 H-NMR (400MHz):} δ 0.92-0.95 (t, 3H), 1.38-1.47 (m, 2H), 1.71-1.79 (m, 2H), 2.34 (s, 3H), 2.68-2.72 (t, 2H ), 3.48 (s, 3H), 3.53 (s, 3H), 3.83 (s, 2H), 5.30 (s, 2H), 7.22-7.85

< Example  238> 5- [2- (1,3,3a, 4,5,6,7,7a- Octahydroisoindole Yl) -2- Sulfanylideneethyl ] -2-butyl-6- methyl -3 - [[4- [2- (5- Sulfanilide -4H-1,2,4- Oxadiazole Yl) phenyl] methyl] pyrimidin-4-one {5- [2- (1,3,3a, 4,5,6,7,7a-octahydroisoindol- 2- yl) -2-sulfanylideneethyl Yl] phenyl] phenyl] methyl] pyrimidin-4-yl} -2-methyl-3 - [[4- [2- (5-sulfanylidene- Manufacturing

^{1 H-NMR (400MHz):} δ 0.93 (t, 3H), 1.28-1.75 (m, 14H), 2.05 (m, 2H), 2.65 (t, 2H), 2.90 (s, 3H), 3.68-3.86 ( 1H), 7.70 (t, 1H), 7.70 (d, 1H), 7.25 (s, 2H), 7.17-7.29

< Example  239> 2-Butyl-6- methyl -5- [2- (4- Methylpiperidine Yl) -2- Sulfanylideneethyl ] -3 - [[4- [2- (5- Sulfanilide -4H-1,2,4- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl 2-butyl-6-methyl-5- 2- (4-methylpiperidin-1-yl) -2-sulfanylideneethyl] -3 - [[4- [2- (5-sulfanylidene- 4H-1,2,4-oxadiazol-3-yl) phenyl] phenyl] methyl] pyrimidin-4-one}

^{1 H-NMR (400MHz):} δ 0.93 (t, 3H), 1.28-1.73 (m, 12H), 2.05 (m, 2H), 2.65 (t, 2H), 2.90 (s, 3H), 3.70-3.86 ( (m, 4H), 5.28 (s, 2H), 7.17-7.30 (m, 4H), 7.42 (d,

< Example  240> 3- [2- [4 - [[2-butyl-5- [2- (2,5- Dimethylpyrrolidine Yl) -2- Sulfanylideneethyl ]-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5- one {3- [2- [4 - [[2-butyl-5- [2- (2,5-dimethylpyrrolidin- 1 -yl) -2-sulfanylideneethyl] -4-methyl-6- oxopyrimidin- -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.39 (m, 10H), 1.71 (m, 6H), 2.38 (s, 3H), 2.45 (m, 5H), 2.63 (t, 2H) 2H), 7.28 (m, 2H), 7.42 (d, 1H), 7.49 (t, 7.70 (d, 1 H)

< Example  241> 3- [2- [4 - [[2-butyl-5- [2 - [(2S, 6R) Dimethylpiperidine -1-yl] -2- Phanylidene Yl] -4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[2-butyl- 5- [2- [(2S, 6R) -2,6-dimethylpiperidin- 1-yl] -2-sulfanylideneethyl] -4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.39 (m, 10H), 1.71 (m, 6H), 1.90 (m, 3H), 2.38 (s, 3H), 2.45 (m, 5H) 2H), 7.28 (m, 2H), 7.42 (d, 1H), 7.49 (t, 7.61 (t, 1 H), 7.70 (d, 1 H)

< Example  242> 3- [2- [4 - [[5- [2 - [(4 aS , 7aR) -1,3,4,4a, 5,6,7,7a- Octahydrocyclopenta [c] pyridine Yl] -2- Sulfanylideneethyl ] -2-butyl-4- methyl -6- Oxopyrimidine Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one To a solution of 3- {2- [4 - [[5- [2 - [(4aS, 7aR) 2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] -1,3,4,4a, 5,6,7,7a-octahydrocyclopenta [ phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.39-1.74 (m, 14H), 2.28 (s, 3H), 2.36 (m, 1H), 2.40 (m, 3H), 2.63 (t, 2H), 7.28 (m, 2H), 7.48 (d, 1H), 7.49 (t, 1H), 7.61 , &Lt; / RTI &gt; 1H), 7.70 (d, 1H)

< Example  243> 3- [2- [4 - [[2-Butyl- methyl -5- [2 - [(2S) -2- Methylpyrrolidine -1-yl] -2-sulfanylidenemethyl] -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5 - one {3- [2- [4 - [[2-butyl-4-methyl-5- [2 - [(2S) -2-methylpyrrolidin- 1 -yl] -2-sulfanylideneethyl] -6-oxopyrimidine -1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.39-1.74 (m, 5H), 2.28 (s, 3H), 2.36 (m, 4H), 2.40 (m, 5H), 2.63 (t, 2H), 7.48 (d, 1H), 7.49 (t, 1H), 7.61 (t, 2H), 7.28 , &Lt; / RTI &gt; 1H), 7.70 (d, 1H)

< Example  244> 3- [2- [4 - [[2-Butyl- methyl -5- [2 - [(2R) -2- Methylpyrrolidine -1-yl] -2-thioxo-ethyl] -6-oxo-pyrimidin- methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[2-butyl-4-methyl-5- [2 - [(2R) -2-methylpyrrolidin- 1- yl] -2-thioxo-ethyl] -6 -oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.39-1.74 (m, 5H), 2.28 (s, 3H), 2.36 (m, 4H), 2.40 (m, 5H), 2.63 (t, 2H), 7.48 (d, 1H), 7.49 (t, 1H), 7.61 (t, 2H), 7.28 , &Lt; / RTI &gt; 1H), 7.70 (d, 1H)

< Example  245> 3- [2- [4 - [[5- [2- (7- Azabicyclo [2.2.1] heptane -7-yl) -2- Sulfanylideneethyl ] -2-butyl-4- methyl -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (7-azabicyclo [2.2.1] heptan- -sulfanylideneethyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

¹ H-NMR (400 MHz):? 0.91 (t, 3H), 1.34-1.44 (m, 2H), 1.50-1.75 (m, 6H) 2H), 7.27 (d, 2H), 7.39 (d, 1H), 7.49 (t, , 7.61 (t, 1 H), 7.80 (d, 1 H)

< Example  246> 3- (4 '- ((2-Butyl-4- methyl -5- (2- (2- methyl -7,8- Dihydropyrido [4,3-d] pyrimidine -6 (5H) -yl) -2- Thioxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) bye 2- (4-methyl-5- (2- (2-methyl-pyridin- 6,8-dihydropyrido [4,3-d] pyrimidin-6 (5H) -yl) -2-thioxoethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl- , 4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.86-0.91 (m, 3H), 1.30-1.41 (m, 2H), 1.66-1.67 (m, 2H), 2.44-2.64 (m, 5H), 3.01-3.04 (m (M, 3H), 5.30-5.34 (m, 3H), 6.92-7.79 (m, 8H)

< Example  247> 3- (4 '- ((2-Butyl-4- methyl -6-oxo-5- (2- Thioxo -2- (3- ( Trifluoromethyl ) -5,6- Dihydro - [1,2,4] Triazolo Yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 ((4H) 4H) -one {3- (4'- ((2-butyl-4-methyl-6-oxo-5- (2-thioxo-2- 3- (trifluoromethyl) -5,6- 2,4] triazolo [4,3-a] pyrazin-7 (8H) -yl) ethylpyrimidin-1 (6H) -yl) methyl) biphenyl- (4H) -one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.39-1.74 (m, 2H), 2.28 (s, 3H), 2.36 (m, 4H), 2.40 (m, 4H), 2.63 (t, 2H), 7.48 (d, 1H), 7.49 (t, 1H), 7.61 (t, 2H), 7.28 , &Lt; / RTI &gt; 1H), 7.70 (d, 1H)

< Example  248> 2- [2-Butyl-4- Cyclopropyl -6-oxo-1 - [[4- [2- (5-oxo-4H- buy Yl) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N, N- Dimethylethanethiol Amide {2- [2- butyl -4- cyclopropyl -6- oxo -1 - [[4- [2- (5- oxo -4H-1,2,4- oxadiazole -3-yl) phenyl] phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylethanethioamide}

^{1 H-NMR (400MHz):} δ 0.95 (d, 2H), 0.96 (t, 3H), 1.18 (d, 2H), 1.20 (m, 2H), 1.69 (m, 2H), 2.01 (t, 1H) 2H), 2.63 (s, 3H), 3.51 (s, 3H), 3.98 (s, 2H) 7.41 (d, 1H), 7.48 (t, 1H), 7.61 (t,

< Example  249> 2- [2-Butyl-4- Cyclopropyl -6-oxo-1 - [[4- [2- (5-oxo-4H- buy Yl) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- methyl 2-butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H- 3-yl) phenyl] phenyl] methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylethanethioamide}

^{1 H-NMR (400MHz):} δ 0.94 (t, 3H), 0.96 (m, 2H), 1.10 (d, 6H), 1.25 (d, 2H), 1.31 (m, 2H), 1.64 (m, 2H) , 1.94 (s, 1H), 2.01 (m, 1H), 2.62 (t, 2H), 3.17 (s, 1.5H), 3.30 2H), 7.25 (m, 2H), 7.46 (d, 2H), 4.30 (m, 1H), 7.58 (t, IH), 7.62 (t, IH), 7.75

< Example  250> 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- Octahydroisoindole Yl) -2- Sulfanylideneethyl ] -2-butyl-4- Cyclopropyl -6- Oxopyrimidine -1 day] methyl Phenyl] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (1,3,3a, 1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5,7,7a-octahydroisoindol-2-yl) -2-sulfanylideneethyl] -2-butyl-4-cyclopropyl-6-oxopyrimidin- -one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.39-1.74 (m, 16H), 2.28 (s, 3H), 2.36 (m, 1H), 2.38 (m, 1H), 2.63 (t, 2H), 3.58 (m, 2H), 3.65 (s, 2H), 3.87 (m, 2H), 5.25 ), 7.49 (t, IH), 7.61 (t, IH), 7.72 (d, IH)

< Example  251> 2- [2-Butyl-4- Cyclopropyl -6-oxo-1 - [[4- [2- (5-oxo-4H- buy Yl) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- methyl 1-N- (2- Methyl pro 2-butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- 3- yl) phenyl] methyl] pyrimidin-5-yl] -N-methyl-N- (2-methylpropyl) ethanethioamide}

^{1 H-NMR (400MHz):} δ 0.88 (d, 2H), 0.94 (t, 3H), 1.06 (d, 3H), 1.19 (dd, 5H), 1.37 (m, 2H), 1.70 (m, 2H) , 1.94 (m, 1H), 2.84 (t, 2H), 2.72-2.91 (d, 3H), 3.68-3.76 (d, 2H), 7.12 (d, 2H), 7.25 (m, 2H), 7.44

< Example  252> 3- [2- [4 - [[2-Butyl-4- Cyclopropyl -6-oxo-5- (2-piperidin-l-yl-2- Sulfanylideneethyl ) Pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Lt; / RTI &gt; Pyrimidin-1-yl] methyl] phenyl] phenyl] -1H-pyrazolo [3,4-d] pyrimidin- 4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.99-1.02 (m, 5H), 1.22-1.31 (m, 4H), 1.63-1.85 (m, 8H), 2.10 (t, 1H), 2.68 (t, 2H), 2H), 4.05 (s, 2H), 4.29 (t, 2H), 5.25 (s, 2H), 7.16 (t, 4H), 7.44 , 8.10 (d, 1 H)

< Example  253> 3- (4 '- ((2-Butyl-4- Cyclopropyl -6-oxo-5- (2- ( Pyrrolidine Yl) -2- Thioxoethyl ) &Lt; / RTI &gt; pyrimidin-1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadiazole -5 (4H) -one {3- (4 '- ((2-butyl-4-cyclopropyl-6-oxo- 5- (2- (pyrrolidin- 1- yl) -2-thioxoethyl) pyrimidin- ) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.95 (t, 3H), 0.96 (s, 2H), 1.18 (t, 1H), 1.20 (dd, 2H), 1.67 (dd, 2H), 1.86 (m, 4H) 2H), 3.15 (d, 2H), 2.63 (s, 2H), 2.63 (s, 2H) 2H), 7.41 (d, 1H), 7.48 (t, 1H), 7.61 (t,

< Example  254> 3- (4 '- ((2-Butyl-4- Cyclopropyl -5- (2- (2,6- Dimethylpiperazine Yl) -2- Thioxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl (2-butyl-4-cyclopropyl-5- (2- (2, 6-dimethylpiperazin-2-yl) -1-yl) -2-thioxoethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

¹ H-NMR (400 MHz):? 0.95 (t, 3H), 0.96 (m, 4H), 1.18 (t, 2H), 5.18 (s, 2H), 7.15 (d, 2H), 7.26 (d, 2H) 7.41 (d, 1H), 7.48 (t, 1H), 7.61 (t,

< Example  (S) -3- (4 '- ((2-butyl-4- Cyclopropyl -5- (2- (2- Methylpyrrolidine Yl) -2- Thioxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4-oxadiazole-5 (4H) -one {(S) -3- (4 '- ((2-butyl- -methylpyrrolidin-1-yl) -2-thioxoethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

¹ H-NMR (400 MHz):? 0.95 (t, 5H), 0.96 (m, 4H), 1.18 (m, 3H), 1.20 2H), 7.22 (d, 2H), 7.41 (d, IH), 7.31 (d, 7.48 (t, 1 H), 7.61 (t, 1 H), 7.75 (d, 1 H)

< Example  256> 3- (4 '- ((2-butyl-4- Cyclopropyl -5- (2- (3,5- Dimethylpiperidine Yl) -2- Thioxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl (2-butyl-4-cyclopropyl-5- (2- (3,5-dimethylpiperidine -1-yl) -2-thioxoethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

¹ H-NMR (400 MHz):? 0.95 (t, 3H), 0.96 (m, 4H), 1.18 2H), 5.18 (s, 2H), 7.15 (d, 2H), 7.26 (d, 2H) 7.41 (d, 1H), 7.48 (t, 1H), 7.61 (t,

< Example  257> 2- (2-Butyl-4- Cyclopropyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine -5-yl) -N-cyclopropylethanthioamide [2- (2-butyl-4-cyclopropyl-6-oxo- 2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1,6-dihydropyrimidin-5-yl) -N-cyclopropylethanethioamide}

^{1 H-NMR (400MHz):} δ 0.95 (t, 3H), 0.96 (m, 2H), 1.17 (s, 2H), 1.20 (m, 2H), 1.37 (dd, 2H), 2.01 (m, 5H) 2H), 7.26 (d, 2H), 7.41 (d, 1H), 7.48 (t, 1H) 7.61 (t, 1 H), 7.75 (d, 1 H)

< Example  258> 2- (2-Butyl-4- Cyclopropyl -6-oxo-1 - ((2 '- (5-oxo- Dihydro -1,2,4- Oxadiazole -3 days) Biphenyl Yl) methyl ) -1,6- Dihydropyrimidine 5-yl) -N, N-diethylethanethioamide [2- (2-butyl-4-cyclopropyl-6-oxo- 4-yl) methyl) -1,6-dihydropyrimidin-5-yl) -N, N-diethylethanethioamide}

^{1 H-NMR (400MHz):} δ 0.95 (m, 5H), 1.22 (m, 7H), 1.36 (m, 2H), 1.67 (dd, 2H), 2.01 (m, 1H), 2.66 (dd, 2H) (D, 2H), 3.40 (d, 2H), 3.40 (d, 2H) 7.48 (t, 1 H), 7.61 (t, 1 H), 7.75 (d, 1 H)

< Example  259> 3- (4 '- ((2-Butyl-4- Cyclopropyl -5- (2- (3,5- Dimethylmolpolino )-2- Thioxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl (2-butyl-4-cyclopropyl-5- (2- (3,5-dimethylmorpholino) ) -2-thioxoethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H)

^{1 H-NMR (400MHz):} δ 0.92-0.94 (m, 5H), 1.20-1.22 (m, 8H), 1.39 (dd, 2H), 1.71 (t, 2H), 2.68 (dd, 2H), 2.95 ( 2H), 4.60 (d, IH), 5.60 (d, IH) , 7.26 (d, 2H), 7.41 (d, IH), 7.48 (t, IH), 7.61

< Example  260> 3- (4 '- ((2-Butyl-4- Cyclopropyl -5- (2 - ((2S, 6R) -2,6- Dimethylpiperidine Yl) -2- Thioxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl 2 - ((2S, 6R) -l, 2,3,4-tetrahydroisoquinolin- -2,6-dimethylpiperidin-1-yl) -2-thioxoethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl- one}

^{1 H-NMR (400MHz):} δ 0.95 (t, 3H), 1.22 (m, 4H), 1.36 (m, 2H), 1.67 (dd, 3H), 2.01 (m, 3H), 2.66 (dd, 2H) 2H), 3.40 (d, 2H), 3.56 (d, 2H), 3.56-3.73 (m, 4H), 4.45 (m, ), 7.41 (d, IH), 7.48 (t, IH), 7.61

< Example  261> 3- (4 '- ((2-Butyl-4- Cyclopropyl -5- (2- Molpolino -2- Thioxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadiazole -5 (4H) -one {3- (4'- ((2-butyl-4-cyclopropyl-5- (2- morpholino- 2- thioxoethyl) -6- oxopyrimidin- 1 (6H) -yl) methyl) biphenyl -2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.92-0.95 (m, 5H), 1.22 (m, 2H), 1.36 (m, 2H), 1.67 (dd, 2H), 2.19 (m, 1H), 2.68 (t, 2H), 3.70 (s, 2H), 3.70 (d, 2H), 3.70 ), 7.26 (d, 2H), 7.41 (d, IH), 7.48 (t, IH)

< Example  262> 3- (4 '- ((2-Butyl-4- Cyclopropyl -5- (2- (2- Methylpiperidine Yl) -2- Thioxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl (4-cyclopropyl-5- (2- (2-methylpiperidin-1-yl) -yl) -2-thioxoethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

¹ H-NMR (400 MHz):? 0.95 (t, 4H), 1.15-1.17 (m, 4H), 1.35-1.37 2H), 3.16 (d, 2H), 3.80 (dd, 2H), 4.30-4.70 (m, 2H), 5.18 , 7.41 (d, 1 H), 7.48 (t, 1 H), 7.61 (t,

< Example  263> 3- (4 '- ((2-Butyl-4- Cyclopropyl -5- (2- (4- Hydroxypiperidine Yl) -2- Thioxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl (2-butyl-4-cyclopropyl-5- (2- (4-hydroxypiperidin-1-yl) -1,2,4-oxadiazole- -yl) -2-thioxoethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.21 (m, 6H), 1.36 (m, 2H), 1.74 (m, 2H), 1.82 (m, 2H), 2,24 (m, 2H), 2.80 (m, 2H), 3.01 (m, IH), 3.91 (m, 4H), 4.14 (m, ), 7.15 (m, 2H), 7.28 (m, 2H), 7.42

< Example  264> 3- [2- [4 - [[2-Butyl-6-oxo-4- Pyrrolidine -1-yl-2- Phanylidene Yl) pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole 5-one {3- [2- [4 - [[2-butyl-6-oxo-4-propan-2-yl- 5- (2-pyrrolidin- 1 -yl- 2- sulfanylideneethyl) pyrimidin- 1- yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz, CDCl} 3): δ 0.9 (m, 3H), 1.0 (m, 8H), 1.4 (m, 2H), 1.6 (m, 2H), 1.8 (m, 2H), 2.7 (m 2H), 7.0 (m, 4H), 7.4-7.6 (m, 4H)

< Example  265> 3- [2- [4 - [[2-Butyl-6-oxo-5- (2-piperidin- Sulfanylideneethyl ) -4-propane-2- Ylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5- one {3- [2- [4 - [[2-butyl-6-oxo-5- (2-piperidin- 1 -yl-2- sulfanylideneethyl) -4-propan-2-ylpyrimidin-1- yl ] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 0.92-0.98 (m, 6H), 1.40 (m, 2H), 1.70 (m, 2H), 2.34 (s, 3H), 2.66 (t, 2H), 3.72 (m, 4H), 3.84 (s, 2H), 3.95 (t, 2H), 4.34 (t, 2H), 5.26 ), 7.42 (m, IH), 7.49 (t, IH), 7.62

< Example  266> 3- [2- [4 - [[2-butyl-5- [2- (2,6- Dimethylpiperazine Yl) -2- Sulfanylideneethyl ] -6-oxo-4-propane-2- Ylpyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadai 5-one {3- [2- [4 - [[2-butyl-5- 2- (2,6-dimethylpiperazin- 1- yl) -2-sulfanylideneethyl] -6-oxo-4- 2-ylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

¹ H-NMR (400 MHz):? 0.91 (t, 3H), 0.92-0.98 (m, 6H), 1.20-1.40 2H), 7.26 (d, 2H), 3.72 (s, 2H), 3.72 (s, 2H) 2H), 7.42 (m, IH), 7.49 (t, IH), 7.62

< Example  267> 2- [2-Butyl-6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] -4-propane-2- Ylpyrimidine -5-yl] -N, N- Dimethylethanethioamide  Phenyl] phenyl] methyl] -4-propane [0301] The title compound was prepared from {2- [2-butyl-6-oxo- -2-ylpyrimidin-5-yl] -N, N-dimethylethanethioamide}

^{1 H-NMR (400MHz):} δ 0.91 (t, 5H), 0.92-0.98 (m, 6H), 1.20-1.40 (m, 2H), 1.70 (m, 2H), 2.34 (s, 3H), 2.66 ( 2H), 7.24 (d, 2H), 2.80 (m, 6H), 3.84 (s, 2H), 3.95 2H), 7.42 (m, IH), 7.49 (t, IH), 7.62

< Example  268> 2- [2-Butyl-6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] -4-propane-2- Ylpyrimidine -5-yl] -N, N- Diethyl ethanethioamide  Phenyl] phenyl] methyl] -4-propane [0301] The title compound was prepared from {2- [2-butyl-6-oxo- -2-ylpyrimidin-5-yl] -N, N-diethylethanethioamide}

^{1 H-NMR (400MHz):} δ 0.91 (t, 2H), 0.92-0.98 (m, 6H), 1.20-1.40 (m, 2H), 1.70 (m, 2H), 2.34 (s, 3H), 2.66 ( 2H), 7.26 (d, 2H), 2.80 (m, 6H), 3.84 (m, 4H) 2H), 7.42 (m, IH), 7.49 (t, IH), 7.62

< Example  269> 2- [2-Butyl-6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] -4-propane-2- Ylpyrimidine -5-yl] -N- methyl -N-propane-2- Sun ethane thio Phenyl] phenyl] methyl] -4- (4-oxo-4H-1,2,4- propan-2-ylpyrimidin-5-yl] -N-methyl-N-propan-2-ylethanethioamide}

¹ H-NMR (400 MHz):? 0.91 (t, 3H), 0.92-0.98 (m, 6H), 1.20-1.40 (m, 12H) 2H), 7.24 (d, 2H), 7.42 (m, 2H), 3.84 (s, 3H) , 7.49 (t, IH), 7.62 (d, IH), 7.76 (d, IH)

< Example  270> 2- [2-Butyl-6-oxo-1 - [[4- [2- (5-oxo-4H- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] -4-propane-2- Ylpyrimidine -5-yl] -N- Cyclopropyl ethane thioamide Yl) phenyl] phenyl] methyl] -4- (4-oxo-4H-1,2,4- propan-2-ylpyrimidin-5-yl] -N-cyclopropylethanethioamide}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 0.92-0.98 (m, 3H), 1.20-1.40 (m, 6H), 1.70 (m, 2H), 2.34 (s, 3H), 2.66 ( 2H), 7.16 (d, 2H), 7.27 (d, 2H), 7.42 (m, 2H) , 7.49 (t, IH), 7.62 (d, IH), 7.76 (d, IH)

< Example  271> 3- (4 '- ((2-Butyl-4- Isopropyl -5- (2- (2- methyl -7,8- Dihydropyrido [4,3-d] pyrimidine -6 (5H) -yl) -2- Thioxoethyl ) -6-oxo-5,6- Dihydropyri Yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) 5- (2- (2-methyl-7,8-dihydropyrido [4,3-d] pyrimidin-6- (5H) -yl) -2-thioxoethyl) -6-oxo-5,6-dihydropyrimidin- (4H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.87-0.96 (m, 3H), 1.19-1.44 (m, 8H), 1.71-1.81 (m, 3H), 1.94-2.05 (d, 3H), 2.43-3.01 (m , 4H), 4.28-4.62 (m, 3H), 5.26-5.37 (m, 3H), 6.88-7.80 (m, 8H)

< Example  272> 3- (4 '- ((2-Butyl-5- (2- (3,5- Dimethylpiperidine -1-yl) -2- Thioxoethyl )-4- Isopropyl -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl (4 - ((2-butyl-5- (2- (3,5-dimethylpiperidin-1- yl) ) -2-thioxoethyl) -4-isopropyl-6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H)

¹ H-NMR (400 MHz):? 0.86 (t, 3H), 0.88 (m, 2H), 0.91 (m, 6H) 2H), 7.08 (m, IH), 2.66 (m, 2H), 3.01 (m, 1H), 7.83 (d, IH), 7.48 (m, IH)

< Example  273> 3- (4 '- ((2-butyl-5- (2 - ((2R, 6S) Dimethylpiperidine -1-yl) -2-thioxoethyl) -4- Isopropyl -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl 5- (2 - ((2R, 6S) -2,6-dihydroxy-isoquinolin- 2-yl) -1,2,4-oxadiazol-5 (4H) - (4-methylpiperidin-1-yl) -2-thioxoethyl) -4-isopropyl- one}

¹ H-NMR (400 MHz):? 0.90 (t, 3H), 0.92 (m, 2H), 1.17 (m, 6H), 1.29 (dd, (M, 2H), 3.95 (d, 2H), 2.45 (m, 2H) ), 7.09 (m, 2H), 7.11 (m, 2H), 7.25 (m, IH), 7.33 (d,

< Example  274> 3- (4 '- ((2-Butyl-4- Isopropyl -5- (2- (2- Methylpiperidine -1-yl) -2- At iox Yl) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadia (4-isopropyl-5- (2- (2-methylpiperidin-1-yl) -2-thioxoethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.93 (m, 7H), 1.25 (m, 8H), 1.41 (m, 2H), 1.80 (m, 4H), 2.69 (m, 4H), 3.06 (m, 3H) 2H), 7.38 (d, IH), 3.88 (s, 2H), 4.28 (d, 7.48 (d, 1 H), 7.60 (d, 1 H), 7.79 (d, 1 H)

< Example  275> 3- (4 '- ((2-Butyl-4- Isopropyl -5- (2- (3- Methylpiperidine -1-yl) -2- At iox Yl) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadia (4-isopropyl-5- (2- (3-methylpiperidin-1-yl) -2-thioxoethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.21 (m, 8H), 1.33 (m, 3H), 1.66 (m, 2H), 1.78 (m, 5H), 2.69 (m, 2H) , 3.08 (m, 2H), 3.27 (t, 1H), 3.88 (m, 2H), 4.28 (d, 0.5H) 1H), 7.76 (d, IH), 7.83 (d, IH), 7.01 (m, 2H) )

< Example  276> 3- (4 '- ((2-Butyl-4- Isopropyl -5- (2- Molpolino -2- Thioxoethyl Yl) -1,2,4-oxadiazole-5 (4H) -one {3- (4 '- (2-butyl-4-isopropyl-5- (2-morpholino-2-thioxoethyl) -6-oxopyrimidin-1 (6H) (4H) -one}

^{1 H-NMR (400MHz):} δ 0.90 (t, 3H), 0.91 (m, 6H), 1.36 (m, 2H), 1.74 (m, 2H), 2.66 (m, 2H), 3.01 (m, 1H) 2H), 7.09 (m, 2H), 3.59 (m, 2H), 3.59 (m, 7.48 (m, 1 H), 7.62 (m, 1 H), 7.83 (d, 1 H)

< Example  277> 3- (4 '- ((2-Butyl-5- (2- (2,6- Dimethylmolpolino )-2- Thioxoethyl )-4- Isopropyl -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl Yl) -1,2,4- Oxadai (4H) -one {3- (4 '- ((2-butyl-5- (2- (2,6- dimethylmorpholino) -2-thioxoethyl) -4-isopropyl-6-oxopyrimidin- ) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.90 (t, 3H), 0.91 (m, 12H), 1.36 (m, 2H), 1.74 (m, 2H), 2.28 (m, 1H), 2.66 (m, 2H) 2H), 7.01 (m, 2H), 3.50 (m, 2H), 3.58 (m, 1H), 7.83 (d, IH), 7.48 (m, IH)

< Example  (S) -3- (4 '- ((2-butyl-4- Isopropyl -5- (2- (2- Methylpyrrolidine Yl) -2- Thioxoethyl ) -6- Oxopyrimidine -1 (6H) -yl) methyl ) Biphenyl (2-butyl-4-isopropyl-5- (2- (2 &lt; / RTI &gt; -methylpyrrolidin-1-yl) -2-thioxoethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazol-5 (4H) -one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.11 (d, 2H), 1.19 (m, 6H), 1.21 (d, 1H), 1.37 (m, 2H), 1.74 (m, 2H) , 1.92 (m, 3H), 2.66 (m, 2H), 3.01 (m, 1H), 7.83 (d, IH), 7.48 (m, IH)

< Example  279> 2- [2-Butyl-4-ethyl-6-oxo-1 - [[4- [2- (5- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N, N- Dimethylethanethioamide  Phenyl] phenyl] methyl] -1H-pyrazolo [3,4-d] pyrimidin- pyrimidin-5-yl] -N, N-dimethylethanethioamide}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.20 (t, 3H), 1.40 (m, 2H), 1.85 (m, 2H), 2.64 (t, 2H), 2.86 (t, 2H) 2H), 7.26 (s, 2H), 7.27 (m, 5H), 7.42 (m, 7.76 (d, 1 H)

< Example  280> 2- [2-Butyl-4-ethyl-6-oxo-1 - [[4- [2- (5- Oxadiazole -3 days) Phenyl ] Phenyl ] methyl ] Pyrimidin-5-yl] -N- methyl -N-propane-2- Sun Ethan Thioamai 4-ethyl-6-oxo-1- [4- [2- (5-oxo-4H-1,2,4-oxadiazol-3- yl) phenyl] phenyl] methyl ] pyrimidin-5-yl] -N-methyl-N-propan-2-ylethanethioamide}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.20 (m, 9H), 1.40 (m, 2H), 1.85 (m, 3H), 2.64 (t, 2H), 2.86 (t, 2H) , 7.50 (s, 2H), 7.27 (m, 5H), 7.42 (m, (d, 1 H)

< Example  281> 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- Octahydroisoindole Yl) -2- Sulfanylideneethyl ] -2-butyl-4-ethyl-6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4-oxadiazol-5-one {3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a- 1-yl] methyl] phenyl] -4H-1,2,4-oxadiazol-5-one} Produce

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.20 (m, 3H), 1.40 (m, 2H), 1.70 (m, 3H), 1.96 (m, 2H), 2.86 (t, 2H) 2H), 7.24 (m, 2H), 3.84 (s, 2H), 3.95 (m, 2H), 5.26 7.49 (t, 1 H), 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  282> 3- [2- [4 - [[2-Butyl-4-ethyl- Pyrrolidine -1-yl-2- Sulfanylideneethyl ) Pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Yl) methyl] -1H-pyrazolo [3,4-d] pyrimidin- phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.20 (m, 3H), 1.40 (m, 2H), 1.70 (m, 3H), 1.96 (m, 2H), 2.10 (t, 2H) 2H), 2.36 (t, 2H), 2.60-2.90 (m, 4H), 3.84 (s, 2H), 3.95 (m, ), 7.49 (t, IH), 7.62 (d, IH), 7.76 (d, IH)

< Example  283> 3- [2- [4 - [[2-Butyl-4-ethyl-6-oxo-5- (2-piperidin- Sulfanylideneethyl ) Pyrimidin-1-yl] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole Yl) methyl] -1H-pyrazolo [3,4-d] pyrimidin- phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

¹ H-NMR (400 MHz):? 0.91 (t, 3H), 1.20 (m, 3H), 1.40 (m, 2H), 1.70-1.85 (m, 8H), 2.60-2.90 2H), 7.26 (s, 2H), 7.27 (m, 4H), 7.42 (m, 1H), 7.49 , 1H)

< Example  284> 3- [2- [4 - [[2-Butyl-4-ethyl- Morpholine -4-yl-2- Sulfanylideneethyl ) -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[2-butyl-4-ethyl-5- (2- morpholin-4-yl-2- sulfanylideneethyl) -6- oxopyrimidin- 1 -yl] methyl] phenyl ] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.20 (t, 3H), 1.40 (m, 2H), 1.70 (m, 2H), 2.64 (dd, 2H), 2.86 (t, 2H) 1H), 2.90 (m, 4H), 3.84 (s, 2H), 3.95 (m, 4H), 5.26 7.49 (t, 1 H), 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  285> 3- [2- [4 - [[2-Butyl-4-ethyl-5- [2- Methylpiperidine Yl) -2- Sulfanylideneethyl ] -6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5-one {3- [2- [4 - [[2-butyl-4-ethyl-5- [2- (4-methylpiperidin- 1- yl) -2-sulfanylideneethyl] -6-oxopyrimidin- ] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.92 (t, 3H), 1.41 (m, 8H), 1.71 (m, 8H), 2.31 (s, 3H), 2.68 (t, 2H), 3.52 (m, 4H) 2H), 7.28 (d, 2H), 7.42 (m, 1H), 7.48 (t, 7.77 (d, 1 H)

< Example  286> 3- [2- [4 - [[2-butyl-5- [2- (3,3- Dimethylpiperidine Yl) -2- Sulfanylideneethyl ] -4-ethyl-6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole 5- {3- [2- [4 - [[2- butyl -5- [2- (3,3- dimethylpiperidine -One- yl )-2- sulfanylideneethyl ] -4-ethyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.43 (m, 9H), 1.52 (m, 5H), 1.85 (m, 3H), 2.64 (t, 2H), 2.86 (t, 2H) 2H), 3.85 (s, 2H), 7.27 (m, 4H), 7.42 (m, 7.62 (d, 1 H), 7.76 (d, 1 H)

< Example  287> 3- [2- [4 - [[2-butyl-5- [2- (3,5- Dimethylmorpholine Yl) -2- Sulfanylideneethyl ] -4-ethyl-6- Oxopyrimidine -1 day] methyl ] Phenyl ] Phenyl ] -4H-1,2,4- Oxadiazole -5 - one {3- [2- [4 - [[2-butyl-5- [2- (3,5-dimethylmorpholin- 4-yl) -2-sulfanylideneethyl] -4-ethyl-6-oxopyrimidin- -yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one}

^{1 H-NMR (400MHz):} δ 0.91 (t, 3H), 1.20 (m, 9H), 1.40 (m, 2H), 1.70 (m, 2H), 2.64 (dd, 2H), 2.86 (t, 2H) 1H), 2.90 (m, 3H), 3.84 (s, 2H), 3.95 (m, 3H), 5.26 (s, 7.49 (t, 1 H), 7.62 (d, 1 H), 7.76 (d, 1 H)

The structures of the compounds of the present invention prepared in Examples 1 to 287 are summarized in Table 1 below.

[Table 1]

< Experimental Example  1> Calcium mobilization analysis (Calcium mobilization analysis)

1. Experimental Method

- Cells used: PathHunter® CHO-K1 AGTR1 β-Arrestin Cell Line (DiscoverX, 93-0312C2)

- Usage medium: Assay Complete Cell Plating 2 Reagent

- Use kit: Calcium NoWash plus (Ca NW plus) Assay kit (DiscoverX, 90-0091)

[Day-1]

Cells were seeded in 96-well plates at 2 × 10 ⁴ / well and incubated for 1 day at 37 ° C in CO _{2 at} 5%.

[Day-2]

1) Remove the plate medium, add 9 mL of Dye loading buffer (20 mM HEPES in HBSS, pH 7.4), additive A from 1 mL of the test kit, 10 μL of CaNW dye and 100 μL of Probenicid solution Well, mixed with 100 μL / well, and incubated at 37 ° C in 5% CO ₂ for 1 hour.

2) 25 μL of the compound solution (concentration: 20 nM, 200 nM) of each example was further added, and the mixture was allowed to stand at room temperature for 30 minutes.

3) After transferring to Flexstation 3 (Molecular Devices), the Ca mobilization inhibitory potency was determined under the following conditions.

Excitation at 494 nm, emission at 516 nm

- 2 minutes at 2 intervals

- Agonist (angiotensin) treatment concentration: 0.1 nM

- Agonist (angiotensin) Throughput: 25 μL

2. Experimental results

[Table 2]

< Experimental Example  2> PPAR gamma Transactivation  Assay Protocol

1. Experimental Method

- Cells used: Cos-7 (Fibroblast-like cell line derived from monkey kidney tissue)

- Use medium: Cos-7 cell_DMEM 10% FBS (DMEM: Invitrogen, # 11995-065 or 073)

The compounds of the respective Examples were dissolved in DMSO to prepare a solution having a concentration of 1 mM, followed by dilution with 10% FBS medium to conduct a solution with a concentration of 10 μM.

[Day-1]

Cells were seeded in 48 well plates at 3 × 10 ⁴ cells / 250 μL / well and incubated at 37 ° C and 5% CO ₂ for 24 h.

[Day-2]

1) Each well of the plate was washed twice with 0.5 mL of PBS, and 250 μL of serum-free media (DMEM) was added to each well. The plate was placed in a 5% CO ₂ incubator at 37 ° C.

2) Prepare the following Mix 1 and Mix 2, mix Mix 1 and Mix 2 well and leave room temperature for 5 minutes.

- Mix 1

- Mix 2

- Lipofectamine 3000 (Invitrogen, # L3000008)

- Opti-MEM media (Invitrogen, # L31985-070)

3) Add 25 μL of well mixed Mix 1 and Mix 2 to the wells of the incubator and incubate for 6 hours at 37 ° C in a 5% CO ₂ incubator.

4) After removing the culture medium of the plate, 250 μL of the compound solution of each Example was added to each well, followed by incubation at 37 ° C in a 5% CO ₂ incubator for 20 hours.

[Day-3]

1) Wash the wells with 1 × PBS, and add 65 μL of passive lysis buffer (PLB) to each well. After shaking at 80 rpm for 15 min, transfer to e-tube and incubate at 4 ° C at 13000 rpm for 1 Gt; min. &Lt; / RTI &gt;

2) Transfer 20 μL of the supernatant to a white well plate, add 100 μL of luciferase buffer to each well, and measure the firefly activity using a luminometer.

3) Renilla was calibrated to calculate Firefly activity, and PPARγ activity was measured based on DMSO.

2. Experimental results

[Table 3]

Claims (8)

Claims 1. A compound represented by the following formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof:
(I)

In the formula (I)
Ra ₁ and Ra ₂ Are each independently selected from the group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, C2-C6 heterocycloalkyl, C2-C5 primary or secondary amine, C2-C5 alkoxy, or C2- Alkyl or C3-C7 cycloalkyl may be substituted with halo,
Rb ₁ , Rb ₂ , Rc ₁ and Rc ₂ Are each independently H, halo, Ci-C4 alkyl or Ci-C4 haloalkyl,
Rd ₁ and Rd ₂ Are each independently H or Ci-C4 alkyl,
X ₁ and X ₂ are each independently O or S,
Y is selected from the group consisting of C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl or none, wherein one or more H of said C1-C4 alkyl, C2-C4 alkenyl or C2- , Hydroxy, nitro, cyano or sulfonyl.
Z is OR ₁ or NR ₂ R _3,
R ₁ is H, C ₁ -C 6 alkyl, C 1 -C 4 alkyl-O (C 1 -C 4 alkyl), C 3 -C 7 cycloalkyl, phenyl or C 1 -C 4 alkyl-phenyl wherein the C 3 -C 7 cycloalkyl, Wherein at least one H of the C1-C4 alkyl-phenyl ring may be substituted with halo, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, nitro, carboxylic acid or sulfonyl,
R ₂ and R ₃ are each independently H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl or C 1 -C 6 alkoxy, wherein at least one H of said C 1 -C 6 alkyl is optionally substituted by C 1 -C 4 alkoxy, Heteroaryl, &lt; / RTI &gt; or
R ₂ and R _{3 taken} together with the connected nitrogen atom form a 5-membered to 7-membered monocyclic ring or a 7-to 12-membered ring, wherein one or more H of said single ring or double ring is optionally substituted with halo, Alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, hydroxy, carboxylic acid, nitro, sulfonyl, C3-C7 cycloalkyl, C2-C6 heterocycloalkyl, aryl or heteroaryl. The method according to claim 1,
Ra ₁ and Ra ₂ Are each independently C1-C6 alkyl or C3-C7 cycloalkyl, wherein one or more H of said C1-C6 alkyl or C3-C7 cycloalkyl may be substituted with halo,
Rb ₁ , Rb ₂ , Rc ₁ and Rc ₂ Lt; / RTI &gt; are each independently H or halo,
Rd ₁ and Rd ₂ Are each independently H or Ci-C4 alkyl,
X ₁ and X ₂ are each independently O or S,
Y is C1-C4 alkyl or is not null, wherein one or more H of said C1-C4 alkyl may be substituted with halo, hydroxy, nitro, cyano or sulfonyl,
Z is OR ₁ or NR ₂ R _3,
R ₁ is H, C ₁ -C 4 alkyl, C 1 -C 4 alkyl-O (C 1 -C 4 alkyl), C 3 -C 7 cycloalkyl, phenyl or C 1 -C 4 alkyl-phenyl wherein the C 3 -C 7 cycloalkyl, Wherein at least one H of the C1-C4 alkyl-phenyl ring may be substituted with halo, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, nitro, carboxylic acid or sulfonyl,
R ₂ and R ₃ are each independently H, C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl or C 1 -C 6 alkoxy wherein at least one H of said C 1 -C 4 alkyl is C 1 -C 4 alkoxy, hydroxy or heteroaryl , Or &lt; RTI ID = 0.0 &gt;
R ₂ and R ₃ together with the nitrogen atom to which they are attached form a 5- to 7-membered single ring, a 6-to 8-member bridge double ring, an 8-to-10-member fused double ring, or a 9- Wherein one or more H of the double ring, the single ring, the bridge double ring, the fused double ring or the spiro may be substituted with halo, C1-C4 alkyl or C1-C4 haloalkyl, aryl or heteroaryl has exist},
A compound represented by the formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof. 3. The method of claim 2,
Ra ₁ and Ra ₂ Are each independently C1-C4 alkyl or C3-C6 cycloalkyl, wherein one or more H of said C1-C6 alkyl or C3-C7 cycloalkyl may be substituted with halo,
Rb ₁ , Rb ₂ , Rc ₁ and Rc ₂ Lt; / RTI &gt; are each independently H or halo,
Rd ₁ and Rd ₂ Are each independently H or Ci-C4 alkyl,
X ₁ and X ₂ are each independently O or S,
Y is C1-C4 alkyl or is not null, wherein one or more H of said C1-C4 alkyl may be substituted with halo, hydroxy, nitro, cyano or sulfonyl,
Z is OR ₁ or NR ₂ R _3,
R ₁ is H, C ₁ -C 4 alkyl, C 1 -C 4 alkyl-O (C 1 -C 4 alkyl), C 3 -C 7 cycloalkyl, phenyl or C 1 -C 4 alkyl-phenyl wherein the C 3 -C 7 cycloalkyl, One or more H of the C1-C4 alkyl-phenyl ring may be substituted by halo, C1-C4 alkyl, C1-C4 alkoxy or hydroxy}
R ₂ and R ₃ are each independently H, C 1 -C 4 alkyl, C 3 -C 7 cycloalkyl or C 1 -C 6 alkoxy wherein at least one H of said C 1 -C 6 alkyl is optionally substituted by C 1 -C 4 alkoxy, hydroxy or heteroaryl , Or &lt; RTI ID = 0.0 &gt;
R &lt; ₂ &gt; and R &lt; ₃ &gt; together with the connected nitrogen atom form one of the following rings wherein one or more H of said ring may be substituted by halo, C1-C4 alkyl or C1-

Wherein R ₄ is H, C 1 -C 4 alkyl, aryl or heteroaryl wherein said aryl or heteroaryl may be substituted with halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, nitro, cyano or sulfonyl has exist},
A compound represented by the formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof. The compound according to claim 1, wherein the compound is any one selected from the group consisting of the following compounds, an optical isomer thereof, or a pharmaceutically acceptable salt thereof:
1) Ethyl 2- (2-butyl-4-isopropyl-6-oxo-1 - ((2 ' Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
2) Preparation of 2- (2-butyl-4-isopropyl-6-oxo-1 - ((2 &apos;-( 5-oxo-4,5-dihydro- ) Biphenyl-4-yl) methyl) -l, 6-dihydropyrimidin-5-yl) acetic acid;
3) Preparation of methyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 &apos;-( 5-oxo-4,5-dihydro- ) Biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
4) propyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2- ) Biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
5) Synthesis of butyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- ) Biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
6) Pentyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 &apos;-( 5-oxo-4,5-dihydro- ) Biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
7) Isopropyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 &apos;-( 5-oxo-4,5-dihydro- Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
8) Preparation of isobutyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro- Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
9) Preparation of 2-methylbutyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
10) Benzyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 &apos;-( 5-oxo-4,5- dihydro- ) Biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
11) Synthesis of 2-methoxyphenethyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- Yl)) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
12) Cyclohexyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
13) (lr, 4r) -4-Methylcyclohexyl 2- (2-butyl-4-methyl-6-oxo- Yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
14) 2- (2-Butyl-4-cyclopropyl-6-oxo-1 - ((2 &apos;-( 5-oxo-4,5-dihydro- ) Biphenyl-4-yl) methyl) -l, 6-dihydropyrimidin-5-yl) acetic acid;
15) Preparation of 2-methylbutyl 2- (2-butyl-4-isopropyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
16) pentan-3-yl 2- (2-butyl-4-isopropyl-6-oxo- Yl)) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
17) Isopropyl 2- (2-butyl-4-isopropyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro- Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
18) 1-Methoxypropane 2-yl 2- (2-Butyl-4-isopropyl-6-oxo-1 - ((2 '- (5-oxo-4,5-dihydro- -Oxadiazol-3-yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
19) Ethyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 &apos;-( 5-oxo-4,5-dihydro- ) Biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
20) Preparation of ethyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- ) Biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) propanoate;
21) Ethyl 2- (2-butyl-4-methyl-1 - ((2 '- (4-methyl- ) Biphenyl-4-yl) methyl) -6-oxo-1,6-dihydropyrimidin-5-yl) acetate;
22) Preparation of ethyl 2- (2- (1-bromobutyl) -4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- Diazo-3-yl) biphenyl-4-yl) methyl) -l, 6-dihydropyrimidin-5-yl) acetate trifluoroacetic acid salt;
23) Preparation of ethyl 2- (2-butyl-4-methyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- ) Biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) -2-hydroxyacetate trifluoroacetic acid salt;
24) 3- [2- [4 - [[5- [2 - [(1R) -2,3,3a, 4,5,6,7,7a-octahydroindol- -Ethyl] -2-butyl-4-cyclopropyl-6-oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
25) Preparation of ethyl 2- (4-tert-butyl-2-butyl-6-oxo-1 - ((2 '- (5-oxo-4,5- dihydro- Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
26) Phenyl 2- (2-butyl-4-isopropyl-6-oxo-1 - ((2 &apos;-( 5-oxo-4,5-dihydro- Yl) biphenyl-4-yl) methyl) -1, 6-dihydropyrimidin-5-yl) acetate;
Methyl-6-oxo-5- (2-oxo-2-pyrrolidin- 1 -ylethyl) pyrimidin- 1 -yl] methyl ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
28) {2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylacetamide;
29) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-propylacetamide;
30) N-Butyl-2- [2-butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ) Phenyl] phenyl] methyl] pyrimidin-5-yl] acetamide;
31) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-diethylacetamide;
32) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-propan-2-ylacetamide;
33) 2- (2-Butyl-4-methyl-6-oxo-1 - ((2- Biphenyl-4-yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N-isopropyl-N-methylacetamide;
34) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methyl-N- (2-methylpropyl) acetamide;
35) {3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7a-octahydroisoindol- -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
36) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- (2-oxo-2-piperidin- 1 -ylethyl) pyrimidin- ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
37) 3- [2- [4 - [[2-Butyl-4-methyl-5- (2-morpholin- ] -4H-l, 2,4-oxadiazol-5-one;
38) 3- [2- [4 - [[2-butyl-5- [2- (3,5- dimethylpiperidin- 1 -yl) -2-oxoethyl] 1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
39) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N- (1 -hydroxypropan-2-yl) acetamide;
40) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-dimethylacetamide;
41) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methoxy-N-methylacetamide;
42) 2-butyl-N, N, 4-trimethyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidine-5-carboxamide;
43) Synthesis of 2-butyl-N, 4-dimethyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] -N-propan-2-ylpyrimidine-5-carboxamide;
44) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- (piperidine- 1- carbonyl) pyrimidin- 4H-1,2,4-oxadiazol-5-one;
45) 3- [2- [4 - [[2-Butyl-4-methyl-5- (morpholine- 4- carbonyl) -6-oxopyrimidin- 4H-1,2,4-oxadiazol-5-one;
46) 3- [2- [4 - [[5- (1,3,3a, 4,5,6,7a-octahydroisoindole- 2- carbonyl) 6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
47) 2-butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- -N-propan-2-ylpyrimidine-5-carboxamide;
48) Synthesis of 2-butyl-N-cyclohexyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Phenyl] methyl] pyrimidine-5-carboxamide;
49) 2-Butyl-N, 4-dimethyl-N- (2-methylpropyl) -6- Yl) phenyl] phenyl] methyl] pyrimidine-5-carboxamide;
50) 3- [2- [4 - [[2-Butyl-5- (3,5-dimethylpiperidine-1-carbonyl) -4-methyl-6- oxospi rimidin- Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
51) Synthesis of 2-butyl-4-methyl-N- (2-methylpropyl) -6-oxo-1 - [[4- [2- Yl) phenyl] phenyl] methyl] pyrimidine-5-carboxamide;
52) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a-octahydroisoindol- Methyl-6-oxo-2-propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
53) N-Methoxy-N-methyl-2- [4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H- Yl) phenyl] phenyl] methyl] -2-propylpyrimidin-5-yl] acetamide;
54) N, N-Dimethyl-2- [4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] phenyl] methyl] -2-propylpyrimidin-5-yl] acetamide;
55) 3- [2- [4- [[4-Methyl-6-oxo-5- (2-oxo-2- pyrrolidin- 1 -ylethyl) -2- propylpyrimidin- ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
56) 3- [2- [4 - [[4-Methyl-6-oxo-5- (2-oxo-2-piperidin- 1- ylethyl) -2-propylpyrimidin- ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
57) 3- [2- [4 - [[5- [2- (3,5-Dimethylpiperidin-1-yl) -2-oxoethyl] Pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
58) 3- [2- [4- [[5- [2- (3,5-Dimethylmorpholin-4-yl) -2-oxoethyl] -4-methyl- Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
59) N-methyl-2- [4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] -2-propylpyrimidin-5-yl] -N-propan-2-ylacetamide;
60) 3- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-dimethylpropanamide;
61) 3- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylpropanamide;
62) 3- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-cyclopropylpropanamide;
Methyl) -6-oxo-5- (3-oxo-3-piperidin- 1 -ylpropyl) pyrimidin- 1 -yl] methyl ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
64) 3- [2- [4 - [[2-Butyl-4-methyl-5- (3 -morpholin- ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
65) 3- [2- [4 - [[5- [3- (1,3,3a, 4,5,6,7a-octahydroisoindol-2-yl) -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
66) 3- [2- [4 - [[2-Butyl-4-methyl-5- [3- (4-methylpiperidin- 1 -yl) -3-oxopropyl] -6-oxopyrimidine -1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
67) Synthesis of 3- [2- [4 - [[2-butyl-5- [3- (3,3-dimethylpiperidin- 1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
68) 3- [2- [4 - [[2-butyl-5- [3- (3,5- dimethylmorpholin- Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
69) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a-octahydroisoindol- 2-yl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
70) 2- [2-Butan-2-yl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ) Phenyl] phenyl] methyl] pyrimidin-5-yl] -N-methoxy-N-methylacetamide;
71) 2- [2-Butan-2-yl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ) Phenyl] phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylacetamide;
72) 2- [2-Butan-2-yl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ) Phenyl] phenyl] methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylacetamide;
73) 3- [2- [4 - [[2-Butan-2-yl-5- [2- (2,6- dimethylpiperidin- 1 -yl) -6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
74) 3- [2- [4 - [[2-Butan-2-yl-5- [2- (2,6- dimethylmorpholin- 6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
75) 3- [2- [4 - [[2-Butyl-5- [2- (3,4-dihydro- lH-isoquinolin- -Oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
76) 3- [2- [4 - [[5- [2- (3,4,4a, 5,6,7,8,8a-octahydro-1 H -isoquinolin- Ethyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
77) 3- [2- [4 - [[2-Butyl-4-methyl-5- [2- (2-methylpyrrolidin- 1 -yl) -2-oxoethyl] -6-oxopyrimidine -1-yl] methyl] phenyl] phenyl] -2H-1,2,4-oxadiazol-5-one;
78) 3- [2- [4 - [[5- [2- (3,4,4a, 5,6,7,8,8a-octahydro-2H-quinolin- ] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -2H-1,2,4-oxadiazol-5-one;
79) 3- [2- [4 - [[2-Butyl-5- (2-indol- Phenyl] phenyl] -2H-1,2,4-oxadiazol-5-one;
80) 3- [2- [4 - [[2-butyl-4-methyl-5- [2- (2-methyl-1,3,3a, 4,6,6a- hexahydropyrrolo [ -c] pyrrol-5-yl) -2-oxoethyl] -6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
81) 3- [2- [4 - [[5- [2- (3,3a, 4,5,6,6a-hexahydro-1H-cyclopenta [ Ethyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
82) 3- [2- [4 - [[2-Butyl-5- [2- (1,3- dihydroisoindol- Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
83) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- [ Pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
84) Synthesis of 3- [2- [4 - [[2-butyl-5- [2- (2,3-dihydroindol- 1- yl) -2-oxoethyl] Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
85) 3- [2- [4 - [[2-butyl-5- [2- (4-fluoro-1,3- dihydroisoindol- -6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
86) 2- [2-Cyclopropyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylacetamide;
87) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7a-octahydroisoindol- 2-cyclopropyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
88) 3- (4'- ((2-Butyl-4-methyl-5- (2- (octahydro- lH- indol- 1 -yl) -2-oxoethyl) -6-oxopyrimidin- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
89) 3- (4'- ((2-Butyl-5- (2- (dihydro-lH-pyrido [1,2- a] pyrazin-2 (6H, 7H, 8H, 9H, 9aH) Yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -On;
90) 3- [2- [4 - [[5- [2- (7-Azabicyclo [2.2.1] heptan- -Oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
91) 3- [2- [4 - [[5- [2- (7-Azabicyclo [2.2.1] heptan-7-yl) -2-oxoethyl] -4- -Propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
92) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo- 5- [2-oxo- 2- [4- (trifluoromethyl) piperidin- ] Ethyl] pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
93) 3- [2- [4- [[5- [2- (8-Azaspiro [4.5] decan-8-yl) -2-oxoethyl] 1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
94) 3- [2- [4 - [[5- [2- (8-Azaspiro [4.5] decan-8- Pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
95) 3- [2- [4 - [[2-butyl-5- [2- (4,4-dimethylpiperidin- 1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
96) 3- [2- [4 - [[5- [2- (4,4-Dimethylpiperidin- 1 -yl) -2-oxoethyl] Pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
97) 3- [2- [4 - [[2- (2,5-Dimethylpyrrolidin- 1 -yl) -2-oxo-ethyl] Oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -2H-1,2,4-oxadiazol-5-one;
98) Synthesis of 3- [2- [4 - [[2-butyl-4-methyl-5- [2 - [(2S) -2- methylpyrrolidin- Oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
99) 3- [2- [4 - [[2-butyl-5- [2 - [(2S, 6R) -2,6-dimethylpiperidin- Methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
100) 3- [2- [4 - [[5- [2 - [(4aS, 8aR) -3,4,4a, 5,6,7,8,8a-octahydro-2H-quinolin- ] -2-oxoethyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
101) 3- (4 '- ((2-Butyl-4-methyl-5- (2- Yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one ;
102) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylacetamide;
103) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a-octahydroisoindol- 2-butyl-4-cyclopropyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
104) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylacetamide;
105) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-methyl-N- (2-methylpropyl) acetamide;
106) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-isopropyl-N-methylacetamide;
Oxo-2-pyrrolidin-1-ylethyl) pyrimidin-1-yl] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
108) 3- [2- [4 - [[2-Butyl-4-cyclopropyl-5- [2- (3,5- dimethylpiperidin- 1 -yl) Oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
109) 3- [2- [4 - [[2-Butyl-4-cyclopropyl-6-oxo-5- (2- oxo-2-piperidin- 1- ylethyl) pyrimidin- Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
110) 3- [2- [4 - [[2-Butyl-4-cyclopropyl-5- (2-morpholin- Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
111) 2- [2-butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N- (1-hydroxypropan-2-yl) acetamide;
112) N-Butyl-2- [2-butyl-4- cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H- Yl) phenyl] phenyl] methyl] pyrimidin-5-yl] acetamide;
113) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-propylacetamide;
114) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-propan-2-ylacetamide;
115) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-methoxy-N-methylacetamide
116) 3- (4'- ((2-Butyl-4-cyclopropyl-6-oxo-5- (2-oxo-2- (pyrrolidin- 1- yl) ethyl) pyrimidin- Yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
117) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (2,6- dimethylpiperazin- 1 -yl) -2-oxoethyl) (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
118) (S) -3- (4 '- ((2-Butyl-4-cyclopropyl- 5- (2- (2- methylpyrrolidin- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
119) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (3,5- dimethylpiperidin- 1 -yl) -2-oxoethyl) (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
120) 2- (2-Butyl-4-cyclopropyl-6-oxo-1 - ((2 &apos;-( 5-oxo-4,5-dihydro- ) Biphenyl-4-yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N- cyclopropylacetamide;
121) 2- (2-Butyl-4-cyclopropyl-6-oxo-1 - ((2 &apos;-( 5-oxo-4,5-dihydro- ) Biphenyl-4-yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N, N- diethylacetamide;
122) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (3,5- dimethylmorpholino) -2-oxoethyl) -6-oxopyrimidin- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
123) 3- (4 '- ((2-Butyl-4-cyclopropyll-5- (2 - ((2S, 6R) -2,6-dimethylpiperidin- Ethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
124) 3- (4 '- ((2-Butyl-4-cyclopropyl-5- (2-morpholino- 2- oxoethyl) -6-oxopyrimidin- Biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
125) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (2- methylpiperidin- 1 -yl) -2-oxoethyl) -6-oxopyrimidine- 1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
126) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (4- hydroxypiperidin- 1 -yl) -2-oxoethyl) -6-oxopyrimidine -1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
127) 3- [2- [4 - [[2-Butyl-6-oxo-5- (2-oxo-2-piperidin- 1 -ylethyl) -4- propan- -Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
128) 3- [2- [4 - [[2-butyl-5- [2- (2,6- dimethylpiperazin- 1 -yl) -2- oxoethyl] 2-ylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
129) 2- [2-butyl-6-oxo-1 - [[4- [2- (5-oxo- 4-propan-2-ylpyrimidin-5-yl] -N, N- dimethylacetamide;
130) 2- [2-butyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- 4-propan-2-ylpyrimidin-5-yl] -N, N-diethylacetamide;
Yl) phenyl] phenyl] methyl] - (2-methyl- 4-propan-2-ylpyrimidin-5-yl] -N-methyl-N-propan-2-ylacetamide;
132) 2- [2-butyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- 4-propan-2-ylpyrimidin-5-yl] -N-cyclopropylacetamide;
133) 3- (4'- ((2-Butyl-5- (2- (3,5-dimethylpiperidin- 1 -yl) -2-oxoethyl) -4-isopropyl- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
134) 3- (4 '- ((2-Butyl-5- (2 - ((2R, 6S) -2,6-dimethylpiperidin- Propyl-6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
135) 3- (4'- ((2-Butyl-4-isopropyl-5- (2- (2- methylpiperidin- 1 -yl) -2-oxoethyl) -6-oxopyrimidine- 1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
136) 3- (4'- ((2-Butyl-4-isopropyl-5- (2- (3-methylpiperidin- 1 -yl) -2-oxoethyl) -6-oxopyrimidine- 1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
137) 3- (4'- ((2-butyl-4-isopropyl-5- (2-morpholino- 2- oxoethyl) -6- oxopyrimidin- 1 (6H) Biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
138) 3- (4'- ((2-Butyl-5- (2- (2,6- dimethylmorpholino) -2-oxoethyl) -4-isopropyl-6-oxopyrimidin- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
139) (S) -3- (4 '- ((2-Butyl-4-isopropyl- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
140) 2- [2-Butyl-4-ethyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-dimethylacetamide;
141) 2- [2-Butyl-4-ethyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylacetamide;
142) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7a-octahydroisoindol- 2-butyl-4-ethyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
143) 3- [2- [4 - [[2-Butyl-4-ethyl-6-oxo-5- (2-oxo-2- pyrrolidin- 1 -ylethyl) pyrimidin- ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
144) 3- [2- [4 - [[2-Butyl-4-ethyl-6-oxo-5- (2- oxo-2-piperidin- 1- ylethyl) pyrimidin- ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
145) 3- [2- [4 - [[2-Butyl-4-ethyl-5- (2-morpholin- ] Phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
146) 3- [2- [4 - [[2-Butyl-4-ethyl-5- [2- (4-methylpiperidin- 1 -yl) -2-oxoethyl] -6-oxopyrimidine -1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
147) 3- [2- [4 - [[2-Butyl-5- [2- (3,3- dimethylpiperidin- 1 -yl) 1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
148) 3- [2- [4 - [[2-butyl-5- [2- (3,5- dimethylmorpholin- Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
149) 3- (4'- ((2-Butyl-4-methyl-6-oxo-5- (2-oxo- 2- (thiazolidin- 3- yl) ethyl) pyrimidin- Yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
150) 3- (4'- ((2-Butyl-4-methyl-5- (2- (4- methylpiperidin- 1 -yl) -2-oxoethyl) -6-oxopyrimidin- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
151) 3- (4 '- ((2-Butyl-5- (2- (2,6- dimethylmorpholino) -2-oxoethyl) -4-methyl-6-oxopyrimidin- 6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
152) 2- (2-Butyl-4-methyl-6-oxo-1 - ((2- Yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N- (2-methoxyethyl) acetamide;
153) 2- (2-Butyl-4-methyl-6-oxo-1 - ((2- Yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N- (2- (thiophen-2-yl) ethyl) acetamide;
154) 2- (2-Butyl-4-methyl-6-oxo-1 - ((2- Yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N, N-diisopropylacetamide;
155) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-dimethylethanethioamide;
156) 3- (4 '- ((5- (2- (1H-isoindol-2 (3H, 3aH, 4H, 5H, 6H, 7H, 7aH) Butyl-4-methyl-6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
157) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methyl-N- (2-methylpropyl) ethanethioamide;
158) 3- [2- [4- [[2-Butyl-4-methyl-6-oxo-5- (2-piperidin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
159) 3- [2- [4 - [[2-Butyl-4-methyl-5- (2-morpholin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
160) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-propan-2-ylethanethioamide;
161) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylethanethioamide;
162) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- (2-pyrrolidin- 1 -yl-2-sulfanylidenemethyl) pyrimidin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
163) 3- [2- [4 - [[2- (3,5-Dimethylpiperidin-1-yl) -2-sulfanylidenemethyl] -Oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
164) 2-Butyl-N, 4-dimethyl-N- (2- methylpropyl) -6-oxo-1 - [[4- [2- Yl) phenyl] phenyl] methyl] pyrimidine-5-carbothioamide;
165) 2-butyl-N, N, 4-trimethyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidine-5-carbothioamide;
166) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- (piperidine- 1- carbothioyl) pyrimidin- -4H-l, 2,4-oxadiazol-5-one;
167) 3- [2- [4 - [[2-butyl-4-methyl-5- (morpholine- 4- carbothioyl) -6-oxopyrimidin- -4H-l, 2,4-oxadiazol-5-one;
168) Synthesis of 2-butyl-N, 4-dimethyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] -N-propan-2-ylpyrimidine-5-carbothioamide;
169) 3- [2- [4 - [[5- (1,3,3a, 4,5,6,7,7a-octahydroisoindole-2-carbothioyl) -6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
Methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- -N-propan-2-ylpyrimidine-5-carbothioamide;
171) 2-Butyl-N-cyclohexyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Phenyl] methyl] pyrimidine-5-carbothioamide;
172) 3- [2- [4 - [[2-Butyl-5- (3,5-dimethylpiperidine- 1- carbothioyl) -4-methyl-6-oxopyrimidin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
173) 2-Butyl-4-methyl-N- (2-methylpropyl) -6-oxo-1 - [[4- [2- Yl) phenyl] phenyl] methyl] pyrimidine-5-carbothioamide;
174) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-diethylethanethioamide;
175) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-propylethanethioamide;
176) N-butyl-2- [2-butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4- ) Phenyl] phenyl] methyl] pyrimidin-5-yl] ethanethioamide;
177) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a-octahydroisoindol-2-yl) -2-sulfanylidenemethyl ] -4-methyl-6-oxo-2-propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
178) N-Methoxy-N-methyl-2- [4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H- Yl) phenyl] phenyl] methyl] -2-propylpyrimidin-5-yl] ethanethioamide;
179) N, N-Dimethyl-2- [4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] phenyl] methyl] -2-propylpyrimidin-5-yl] ethanethioamide;
180) 3- [2- [4 - [[4-Methyl-6-oxo-2-propyl-5- (2- pyrrolidin- 1 -yl- 2- sulfanylideneethyl) pyrimidin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
181) 3- [2- [4 - [[4-Methyl-6-oxo-5- (2-piperidin- 1 -yl-2-sulfanylidenemethyl) -2-propylpyrimidin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
182) 3- [2- [4 - [[5- [2- (3,5-Dimethylpiperidin- 1 -yl) -2-sulfanylidenemethyl] -4-methyl- -Propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
183) 3- [2- [4 - [[5- [2- (3,5-Dimethylmorpholin-4-yl) -2-sulfanylidenemethyl] -4- Propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
184) N-methyl-2- [4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H- Phenyl] methyl] -2-propylpyrimidin-5-yl] -N-propan-2-ylethanethioamide;
185) 3- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-dimethylpropanethioamide;
186) 3- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methyl-N-propane-2-ylpropanethioamide;
187) 3- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-cyclopropylpropanethioamide;
188) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- (3-piperidin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
189) 3- [2- [4 - [[5- [3- (1,3,3a, 4,5,6,7,7a-octahydroisoindol-2-yl) -3-sulfanylidene propyl ] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
190) 3- [2- [4 - [[2-Butyl-4-methyl-5- [3- (4-methylpiperidin- 1 -yl) -3-sulfanylidenepropyl] -6- Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
191) 3- [2- [4 - [[2-butyl-5- [3- (3,3- dimethylpiperidin- 1 -yl) -3-sulfanylidenepropyl] -Oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
192) 3- [2- [4 - [[2-butyl-5- [3- (3,5- dimethylmorpholin- Oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
193) 3- [2- [4 - [[2-Butyl-4-methyl-5- (3 -morpholin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
194) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a-octahydroisoindol-2-yl) -2-sulfanylidenemethyl ] -2-butan-2-yl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
195) 2- [2-Butan-2-yl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ) Phenyl] phenyl] methyl] pyrimidin-5-yl] -N-methoxy-N-methylethanethioamide;
196) 2- [2-Butan-2-yl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ) Phenyl] phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylethanethioamide;
197) 2- [2-Butan-2-yl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ) Phenyl] phenyl] methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylethanethioamide;
198) 3- [2- [4 - [[2-Butan-2-yl- 5- [2- (2,6- dimethylpiperidin- 1 -yl) -2-sulfanylidenemethyl] Methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
199) 3- [2- [4 - [[2-butan-2-yl-5- [2- (2,6- dimethylmorpholin- Methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
200) 3- (4'- ((2-Butyl-5- (2- (3,5-dimethylpiperidin-1-yl) -2- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
201) Synthesis of 3- [2- [4 - [[2-butyl-5- [2- (3,4-dihydro-1H-isoquinolin-2-yl) -2-sulfanylidenemethyl] -6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
202) 3- [2- [4 - [[5- [2- (3,4,4a, 5,6,7,8,8a-octahydro-1H-isoquinolin- Methylidene] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
203) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- [2-sulfanylidene-2- (1,3-thiazolidin- ] Pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
204) Synthesis of 3- [2- [4 - [[2-butyl-4-methyl-5- [2- (4-methylpiperidin- 1 -yl) -2-sulfanylideneethyl] Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
205) Synthesis of 3- [2- [4 - [[2-butyl-5- [2- (2,6- dimethylmorpholin-4-yl) -2-sulfanylidenemethyl] Oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
206) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methoxy-N-methylethanethioamide;
207) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N- (2-methoxyethyl) -N-methylethanethioamide;
208) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N- (2-thiophen-2-ylethyl) ethanethioamide;
208) 2- (2-Butyl-4-methyl-6-oxo-1 - ((2- Yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N, N-diisopropylacetamide;
209) 2- [2-butyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-di (propan-2-yl) ethanethioamide;
210) 3- [2- [4 - [[2-butyl-5- (2-indol- Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
211) Synthesis of 3- [2- [4 - [[2-butyl-4-methyl-5- [2- (2-methylpyrrolidin- 1 -yl) -2-sulfanylidenemethyl] Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
212) 2- [2-Cyclopropyl-4-methyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylethanethioamide;
213) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7a-octahydroisoindol-2-yl) -2-sulfanylidenemethyl ] -2-cyclopropyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
214) 3- [2- [4 - [[5- [2- (2,3,3a, 4,5,6,7,7a-octahydroindol- 1- yl) -2-sulfanylideneethyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
215) 3- [2- [4 - [[2-butyl-5- [2- (1,3- dihydroisoindol-2-yl) -2- sulfanylidenemethyl] Oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
216) Preparation of 3- [2- [4 - [[2-butyl-5- [2- (2,3-dihydroindol- 1 -yl) -2-sulfanylidenemethyl] 1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
217) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- [2- Ethyl] pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
218) 3- [2- [4 - [[5- [2- (3,3a, 4,5,6,6a-hexahydro-lH-cyclopenta [ Methylidene] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
219) 3- [2- [4 - [[2-Butyl-5- [2- (1,3- dihydroisoindol-2-yl) -2- sulfanylidenemethyl] Oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
220) 3- [2- [4 - [[2-Butyl-4-methyl-5- [2- [4- (4-nitrophenyl) piperazin- 1 -yl] -2-sulfanylidenemethyl] -6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
221) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7a-octahydroisoindol-2-yl) -2-sulfanylidenemethyl ] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] -4-fluorophenyl] -4H-1,2,4-oxadiazol-5-one;
222) 2- [2-butyl-1 - [[4- [5-fluoro-2- (5-oxo-4H-1,2,4-oxadiazol- -4-methyl-6-oxopyrimidin-5-yl] -N-methoxy-N-methylethanethioamide;
223) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo- 5- (2- pyrrolidin- 1 -yl- ] Methyl] phenyl] -4-fluorophenyl] -4H-1,2,4-oxadiazol-5-one;
224) 3- [2- [4 - [[2- (3,5-Dimethylpiperidin-1-yl) -2-sulfanylideneethyl] -Oxopyrimidin-1-yl] methyl] phenyl] -4-fluorophenyl] -4H-1,2,4-oxadiazol-5-one;
225) 3- [2- [4 - [[2-Butyl-5- [2- (3,5- dimethylmorpholin-4-yl) -2- sulfanylidenemethyl] Oxo-pyrimidin-1-yl] methyl] phenyl] -4-fluorophenyl] -4H-1,2,4-oxadiazol-5-one;
226) 2- [2-butyl-1 - [[4- [5-fluoro-2- (5-oxo-4H-1,2,4-oxadiazol- -4-methyl-6-oxopyrimidin-5-yl] -N-methyl-N- (2-methylpropyl) ethanethioamide;
227) 3- [2- [4 - [[2-Butyl-4-methyl-5- [2- (2-methyl-1,3,3a, 4,6,6a- hexahydropyrrolo [ -c] pyrrol-5-yl) -2-sulfanylidenemethyl] -6-oxopyrimidin-1- yl] methyl] phenyl] phenyl] -4H- On;
228) 3- (4'- ((2-Butyl-5- (2- (hexahydrocyclopenta [c] pyrrol- Oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
229) 3- [2- [4 - [[5- [2- (1,3,4,6,7,8,9,9a-octahydropyrido [1,2- a] pyrazin- ) -2-sulfanylideneethyl] -2-butyl-4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H- On;
230) 3- [2- [4 - [[5- [2- (2,3,3a, 4,5,6,7a-octahydroindol- -2-butyl-4-methyl-6-oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -2H-1,2,4-oxadiazol-5-one;
231) 3- [2- [4 - [[5- [2- (7-Azabicyclo [2.2.1] heptan-7-yl) -2-sulfanylidenemethyl] -4- -2-propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
232) 3- [2- [4 - [[2-Butyl-4-methyl-6-oxo-5- [2-sulfanylidene-2- [4- (trifluoromethyl) piperidin- Yl] ethyl] pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
233) 3- [2- [4 - [[5- [2- (8-Azaspiro [4.5] decan-8-yl) -2- sulfanylidenemethyl] -Oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
234) 3- [2- [4 - [[5- [2- (8-Azaspiro [4.5] decan-8-yl) -2-sulfanylidenemethyl] -4- -Propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
235) 3- [2- [4 - [[2-butyl-5- [2- (4,4-dimethylpiperidin- 1 -yl) -2-sulfanylidenemethyl] -Oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
236) 3- [2- [4 - [[5- [2- (4,4-Dimethylpiperidin- 1 -yl) -2-sulfanylidenemethyl] -Propylpyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
237) 2- [2-Butyl-4-methyl-6-oxo-1 - [[4- [2- (5-sulfanylidene-4H-1,2,4-oxadiazol- ] Phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylethanethioamide;
238) 5- [2- (1,3,3a, 4,5,6,7,7a-octahydroisoindol-2-yl) -2-sulfanylideneethyl] -2-butyl- 3 - [[4- [2- (5-sulfanylidene-4H-1,2,4-oxadiazol-3-yl) phenyl] phenyl] methyl] pyrimidin-4-one;
239) 2-Butyl-6-methyl-5- [2- (4-methylpiperidin- 1 -yl) -2-sulfanylidenemethyl] -3 - [[4- [2- Di-4H-1,2,4-oxadiazol-3-yl) phenyl] phenyl] methyl] pyrimidin-4-one;
240) 3- [2- [4 - [[2-butyl-5- [2- (2,5-dimethylpyrrolidin- 1 -yl) -2-sulfanylidenemethyl] -Oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
241) 3- [2- [4 - [[2-butyl-5- [2 - [(2S, 6R) -2,6- dimethylpiperidin- 1 -yl] -2-sulfanylidenemethyl] -4-methyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H6- 1,2,4-oxadiazol-5-one;
242) 3- [2- [4 - [[5- [2 - [(4aS, 7aR) -1,3,4,4a, 5,6,7,7a-octahydrocyclopenta [c] Methyl] -6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazole- 5-one;
243) 3- [2- [4 - [[2-Butyl-4-methyl-5- [2 - [(2S) -2-methylpyrrolidin- 1 -yl] -2-sulfanylidenemethyl] 6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
244) 3- [2- [4 - [[2-Butyl-4-methyl-5- [2 - [(2R) -2- methylpyrrolidin- 6-oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
245) 3- [2- [4 - [[5- [2- (7-Azabicyclo [2.2.1] heptan-7-yl) -2-sulfanylideneethyl] -2- -6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
246) 3- (4 '- ((2-Butyl-4-methyl-5- (2- Yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) - On;
247) 3- (4'- ((2-Butyl-4-methyl-6-oxo-5- (2-thioxo-2- (3- (trifluoromethyl) -5,6-dihydro- [ Yl) methyl) biphenyl-2-yl) -1,2,3,4-tetrahydroisoquinoline; 4-oxadiazol-5 (4H) -one;
248) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N, N-dimethylethanethioamide;
249) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylethanethioamide;
250) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a-octahydroisoindol-2-yl) -2-sulfanylidenemethyl ] -2-butyl-4-cyclopropyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
251) 2- [2-Butyl-4-cyclopropyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Phenyl] methyl] pyrimidin-5-yl] -N-methyl-N- (2-methylpropyl) ethanethioamide;
252) 3- [2- [4 - [[2-Butyl-4-cyclopropyl-6-oxo-5- (2-piperidin- 1 -yl- 2- sulfanylideneethyl) pyrimidin- Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
253) 3- (4'- ((2-Butyl-4-cyclopropyl-6-oxo-5- (2- (pyrrolidin- 1 -yl) -2- thioxoethyl) pyrimidin- Yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
254) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (2,6- dimethylpiperazin- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
255) (S) -3- (4 '- ((2-Butyl-4-cyclopropyl- 5- (2- (2-methylpyrrolidin- Oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
256) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (3,5- dimethylpiperidin- (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
257) 2- (2-Butyl-4-cyclopropyl-6-oxo-l - ((2 &apos;-( 5-oxo-4,5-dihydro- ) Biphenyl-4-yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N- cyclopropylethanethioamide;
258) 2- (2-Butyl-4-cyclopropyl-6-oxo-1 - ((2 &apos;-( 5-oxo-4,5- dihydro- ) Biphenyl-4-yl) methyl) -l, 6-dihydropyrimidin-5-yl) -N, N-diethylethanethioamide;
259) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (3,5- dimethylmorpholino) -2- thioxo- ethyl) 1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
260) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2 - ((2S, 6R) -2,6-dimethylpiperidin- Ethyl) -6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
261) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2-morpholino- 2- thioxoethyl) -6-oxopyrimidin- 1 (6H) ) Biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
262) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (2- methylpiperidin- 1 -yl) -2- thioxoethyl) -6-oxopyrimidine -1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
263) 3- (4'- ((2-Butyl-4-cyclopropyl-5- (2- (4- hydroxypiperidin- 1 -yl) -2- thioxoethyl) (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
264) 3- [2- [4 - [[2-Butyl-6-oxo-4-propan-2-yl- 5- (2- pyrrolidin- 1 -yl- 2- sulfanylideneethyl) -1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
265) 3- [2- [4 - [[2-Butyl-6-oxo-5- (2-piperidin- 1 -yl-2-sulfanylidenemethyl) -4- propan- -1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
266) 3- [2- [4 - [[2-butyl-5- [2- (2,6- dimethylpiperazin- 1 -yl) -2-sulfanylidenemethyl] Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
267) 2- [2-butyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- Yl] -N, N-dimethylethanethioamide;
268) 2- [2-Butyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- 4-propan-2-ylpyrimidin-5-yl] -N, N-diethylethanethioamide;
269) 2- [2-butyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- 4-propan-2-ylpyrimidin-5-yl] -N-methyl-N-propan-2-ylethanethioamide;
270) 2- [2-Butyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- 4-propan-2-ylpyrimidin-5-yl] -N-cyclopropylethanethioamide;
271) 3- (4 '- ((2-Butyl-4-isopropyl-5- (2- Yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole (commercially available) &Lt; / RTI &gt; 5 (4H) -one;
272) 3- (4'- ((2-Butyl-5- (2- (3,5-dimethylpiperidin- 1 -yll) -2-thioxoethyl) Oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
273) 3- (4 '- ((2-Butyl-5- (2 - ((2R, 6S) -2,6-dimethylpiperidin- Isopropyl-6-oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
274) 3- (4'- ((2-Butyl-4-isopropyl-5- (2- (2-methylpiperidin- 1 -yl) -2-thioxoethyl) -6-oxopyrimidine -1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
275) 3- (4'- ((2-Butyl-4-isopropyl-5- (2- (3-methylpiperidin- 1 -yl) -2-thioxoethyl) -6-oxopyrimidine -1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
276) 3- (4'- ((2-butyl-4-isopropyl-5- (2-morpholino-2- thioxoethyl) -6-oxopyrimidin- ) Biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
277) 3- (4 '- ((2-Butyl-5- (2- (2,6- dimethylmorpholino) -2-thioxoethyl) -4-isopropyl-6-oxopyrimidine- 1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
278) (S) -3- (4 '- ((2-Butyl-4-isopropyl- Oxopyrimidin-1 (6H) -yl) methyl) biphenyl-2-yl) -1,2,4-oxadiazole-5 (4H) -one;
279) 2- [2-Butyl-4-ethyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N, N-dimethylethanethioamide;
280) 2- [2-Butyl-4-ethyl-6-oxo-1 - [[4- [2- (5-oxo-4H-1,2,4-oxadiazol- ] Methyl] pyrimidin-5-yl] -N-methyl-N-propan-2-ylethanethioamide;
281) 3- [2- [4 - [[5- [2- (1,3,3a, 4,5,6,7,7a-octahydroisoindol-2-yl) -2-sulfanylidenemethyl ] -2-butyl-4-ethyl-6-oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
282) 3- [2- [4 - [[2-Butyl-4-ethyl-6-oxo-5- (2- pyrrolidin- 1 -yl- 2- sulfanylideneethyl) pyrimidin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
283) 3- [2- [4 - [[2-Butyl-4-ethyl-6-oxo-5- (2-piperidin- 1 -yl-2-sulfanylidenemethyl) pyrimidin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
284) 3- [2- [4 - [[2-Butyl-4-ethyl-5- (2-morpholin- ] Methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
285) 3- [2- [4 - [[2-Butyl-4-ethyl-5- [2- (4-methylpiperidin- 1 -yl) -2-sulfanylideneethyl] -6- Yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one;
286) 3- [2- [4 - [[2-butyl-5- [2- (3,3- dimethylpiperidin- 1 -yl) -2-sulfanylidenemethyl] -Oxopyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one; And
287) 3- [2- [4 - [[2-Butyl-5- [2- (3,5- dimethylmorpholin-4-yl) -2- sulfanylidenemethyl] Oxo-pyrimidin-1-yl] methyl] phenyl] phenyl] -4H-1,2,4-oxadiazol-5-one. A pharmaceutical composition for the treatment or prevention of hypertension or diabetes comprising the compound of any one of claims 1 to 4, an optical isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. 6. The pharmaceutical composition according to claim 5, wherein the hypertension is essential hypertension. 6. The pharmaceutical composition according to claim 5, wherein the diabetes is type 2 diabetes. 6. The pharmaceutical composition according to claim 5 for treating or preventing hypertension and diabetes simultaneously.